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Abstract 
 
The purpose of this study was to investigate the effects of three different glycemic 
control conditions (tight, conventional, and standard) in the intraoperative period on: 1) 
postoperative surgical site infections, and 2) postoperative procalcitonin, and C-reactive 
protein levels in patients undergoing open-heart surgery. Secondary aims of the study 
were to investigate the effects of the three glycemic treatment conditions on: 1) 
intraoperative blood glucose; 2) intraoperative glycemic stability; and 3) intensive care 
unit length of stay, in patients undergoing open-heart surgery.  
An experimental design with a multilevel, single factor, within-subjects design 
was utilized. Patients were nested within anesthesia provider teams. The design was 
counterbalanced by means of a Latin square, where each of three anesthesia provider 
teams dispensed each of three glycemic control conditions once. Thirty-seven 
participants were randomized to either tight glycemic control (n =15), which maintained 
blood glucose 110-149 mg/dl via continuous intravenous insulin infusion, conventional 
glycemic control (n = 11), which maintained blood glucose 150-180 mg/dl via continuous 
intravenous insulin infusion, or standard glycemic control (n =11) which maintain blood 
glucose 150-180 mg/dl via intravenous bolus injections of insulin.  
The main findings of this study were that there were no significant differences 
between the three glycemic interventional treatment groups in 1) thirty-day surgical site 
infections, 2) postoperative C-reactive protein or procalcitonin concentrations 3) 
intensive care unit length of stay, 4) intraoperative blood glucose levels, or 5) glycemic 
	  	  vii	  
stability. An association between intraoperative peak blood glucose and surgical site 
infection was established. Participants that experienced higher peak blood glucose levels 
intraoperatively exhibited increased surgical site infections.  Procalcitonin levels were 
significantly elevated in participants that experienced a surgical site infection, but C-
reactive protein showed no significant difference between participants with or without a 
surgical site infection. Coronary artery bypass graft surgery concomitant with valve 
replacement surgery was associated with a higher rate of surgical site infections 
compared coronary artery bypass graft surgery or valve surgery independently.  
In conclusion, an association was found between higher peak intraoperative blood 
glucose levels and increased surgical site infections, therefore maintaining intraoperative 
blood glucose levels below 180 mg/dl via a continuous intravenous infusion of insulin, 
may reduce postoperative surgical site infections in the open-heart patient. The use of 
tight glycemic control during the intraoperative period can be achieved safely, with the 
use of judicious protocols, but its benefits remain unproven. Inflammatory biomarker 
procalcitonin was predictive of infection, where C-reactive protein was not. The addition 
of procalcitonin to routine postoperative blood work, in open-heart patients, may benefit 
providers in the diagnosis and early treatment of surgical site infections. This study was 
underpowered. Further studies with appropriate sample size, may be able to determine if 
tight glycemic control, compared to moderate glycemic control, in the intraoperative 
period is of benefit to patients undergoing open-heart surgery. 
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Chapter One 
Introduction 
According to the American Heart Association [AHA] there were 555,000 total 
open-heart surgeries performed in the United States in 2009 (Roger et al., 2012). 
Coronary artery bypass graft surgery (CABG) accounted for 416,000 of these procedures 
and cardiac valve replacements accounted for 139,000 (Roger et al., 2012).  While there 
were 416, 000 CABG surgical procedures, these were performed on only 242,000 
patients (Roger et al., 2012). Open-heart surgery, while very successful in the alleviation 
of chest pain due to coronary heart disease (CHD) and/or valvular disease carries risks. 
One risk is that of infection including median sternotomy site infections, surgical harvest 
site infections, pneumonias, urinary tract infections, and bacteremia (Ariyaratnam, Bland, 
& Loubani, 2010; Baillot, et al., 2010; Borger et al., 1998; El Oakley et al., 1997; 
Furnary, Wu & Bookin, 2004; Latham, Lancaster, Covington, Pirolo & Thomas, 2001; 
Lola et al., 2011; Mannien, Wille, Kloek, & van Benthem, 2011; Spelman et al., 2000, 
Trick et al., 2000a; Trick et al., 2000b; Zerr et al., 1997).  
Surgical site wound infection, after open-heart surgery, is associated with 
increased hospital stays, increased costs and substantial morbidity and mortality 
(Athanasiou et al., 2003; El Oakley et al., 1997; Fowler et al., 2005; Jonkers, Elenbaas, 
Terporten, Nieman, & Stobberingh, 2003; Knapik et al., 2009; L’Ecuyer, Murphy, Little, 
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& Fraser, 1996; Lola et al., 2011; Vuorisalo, Haukipuro, Pokela, & Syrjala, 1998; Yun et 
al., 2005).  
Previous studies suggest a link between poor glycemic control and surgical site 
infection rates (Borger et al., 1998; El Oakley et al., 1997; Estrada, Young, Nifong, & 
Chitwood, 2003; Fowler et al., 2005; Furnary et al., 2004; Latham et al., 2001; Trick et 
al., 2000b; Zerr et al., 1997). Deep sternal site wound infection, after open-heart surgery, 
is associated with substantial morbidity and a mortality rate as high as 14% (El Oakley et 
al., 1997; Fowler et al., 2005; Knapik et al., 2009; Lola et al., 2011).  Harvest surgical site 
infections are the most common surgical site infection associated with CABG surgery, 
with rates as high as 15.4% (Athanasiou et al., 2003; Jonkers et al., 2003; L’Ecuyer et al., 
1996; Vuorisalo et al., 1998; Yun et al., 2005).  While these infections are associated with 
lower morbidity and mortality than deep sternal wound infections they can have severe 
clinical consequences, such as limb amputations (Lee & Reinstein, 1998; Paletta, et al., 
2000). 
There is evidence that aggressive glycemic control for critically ill hospitalized 
patients improves clinical outcomes, especially for surgical patients and patients with 
CHD (Furnary et al., 2004; Trence, Kelly, & Hirsch, 2003; Trick et al., 2000b; Van den 
Berghe, et al., 2001).  However, these data have been challenged by more recent studies 
that suggest there is no improvement in clinical outcomes, or possibly worse outcomes 
for the critically ill patient who is treated with aggressive glycemic control (Arabi et al., 
2008; Chan et al., 2009; Finfer, et al., 2009; Gandhi et al., 2007; Griesdale, et al., 2008; 
Lazar et al., 2011; Wiener, Wiener, & Larson, 2008).  
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Studies that have explored glycemic control for open-heart surgery specifically in 
the perioperative period (intra- and postoperative), have also reported conflicting results 
on the benefits of tight glycemic control (Furnary, Zerr, Grunkemeier, & Starr, 1999; 
Furnary et al., 2003; Furnary et al., 2004; Gandhi et al., 2007; Goldberg, Siegel, & 
Sherwin, 2004; Guvener, Pasaoglu, Demircin, & Mehmet, 2002; Lazar et al., 2004; 
Schmeltz et al., 2007; Smith, Grattan, Harper, Royston, & Riedel, 2002; Zerr et al., 
1997). While there is consensus that hyperglycemia should be avoided in the 
perioperative period in patients undergoing open-heart surgery, it remains unclear how 
tight the glycemic control should be. A few studies have reported good results with tight 
glycemic control (80-120 mg/dl) in the intraoperative period, showing improved 
outcomes including improved myocardial function (Lazar et al., 2004), decreased wound 
infections (Carr et al., 2005; Emam et al., 2010; Furnary et al., 1999), and decreased 
morbidity and mortality (Furnary et al., 2003).  Other studies reported no improvement in 
mortality and morbidity with tight glycemic control (80 -110 mg/dl), and potentially 
worse outcomes (Chan et al., 2009; Gandhi et al., 2007; Lazar et al., 2011).  
Results from more recent research has triggered national associations to amend 
their guidelines to more conservative glucose parameters.  Currently, the Institute for 
Healthcare Improvement (IHI, 2011) recommends cardiovascular surgery patients, who 
are at a high risk for complications from hyperglycemia, maintain blood glucose levels 
below 180 mg/dl for the first two postoperative days.  The American Diabetes 
Association (ADA, 2012) recommends initiating insulin therapy for persistent 
hyperglycemia starting at a threshold of no greater than 180 mg/dl.  Once insulin therapy 
is initiated, blood glucose levels in critically ill patients should be maintained from 140-
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180 mg/dl (ADA, 2012).  More stringent goals, such as 110-140 mg/dl may be 
appropriate for selected patients, as long as this is achieved without significant 
hypoglycemia (ADA, 2012). 
Further research utilizing randomized controlled trials is needed to investigate 
whether tight or moderate glycemic control in the intraoperative period substantially 
improves clinical outcomes such as postoperative infection. It is also important to 
determine the incidence of intra- and postoperative hypoglycemia experienced with tight 
glycemic control.  
Statement of the Problem 
Postoperative surgical site infection in the open-heart patient population is a 
significant problem for cardiothoracic surgical teams and hospitals. There is paucity of 
literature concerning the impact of intraoperative glycemic control on surgical site wound 
infections in patients undergoing open-heart surgery, including CABG surgery and/or 
cardiac valve surgery. Limited research is available to support which insulin protocol 
and/or blood glucose value, in the intraoperative period, is the safest and most effective 
for glycemic stability or preventing  surgical site infections (SSIs).  A greater 
understanding of glycemic control in the intraoperative period, and its impact on 
postoperative surgical site infection is needed for patients undergoing open-heart surgery.  
Purpose of the Study 
The purpose of this study was to investigate the effects of three different glycemic 
control conditions (tight, conventional, and standard) in the intraoperative period on: 1) 
thirty-day postoperative surgical site infections; and 2) postoperative procalcitonin, and 
C-reactive protein levels in patients undergoing open-heart surgery. Secondary aims of 
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the study were to investigate the effects of the three glycemic treatment conditions on: 1) 
intraoperative blood glucose; 2) intraoperative glycemic stability; and 3) intensive care 
unit (ICU) length of stay (LOS) in patients undergoing open-heart surgery.  
The three protocols were tight glycemic control (blood glucose levels 110-149 
mg/dl) via continuous intravenous infusion of insulin, conventional glycemic control 
(blood glucose levels 150-180 mg/dl) via continuous intravenous infusion of insulin, and 
standard glycemic control (blood glucose levels 150-180 mg/dl) via intravenous bolus 
injections of insulin.  
Specific aims.  
The specific primary aims of this study were to compare the effect of three 
intraoperative glycemic control protocols on:  
1.  Thirty-day postoperative wound infection rates in open-heart surgical patients; 
and  
2.  Procalcitonin and C-reactive protein levels in the immediate postoperative 
period (5 days) in open-heart surgical patients. 
The specific secondary aims of this study were to compare the effect of three 
intraoperative glycemic control protocols on:  
1.  Intraoperative blood glucose levels; 
2.  Intraoperative glycemic stability; and  
3.  Intensive care unit length of stay. 
Hypotheses for aim 1.  
The hypotheses for aim 1 are as follows: 
	  	  6	  
1.  It was hypothesized that patients undergoing open-heart surgery, who received 
a continuous intravenous insulin infusion for tight glycemic control (blood glucose 110-
149 mg/dl) during the intraoperative phase would demonstrate fewer 30 day sternal and 
harvest surgical site wound infections  compared to  patients who received continuous 
intravenous infusion of insulin for conventional glycemic control (blood glucose 150-180 
mg/dl) or standard glycemic control via intravenous bolus injections of insulin (blood 
glucose 150-180 mg/dl). 
2.  It was hypothesized that patients undergoing open-heart surgery, who received 
a continuous intravenous insulin infusion for tight glycemic control (blood glucose 110-
149 mg/dl) during the intraoperative phase would have lower procalcitonin levels and 
lower C-reactive protein levels in the first five days of the postoperative period  
compared to patients who received continuous intravenous infusion of insulin for 
conventional glycemic control (blood glucose 150-180 mg/dl) or standard glycemic 
control via intravenous bolus injections of insulin (blood glucose 150-180 mg/dl). 
Hypotheses for aim 2.  
The hypotheses for aim 2 are as follows: 
1.  It was hypothesized that patients undergoing open-heart surgery who received 
a continuous intravenous insulin infusion for tight glycemic control (blood glucose 110-
149 mg/dl) during the intraoperative period would have significantly lower blood glucose 
levels during this period  compared to patients who received continuous intravenous 
infusion of insulin for conventional glycemic control (blood glucose 150-180 mg/dl) or 
standard glycemic control via intravenous bolus injections of insulin (blood glucose 150-
180 mg/dl). 
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2.  It was hypothesized that patients undergoing open-heart surgery who received 
a continuous intravenous insulin infusion for glycemic control, whether tight control 
(blood glucose 110-149 mg/dl) or conventional control (blood glucose 150-180 mg/dl), 
during the intraoperative phase would have significantly improved glycemic stability in 
the intraoperative period  compared to  patients who received the standard glycemic 
control via intravenous bolus injections of insulin (blood glucose 150-180 mg/dl). 
3.  It was hypothesized that patients undergoing open-heart surgery who received 
a continuous intravenous insulin infusion for tight glycemic control (blood glucose 110-
149 mg/dl) during the intraoperative phase would demonstrate a shorter length of stay in 
the intensive care unit  compared to patients who received continuous intravenous 
infusion of insulin for conventional glycemic control (blood glucose 150-180 mg/dl) or 
standard glycemic control via intravenous bolus injections of insulin (blood glucose 150-
180 mg/dl). 
Definition of Terms 
The following terms were defined and used throughout the study. The study 
definitions were derived partially from their use in previous research and are established 
in open-heart surgery, glycemic control, and postoperative wound infection  
Intraoperative Tight Glycemic Control 
Intraoperative tight glycemic control was defined as the maintenance of blood 
glucose level between 110-149 mg/dl by means of a continuous intravenous infusion of 
regular insulin throughout the intraoperative period. 
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Intraoperative Conventional Glycemic Control 
Intraoperative conventional glycemic control was defined as the maintenance of a 
blood glucose level between 150-180 mg/dl by means of a continuous intravenous 
infusion of regular insulin throughout the intraoperative period.  
Intraoperative Standard Glycemic Control 
Intraoperative standard glycemic control was defined as the maintenance of blood 
glucose level between 150-180 mg/dl by means of bolus intravenous injections of regular 
insulin throughout the intraoperative period. 
Intraoperative Glycemic Stability 
Intraoperative glycemic stability was defined by the maintenance of blood glucose 
levels in the preset target ranges for each group, or normal blood glucose range, during 
the intraoperative period. Target ranges include 110-149 mg/dl for the tight glycemic 
control, 150-180 mg/dl for the conventional glycemic control, and for the standard 
glycemic control. Glycemic stability was considered achieved if blood glucose levels 
were maintained within the preset target range and/or in the normal range for blood 
glucose (80-110 mg/dl). Variation of abnormal blood glucose levels outside of the preset 
target range could occur as long as it was less than three consecutive blood glucose levels 
(< 1.5 hours).  Blood glucose levels were monitored and recorded every thirty minutes in 
the intraoperative period. 
Intraoperative Glycemic Instability 
Intraoperative glycemic instability was defined as three consecutive blood glucose 
levels that were abnormal and outside of the preset target ranges, whether above or below 
the limits during the intraoperative period. Target ranges included 110-149 mg/dl for the 
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tight glycemic control, 150-180 mg/dl for the conventional and standard glycemic 
control. Blood glucose levels were monitored and recorded every thirty minutes in the 
intraoperative period. 
Coronary Artery Bypass Graft Surgery 
Coronary artery bypass graft surgery (CABG) was defined as surgery performed 
with a median sternotomy incision using cardiopulmonary bypass (CPB). Myocardial 
preservation is provided by cardioplegic arrest. The procedure involves bypassing 
coronary blockages with a variety of conduits (Bojar, 2005). Coronary artery bypass graft 
surgery is used to augment restricted coronary blood flow, including collateral pericardial 
blood flow to epicardial arteries and implantation of the internal mammary artery (IMA) 
with unligated side branches into the left ventricular muscle. The technique involves a 
bypass to a narrowed or occluded epicardial coronary > 1 mm in diameter with a small 
diameter conduit (usually reversed saphenous vein or IMA) distal to the narrowed 
segment, with the proximal arterial inflow source being the ascending aorta (Mitchell, 
Shumway, Garman, & Siegel, 2004). 
Off-Pump Coronary Artery Bypass Graft 
Off-pump CABG was defined as a surgical procedure that completes 
revascularization of the heart without cardiopulmonary bypass. The surgery uses a 
median sternotomy incision with deep pericardial sutures to stabilize the heart allowing 
for positioning of the heart without hemodynamic compromise (Bojar, 2005). 
Cardiac Valve Surgery: Aortic Valve  
Aortic valve replacement was defined as a surgical procedure, on full CPB, 
performed through a median sternotomy. The rheumatic, stenotic valve, including aortic 
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annulus, is excised and all calcified areas are debrided to allow the prosthetic valve to be 
securely seated. After excision of the valve leaflets and debridement, the annulus is 
measured and appropriate valve prosthesis is placed. Interrupted sutures are placed 
through the annulus for its entire circumference, than passed through the sewing ring of 
the prosthesis. The prosthesis is lowered into the annulus and securely tied in place 
(Mitchell et al., 2004). 
Cardiac Valve Surgery: Mitral Valve   
Mitral valve surgery was defined as a surgical procedure, on full CPB, performed 
through a median sternotomy. The atrium, atrial appendage and mitral valve are inspected 
and a decision is made to repair or replace the valve. Repair of regurgitant valves used 
primarily by posterior leaflet problems is usually possible. Similarly, annular dilatation 
secondary to left ventricular enlargement is also usually possible by means of a ring 
annuloplasty. Valve replacement is performed after excising the valve leaflets and 
debridement, the annulus is rimmed with interrupted sutures, passed through the sewing 
ring of the valve prosthesis. The prosthesis is carefully positioned and the sutures are tied 
(Mitchell et al., 2004).  
Coronary Artery Bypass Graft/Valve Surgery 
Coronary artery bypass graft/valve surgery was defined as surgery that includes 
CABG surgery in conjunction with a valve repair or replacement. It is performed with a 
median sternotomy incision using cardiopulmonary bypass. Myocardial preservation is 
provided by cardioplegic arrest. The procedure involves bypassing coronary blockages 
with a variety of conduits (Bojar, 2005). The left internal thoracic artery is used as a 
pedicled graft to the left anterior descending artery and is supplemented by saphenous 
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vein grafts or radial artery grafts interposed between the aorta and coronary arteries 
(Bojar, 2005). In addition to the CABG surgery a valve repair or replacement is 
performed. The valve is replaced after excising the valve leaflets and debridement, the 
annulus is rimmed with interrupted sutures, passed through the sewing ring of the valve 
prosthesis. The prosthesis is carefully positioned and the sutures are tied (Mitchell et al., 
2004).  
Hypoglycemia 
Hypoglycemia was defined as a condition that occurs when blood glucose is 
lower than 70 mg/dl (ADA, 2012; Moghissi et al., 2009). Signs include hunger, 
nervousness, shakiness, perspiration, dizziness or light-headedness, sleepiness, and 
confusion. If left untreated, hypoglycemia may lead to unconsciousness. It is also known 
as an insulin reaction if induced by excessive doses of insulin (ADA, 2009). In this study 
the operational definition of hypoglycemia was defined as a blood glucose level of less 
than 70 mg/dl at any time during the intraoperative period or within the first six hours 
postoperatively. 
Superficial Incisional Surgical Site Infection  
Superficial incisional surgical site infection was defined according to the Center 
of Disease Control (CDC) and the National Healthcare Safety Network (NHSN) (Horan, 
Andrus, & Dudeck, 2008). A superficial incisional surgical site infection (SSI) must meet 
the following criterion: Infection occurs within 30 days after the operative procedure and 
involves only skin and subcutaneous tissue of the incision and the patient has at least one 
of the following  
• purulent drainage from the superficial incision;   
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• organisms isolated from an aseptically obtained culture of fluid or tissue from the 
superficial incision; and in addition at least 1 of the following signs or symptoms of 
infection: pain or tenderness, localized swelling, redness, or heat, and superficial 
incision that is deliberately opened by the surgeon and is culture positive or not 
cultured (A culture-negative finding does not meet this criterion); or 
• a diagnosis of superficial incisional SSI by the surgeon or attending physician (Horan 
et al., 2008).  
There are 2 specific types of superficial incisional SSI, they include:  
1) superficial incisional primary defined as a superficial incisional SSI that is 
identified in the primary incision in a patient who has had an operation with one 
or more incisions (chest incision for CABG surgery);  and 
2) superficial incisional secondary defined as a superficial incisional SSI that is 
identified in the secondary incision in a patient who has had an operation with 
more than one incision (donor site incision for CABG surgery) (Horan et al., 
2008). 
Deep Incisional Surgical Site Infection 
Deep incisional surgical site infection was defined according to the Center of 
Disease Control (CDC) and the National Healthcare Safety Network (NHSN) (Horan et 
al., 2008). A deep incisional SSI must meet the following criterion: Infection occurs 
within 30 days after the operative procedure if no implant is left in place or within one 
year if implant is in place and the infection appears to be related to the operative 
procedure, and involves deep soft tissues (fascial and muscle layers) of the incision. In 
addition, the patient must have at least one of the following:  
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• purulent drainage from the deep incision but not from the organ/space 
component of the surgical site;  
• a deep incision spontaneously dehisces or is deliberately opened by a 
surgeon and is culture-positive, or not cultured when the patient has at 
least one of the following signs or symptoms: fever (> 38◦C), or localized 
pain or tenderness; 
• an abscess or other evidence of infection involving the deep incision is 
found on direct examination, during reoperation, or by histopathologic or 
radiologic examination; or 
• a diagnosis of a deep incisional SSI by a surgeon or attending physician 
(Horan et al., 2008).  
There are 2 specific types of deep incisional SSI, they include: 
1. deep incisional primary defined as a deep incisional SSI that is identified 
in a primary incision in a patient who has had an operation with one or 
more incisions (chest incision for CABG surgery); and   
2. deep incisional secondary defined as a deep incisional SSI that is 
identified in the secondary incision in a patient who has had an operation 
with more than one incision (donor site incision for CABG surgery) 
(Horan et al., 2008).  
Potential Infectious State 
Potential infectious state was defined as one of the following: 1) Persistent 
elevations of procalcitonin (PCT) > 1.5 ng/ml past the second postoperative day; 2) 
sustained or increased PCT blood levels (> 1 ng/ml) past the fourth postoperative day; 3) 
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a persistent elevated C-reactive protein (CRP) level of > 100 mg/L past the fourth 
postoperative day; or 4) a PCT blood level > 1 ng/ml combined with a CRP blood level > 
100 mg/L past the fourth postoperative day.  
Perioperative Period 
Perioperative period was defined as the time of arrival to the pre-anesthesia 
holding area through the operative period and the postoperative or intensive care unit 
(ICU) period, ending upon transfer out of the ICU. It was measured in days. 
Intraoperative Period 
Intraoperative period was defined as the time of arrival to the operating room until 
the departure of the operating room, measured in minutes.  
Length of Intensive Care Unit Stay 
Length of intensive care unit stay was defined as the arrival to the intensive care 
unit from the operating room suite until discharge to the ward, measured in days. A 
qualifier was noted if surgeons document that the patient was medically ready to be 
transferred from the ICU to the ward, but logistically the transfer could not be completed. 
This may have occurred when hospital beds on the transferring wards were full and not 
capable of receiving transferring patients. 
Significance to Nurse Anesthesia 
The literature reflects that patients who experience postoperative wound 
infections after open-heart surgery are at greater risk for increased morbidity and 
mortality. Postoperative wound infections also increase hospital LOS and increase costs.  
Because of the high morbidity and mortality associated with open-heart postoperative 
	  	  15	  
infections, and the financial cost to institutions, there is a need to identify ways to reduce 
the incidence of these infections.  
Previous studies investigating surgical site infections in open-heart surgery have 
suggested a link between poor glycemic control and surgical infection rates. Many of 
these studies are observational designs without randomization or control groups. 
Research investigating the perioperative glycemic control is limited, and results of these 
studies are divergent. It is uncertain if tight glycemic control in the perioperative period is 
beneficial and safe in open-heart surgery. Before implementation of practice protocols for 
glycemic control can be considered for evidence-based practice, further studies, in the 
form of randomized controlled trials, are needed. Research is needed to investigate if the 
relationship between hyperglycemia and surgical site infection is a causal relationship, 
and determine what effect tight glycemic control has on postoperative surgical wound 
infections. Investigation of tight glycemic control in the diabetic population verses the 
non-diabetic population related to postoperative infections also needs to be examined, as 
well as the identification of blood glucose ranges that produces optimal patient outcomes 
in both the diabetic and non-diabetic patients. Finally, there is a need to determine if a 
continuous infusion of intravenous insulin is more effective in glycemic control than 
intravenous bolus injections of insulin to control blood glucose levels during the 
perioperative period.  
This study attempted to explore glycemic control, specifically in the 
intraoperative period, by the delivery of varied insulin protocols, and the effects on 
postoperative wound infection in open-heart patients. The specific aim of this study was 
to compare the effect of three glycemic control protocols (tight, conventional, and 
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standard) on postoperative surgical wound infections, procalcitonin and C-reactive 
protein levels. Secondary outcomes that were investigated included the effect of three 
glycemic control protocols on blood glucose levels intraoperatively, glycemic stability 
intraoperatively, and ICU LOS. The next chapter presents the literature supporting the 
study of glycemic control on surgical site infection rates in patients undergoing open-
heart surgery.  
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Chapter Two 
Review of Literature 
This chapter presents a review of empirical literature pertinent to intraoperative 
glycemic control on surgical site infection rates in patients undergoing open-heart 
surgery. The literature review focused on the incidence and impact of surgical site 
infections in open-heart surgical patients, biomarkers currently utilized to identify 
surgical site infections, the influence of hyperglycemia and diabetes in surgical site 
infections, and current studies related to glycemic control in the postoperative, 
perioperative and intraoperative period. Existing gaps in research to date were also 
reviewed.  
Databases utilized for literature search included: Cumulative Index to Nursing and 
Allied Health Literature (CINAHL); PubMed; Cochrane Database; and MD Consult. 
Search terms for glucose included “blood glucose”, “blood glucose level”, “glycemic 
control”, “hyperglycemia”, and “hypoglycemia”. Search terms for infection included 
“deep sternal wound infection (DSWI)”, “harvest site infection (HSI)”, and “surgical site 
infection (SSI)”. Search terms for open-heart surgery included “cardiac surgery”, “open-
heart surgery”, “coronary artery bypass grafting (CABG)”, “cardiovascular surgery”, and 
“cardiac valve surgery”. Search terms for glycemic control intervention included “insulin 
infusion”, “insulin drip”, “glucose-insulin-potassium drip”, “insulin protocols”, and 
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“insulin intervention”. Search terms for biomarkers of infection included “infectious 
biomarkers”, “C-reactive protein”, “procalcitonin”, and “postoperative markers of 
infection”.  
Published studies examining postoperative wound infections and open-heart 
surgical patients with diabetes or hyperglycemia were found primarily in medical 
journals, specifically, the specialty areas of endocrinology, cardiothoracic surgery and 
anesthesiology.  The search was limited to adult human studies specifically looking at 
blood glucose levels, in the pre-, intra- and postoperative period; and wound infections in 
the cardiac surgical patient. While cardiovascular surgery was the major focus of this 
search, other studies related to glycemic control in the critically ill were reviewed and 
incorporated.  Research studies were further restricted to those published in the English 
language and had a publication date of 1997 or later.   
Incidence of Surgical Site Infection 
The incidence and impact of surgical site infection (SSI) in open-heart surgical 
patients has been studied at length (Al-Zaru, AbuAlRub, & Musallam, 2011; Ariyaratnam 
et al., 2010; Baillot et al., 2010; El Oakley et al., 1997; Fowler et al., 2005; Hollenbeak et 
al., 2000; Lola et al., 2011; Mannien et al., 2011; Matros et al., 2010; Olsen et al., 2002; 
Paul et al., 2007; Ridderstolpe, Granfeldt, Ahlfeldt, & Rutberg, 2001; Rosmarakis et al., 
2007; Tokmakoglu, 2010; Vogel, Dombrovskiy, & Lowry, 2010 & Zerr et al., 1997).  
The National Nosocomial Infections Surveillance (NNIS) monitors reported trends in 
health care associated infections in participating United States acute care hospitals. 
Surgical site infections have been estimated by NNIS to occur in approximately 4-16% of 
all hospitalized patients (NNIS, 2004). The CDC estimates that 1.7 million healthcare 
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associated infections occur annually, of which 290,485 are surgical site infections (Scott, 
2009). The estimated cost of SSIs range from $11,874 to $41,559 per infection and cost 
$3.45-10 billion per year nationally in the USA (Al-Zaru et al., 2011; Scott, 2009).  
Mortality associated with healthcare associated infections in U.S. hospitals is estimated at 
98,987; of these 8,205 were related to SSIs (Klevens et al., 2007).   
When open-heart surgery was evaluated, the National Healthcare Safety Network 
(NHSN) reported an overall infection rate of sternal and harvest site wounds of 
approximately 0.35-8.5% for patients with a cardiac risk index of zero to three, 
respectively (Edwards et al., 2009). The NNIS risk index is operation-specific, and 
applied to prospectively collected surveillance data (Mangram, Horan, Pearson, Silver, & 
Jarvis, 1999). The index values range from 0 to 3 points and are defined by three 
independent and equally weighted variables (Mangram et al., 1999). One point is scored 
for each of the following when present: 1) American Society of Anesthesiologists (ASA) 
Physical Status Classification of greater than 2; 2) either contaminated or dirty/infected 
wound classification; and 3) length of operation in excess of T hours, where T is the 
approximate 75th percentile of the duration of the specific operation being performed 
(Mangram et al., 1999). Studies reflect the incidence of mediastinitis or deep sternal 
wound infection (DSWI) post open-heart surgery ranges 0.4-2.7% (Ariyaratnam et al., 
2010; Baillot, et al., 2010; El Oakley et al., 1997; Fowler et al., 2005; Hollenbeak et al., 
2000; Lola et al., 2011; Mannien et al., 2011; Matros et al., 2010; NNIS, 2004; Olsen et 
al., 2002; Ridderstolpe et al., 2001; Rosmarakis et al., 2007; Tokmakoglu, 2010; Vogel et 
al., 2010; Zerr et al., 1997). 
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Risk Factors Associated with Surgical Site Infection 
Many studies investigated SSIs related to CABG surgery in an attempt to identify 
risk factors for SSI. Related risk factors included a diagnosis of diabetes mellitus 
(Ariyaratnam et al., 2010; Borger et al., 1998; Harrington et al., 2004; Ji et al., 2009; Lola 
et al., 2011; Paletta et al., 2000; Spelman et al., 2000; Toumpoulis, Anagnostopoulos,  
DeRose, & Swistel, 2005; Vuorisalo et al., 1998), obesity (Ariyaratnam et al., 2010; 
Olsen et al., 2002; Harrington et al., 2004), advanced age exceeding 65 years 
(Ariyaratnam et al., 2010; Borger et al., 1998; Ji et al., 2009), male gender (Borger et al., 
1998; Spelman et al., 2000), female gender (Paletta et al., 2000; Harrington et al., 2004), 
chronic obstructive pulmonary disease (COPD) (Al-Zaru et al., 2011; Ariyaratnam et al., 
2010) and renal dysfunction (Toumpoulis et al., 2005).  The predominant risk factors that 
were identified for SSIs in the open-heart patient included obesity and diabetes mellitus 
diagnosis. These studies will be described in detail in the next section as they also 
investigated the impact of SSIs.  
Impact of Surgical Site Infections 
Studies that investigated the impact of the infectious process on the outcome 
variable mortality in the open-heart surgery suggested infection was associated with 
increased mortality (Ariyaratnam et al., 2010; Baillot et al., 2010; Coskun, Aytac, 
Aydinli, & Bayer, 2005; El Oakley et al., 1997; Fowler et al., 2005; Hollenbeak et al., 
2000; Lola et al., 2011; Olsen et al., 2002; Paul et al., 2007; Rosmarakis et al., 2007; 
Tokmakoglu, 2010; Vogel et al., 2010; Zerr et al., 1997). One study outcome showed 
infected patients had a decreased mortality when compared to patients without infection 
(Ridderstolpe et al., 2011). They attributed this decreased mortality to the additional 
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surveillance methods and aggressive treatment management in patients with infection, 
while the patients without infections may not have been followed as closely. Several 
studies reviewed the impact of infection on length of stay (LOS) and all studies suggested 
the presence of a postoperative SSI increased hospital and/or intensive care unit (ICU) 
LOS (Al-Zaru et al., 2011; Coskun et al., 2005; El Oakley et al., 1997; Fowler et al., 
2005; Graf et al., 2009; Hollenbeak et al., 2000; Paul et al., 2007; Rosmarakis et al., 
2007; Vogel et al., 2010).  
Deep sternal site infection or mediastinitis, post open-heart, is associated with 
substantial morbidity and with a mortality rate as high as 34.5% (Ariyaratnam et al., 
2010; Baillot et al., 2010; Coskun et al., 2005; El Oakley et al., 1997; Fowler et al., 2005; 
Hollenbeak et al., 2000; Lola et al., 2011; Olsen et al., 2002; Paul et al., 2007; 
Ridderstolpe et al., 2001; Rosmarakis et al., 2007; Vogel et al., 2010; Zerr et al., 1997). 
Deep chest surgical site infections following open-heart surgery were also associated 
with significant increases in LOS, and hospitalization costs (Coskun et al., 2005; El 
Oakley et al., 1997; Fowler et al., 2005; Graf et al., 2009; Hollenbeak et al., 2000; Paul et 
al., 2007; Rosmarakis et al., 2007; Vogel et al., 2010).   
In a Swedish retrospective study of 3,008 adults, Ridderstolpe et al. (2001) 
investigated the incidence of superficial sternal wound complications and deep sternal 
infections or mediastinitis after open-heart surgery. They aimed to identify preoperative, 
intraoperative and postoperative factors that could influence the risk of SSI after open-
heart surgery (Ridderstolpe et al., 2001). Patients were followed from 1996 through 1999 
for the identification of infection by means of telephone questionnaires to patients at 2 
weeks and 6 weeks postoperatively, as well as follow up visits with the respective 
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patient’s cardiologists at 2 and 6 months postoperatively (Ridderstolpe, et al., 2001). 
Forty-two preoperative, intraoperative and postoperative variables were evaluated and 24 
were found to be associated with increased risk of SSIs by univariate analysis 
(Ridderstolpe et al., 2001). Follow up multivariate analysis identified age 75 years, 
obesity, insulin dependent diabetes, smoking, peripheral vascular disease, a New Your 
Heart Association NYHA classification of III-IV, use of bilateral internal mammary 
arteries for grafts, and prolonged ventilator support as independent predictors of 
superficial sternal wound complications and deep sternal wound complications 
(Ridderstolpe et al., 2001).  
Ridderstolpe et al. (2001) found a sternal wound infection rate of 9.7%, with 
patients that underwent CABG surgery experiencing the highest rate of infection 
(10.6%), followed by CABG with valve combined surgery (8.4%), and cardiac valve 
surgery yielding the lowest rate of infection (7.2%). The researchers also revealed that 
superficial wound complication occurred in 194 patients (6.4%), deep sternal wound 
infections occurred in 47 patients (1.6%), and 50 patients (1.7%) experienced 
mediastinitis (Ridderstolpe et al., 2001). The impact of infection in this study revealed a 
30-day mortality rate of 2.7% for patients without sternal wound complications and 0.7% 
for patients with sternal wound complication. Of the patients that experienced a sternal 
wound complication, the mortality rate was 0.5% for superficial sternal wound 
complications and 1.0% for deep sternal infections/mediastinitis (Ridderstolpe et al., 
2001). The one-year mortality rate was 4.8% for patients without sternal wound 
complications and 3.8% for those subjects with sternal wound complications, and while 
not statistically significant, it is interesting that mortality was lower for patients who 
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suffered a sternal wound infection. The researchers attributed the lower mortality rate for 
infected subjects to dedicated follow-up of patients, earlier recognition of infection, and 
aggressive treatment (Ridderstolpe et al., 2001). Limitations of the study included a 
retrospective design and single site study.  
Paul et al. (2007) conducted a prospective observational study of 809 consecutive 
patients undergoing CABG surgery, with and without cardiopulmonary bypass (CPB), 
and CABG valve combination surgery, with a purpose to assess the ability of the NNIS 
risk index, the Euro SCORE, and the Society of Thoracic Surgeons (STS) risk score to 
predict infection and mortality after open-heart surgery. Surveillance for infection 
revealed an overall rate of SSI at 3.6 % (29/809) (Paul et al., 2007). Thirty-four percent 
of these infections were diagnosed after discharge, and 10% were diagnosed more than 
30-days post discharge (Paul et al., 2007). Results of the study implied that the NNIS risk 
index only provided moderate discrimination for infection, and a poor ability to stratify 
patients into infection risk group (Paul et al., 2007). The researchers found the Euro 
SCORE predicted infection, 30-day mortality, and 6-month mortality rate with good 
discrimination (Paul et al., 2007). The preoperative and intraoperative STS risk scores 
showed good discrimination for SSI and excellent discrimination for early and late 
mortality (Paul et al., 2007). Results of multivariate analysis revealed COPD, an 
operation combined with CABG, and diabetes mellitus were significantly associated with 
SSI (Paul et al., 2007).  
Hospital LOS was greatly increased in subjects that experienced a SSI. Subjects 
with a diagnosed SSI had average hospital LOSs of 27+ 19.9 days compared with 7.3 + 
7.4 days for subjects without a SSI (Paul et al., 2007). Six-month all-cause mortality rates 
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were 34.5% in subjects with a SSI compared to 7.6% for subjects without a SSI (Paul et 
al., 2007). Limitations of the study included a single-center study, small cohort of 
patients with infection, and lack of randomization (Paul et al., 2007).  
A five-year multicenter study conducted in the Netherlands described the Dutch 
surveillance methods for SSI post open-heart, and results of data collected between 2002 
and 2007 (Mannien et al., 2011). The study aimed to identify the feasibility of surgical 
site infection surveillance as well as identify patients at high risk for the development of 
SSI after cardiothoracic surgery (Mannien et al., 2011). The study incorporated 
surveillance of surgical site infections from 8 hospitals on 4,066 patients undergoing 
CABG surgery, valve surgery or a combination of CABG surgery with concomitant valve 
surgery (Mannien et al., 2011). The study surveillance period included post discharge 
surveillance period of 45 days. Registration of sternal SSI within the 45-day period was 
mandatory but registration of any harvest SSIs was voluntary (Mannien et al., 2011).  
In total, 4,066 surgical procedures and 183 SSIs were registered (Mannien et al., 
2011). Fifty-three deep sternal SSIs (1.3%), and 44 superficial sternal SSIs (1.1%) were 
identified, revealing a rate of 2.4% for sternal SSIs (Mannien et al., 2011). Harvest sites 
for CABG surgery were performed in 2,691 patients, of which 3.2% (86/2691) developed 
a SSI, thirteen deep infections (0.5%) and 73 superficial (2.7%) (Mannien et al., 2011). 
Of note, sixty-one percent of all SSIs were recorded after discharge from medical centers 
(Mannien et al., 2011).  
Utilizing multilevel multivariate analysis, the significant risk factors identified for 
sternal SSIs were re-thoracotomy (odds ratio [OR] = 5.2, 95% CI [2.5, 10.6], p = .001); 
diabetes (OR = 2.5, 95% CI [1.1, 5.5], p = .03); preoperative LOS > 3 days (OR = 2.1, 
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95% CI [1.1, 4.1], p = .04); and obesity (OR = 2.0, 95% CI [1.0, 3.8]),  p = .04 (Mannien 
et al., 2011). Prolonged extracorporeal circulation (ECC) greater than 123 minutes was 
the only identified risk factor for the development of harvest SSIs (OR= 1.8, 95% CI [0.9, 
3.7]),  p = .08 (Mannien et al., 2011). Limitations of the study were related to remarkable 
differences in patient and procedure characteristics between hospitals, including use of 
ECC, median time of ECC, use of bilateral thoracic arteries, and patient body mass index 
(Mannien et al., 2011). Harvest site infection rates post patient discharge may have been 
underestimated since registration of these infections were voluntary and three hospital did 
not volunteer this data (Mannien et al., 2011).  
Vogel et al. (2010) identified that infection rates for CABG surgery increased 
significantly with increased preoperative LOS. The investigators sought to evaluate the 
association of in-hospital delay of elective procedures and the subsequent impact on 
infectious complications after surgery. The study observed infection rates for three 
surgical procedures CABG surgery, colon resection, and lung resection (Vogel et al., 
2010).  The study utilized a nationwide inpatient sample queried between 2003 and 2007, 
and patients who developed a postoperative infectious complication were identified via 
ICD-9 CM Codes. A total of 87,318 CABG surgeries were evaluated (Vogel et al., 2010). 
Results of the study revealed total infection rates significantly increased after 
elective surgery delays in all three surgeries. Infection rates for CABG surgery increased 
each day surgery was delayed ranging from an infection rate of 6.68% when surgery was 
delayed one day to 18.24% when surgery was delayed 6-10 days (Vogel et al., 2010). 
Trends for increasing infections with increase preoperative LOS were significant for 
pneumonia and sepsis for all procedures (p < .001); and urinary tract infections and SSIs 
	  	  26	  
significantly increased after CABG surgery (Vogel et al., 2010). Postoperative hospital 
mortality rate was also greater, and mean cost of hospital stay increased with increased 
preoperative LOS in all procedures (Vogel et al., 2010). Mean hospital costs for CABG 
surgery increased every day surgery was delayed, costing $28,962 for surgery delayed 1 
day to $42,055 when surgery was delayed 6-10 days; p < .001 (Vogel et al., 2010).  
El Oakley et al. (1997) conducted an observational risk analysis to identify 
variables significant for developing postoperative mediastinitis in patients that underwent 
CABG surgery in a four-year period. Twenty-one out of 4,043 consecutive patients that 
underwent open-heart surgery with CPB developed mediastinitis (0.4%), valve 
endocarditis occurred in 0.1% and superficial wound infection occurred in 3.3% of cases 
(El Oakley et al., 1997). Results of multivariate regression analyses identified that 
diabetes, obesity, re-exploration for bleeding, blood transfusions in excess of 3 units, and 
associated leg wound infections increased the risk of mediastinitis/DSWIs (El Oakley et 
al., 1997). The impact of mediastinitis included significantly higher hospital mortality 
rates as compared to those who had no mediastinitis (14% vs. 3.8%), p < .05 (El Oakley 
et al., 1997). Mean hospital LOS was longer in the patients with mediastinitis compared 
to patients with no infection (36 days vs. 7 days), p < .01 (El Oakley et al., 1997).  
In a retrospective study investigating postoperative outcomes in obese females 
undergoing CABG surgery, Tokmakoglu (2010) found no difference in infection rates 
among females with normal body mass index (BMI) versus morbidly obese females. The 
study covered a period of four years and reviewed 427 female patients were allocated into 
three groups: 1) severe obese with a BMI > 35 kgm2; 2) obese patients with a BMI > 30 
kgm2; 3) normal-slightly obese with a BMI < 30 kgm2 (Tokmakoglu, 2010).  
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The study revealed an overall infection rate of 9.6% and an overall hospital 
mortality rate of 0.7%, yet no statistical difference was noted between the three groups 
for infection or mortality (Tokmakoglu, 2010). The study did find that while the overall 
re-hospitalization rate was 10%, subjects with a BMI > 35 kgm2 had significantly higher 
readmission rate (16.1%) than females with a BMI < 35 kgm2 (9.8%) and a BMI < 30 
kgm2 (6.5%),  p = .02 (Tokmakoglu, 2010). There were a greater number of patients that 
had a diagnosis of diabetes in the group of subjects with a BMI > 35, and they 
experienced more urgent surgeries than the other two groups, which may have influenced 
results since this difference was not controlled for (Tokmakoglu, 2010).  
Using a prospective design Ariyaratnam et al. (2010) investigated the risk factors 
and mortality associated with DSWI.  Data was collected on 7,602 patients undergoing 
CABG with or without valve surgery, between April 1999 and September 2009 
(Ariyaratnam et al., 2010). The study used the 13 STS risk-scoring variables in a logistic 
regression analysis to identify factors that increased DSWI (Ariyaratnam et al., 2010).  
Forty-four (0.59%) patients developed DSWI, and experienced a higher mortality rate 
when compared to patients without DSWI (9.6% vs. 2.6%),  p = .03 (Ariyaratnam et al., 
2010). Logistic regression identified age (OR=1.055, 95% CI [1.016, 1.095], p = .005), 
BMI (OR = 1.076, 95% CI [1.015, 1.141, p = .01), diabetes (OR = 2.00, 95% CI [1.07, 
3.75], p = .03), and COPD (OR = 2.47, 95% CI [1.24, 4.92],  p = .01) as significant 
independent determinants of DSWI from the variables considered (Ariyaratnam et al., 
2010).  
A prospective observational study investigating the risk factors for postoperative 
infections following open-heart surgery was reported by Lola and colleagues (2011). One 
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hundred seventy-two patients that underwent open-heart surgery over a 2 year period 
were evaluated for preoperative, intraoperative and postoperative variables that may 
increase risk for postoperative wound infections (Lola et al., 2011).  
The overall incidence of infection was 13.95% (24/172), including eight 
superficial sternal wound infections (4.65%), five central line infections (2.9%), four 
incidences of pneumonia (2.32%), nine incidences of bacteremia (5.23%), one urinary 
tract infection (0.58%) and one harvest surgical site infection (0.58%; Lola et al., 2011).  
The total mortality attributed to infection in the study was 3.48% (6/172), and mortality 
among subjects diagnosed with infection was 25% (6/24; Lola et al., 2011). 
In a backward stepwise multivariable logistic regression analysis Lola and 
colleagues identified diabetes mellitus (OR = 5.92, 95% CI [1.56, 22.42],  p = .009); 
duration of mechanical ventilation (OR = 1.30, 95% CI [1.005, 1.69],  p = .046); 
development of severe complications in the ICU (OR = 18.66, 95% CI [3.36, 103.61],  p 
= .001); and re-admission to the CVICU (OR = 8.59, 95% CI [2.02, 36.45],  p = .004) as 
independent risk factors associated with development of nosocomial infection after open-
heart surgery (Lola et al., 2011). Limitations to the study included an observational 
design and the small sample size in a single institution.  
Fowler et al. (2005) utilized the STS National Cardiac Database and analyzed 
331,429 CABG surgeries to identify the frequency of major infection, identify 
determinants of major infection, and to convert these determinants into a bedside scoring 
system to estimate a patient’s risk of major infection after CABG surgery. Two logistic 
regression models were developed to estimate the risk of major infection after CABG 
surgery, one with preoperative patient characteristics, and the other with preoperative 
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patient characteristics as well as intraoperative variables (Fowler et al., 2005). Major 
infection occurred in 3.51% (11,636/331,429) of patients, including an incidence of 
mediastinitis of 25.1%, saphenous harvest site infections 32.6%, and sepsis incidence of 
35% (Fowler et al., 2005). Patients with major infection had significantly higher 
mortality (17.3% vs. 3.0%), p < .01 and postoperative LOS > 14 days (47% vs. 5.9%), p 
< .01 than patients without major infection (Fowler et al., 2005).  
Both the preoperative model and the combined model successfully discriminated 
between high and low risk patients (Fowler et al., 2005). A simplified risk scoring system 
of 12 variables accurately predicted risk for major infection (Fowler et al., 2005). Several 
variables were identified as particularly important risk factors including morbid obesity 
(BMI > 40 kgm2), CPB time > 300 minutes, placement of an intra-aortic balloon pump, 
and the presence of 3 or more distal anastomoses (Fowler et al., 2005). Diabetes mellitus 
and obesity were identified as independent risk factors for major infection in the 
preoperative model (Fowler et al., 2005). A limitation included the use of broader 
definitions for infection, and a potential for underreported infectious complications, 
including infections detected post discharge, or more than 30 days after surgery (Fowler 
et al., 2005). Due to the nature of a retrospective analysis, the study was unable to control 
for, or even have the ability to process detailed data of the surgical case, such as type and 
timing of antibiotics, or the use of insulin infusions for glycemic control (Fowler, et al., 
2005).  
Mediastinitis in diabetic patients after open-heart surgery increases operative 
mortality two to threefold (Zerr et al., 1997; Olsen et al., 2002). Olsen et al. (2002) 
sought to determine risk factors for deep and superficial chest wound infections after 
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CABG surgery to develop a predictive model. The researchers retrospectively analyzed 
data collected on 1,980 consecutive patients undergoing CABG surgery from 1996 to 
1999, using the STS database (Olsen et al., 2002).  They found deep chest infections 
occurred in 1.9% (37/1,980), and superficial chest SSIs occurred in 2.3% (46/1,980) of 
patients (Olsen et al., 2002). Multivariate logistic regression revealed obese, diabetic 
patients had a 7.7-fold increased risk of deep chest infections after controlling for intra-
aortic balloon pump use, and postoperative transfusions (Olsen et al., 2002). Independent 
risk factors for superficial SSIs included obesity, diabetes in persons 65 years of age or 
older and current smoking history (Olsen et al., 2002).  Patients with deep chest 
infections suffered an increased post one-year mortality rate compared with that seen in 
uninfected patients (21.6% vs. 7.1%, p = .004). However, this was not noted in patients 
with superficial chest infections (15.2% vs. 7.1%),  p = .75 (Olsen et al., 2002).   
Hollenbeak et al. (2000) examined how deep chest surgical SSIs following CABG 
surgery impacted hospital inpatient LOS, costs, and mortality. They reported a 2.7% 
(41/1,519) deep chest SSI rate in patients who underwent CABG and CABG/valve 
surgery over a two-year period. This prompted an aggressive surveillance protocol and 
the collection of clinical data to determine impact, costs and risk factors. A retrospective 
review of all CABG patients who developed deep chest infection (n = 41) was compared 
to a set of control patients (n = 160) systematically selected as every tenth uninfected 
CABG patient (Hollenbeak et al., 2000). Variables that significantly increased the risk of 
deep chest SSI included obesity, renal insufficiency, connective tissue disease, re-
exploration for bleeding, and antibiotic prophylaxis greater than 60 minutes before 
incision (Hollenbeak et al., 2000).  
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The one-year mortality rate was 22% for patients with deep sternal SSIs versus 
0.6% for uninfected patients (p < .001), and hospital LOS was increased by 20 days for 
infected patients (p < .001). Patients who developed deep sternal SSI incurred $20,012 in 
additional costs in the first year (p < .001). Infected patients who died incurred on 
average three times the cost compared to infected patients who survived (p = .034) 
(Hollenbeak et al., 2000). Limitations of the study included a single center study with a 
retrospective observational design.  
Similarly, Coskun et al. (2005) found an increase in hospital LOS, hospital costs 
and mortality rates when patients suffered infectious complications. Coskun et al. (2005) 
sought to determine the mortality rate, LOS, and cost of sternal SSIs for 176 patients that 
underwent CABG surgery from January 1999 to December 2002. The study utilized an 
active prospective and laboratory based surveillance program to identify patients with 
nosocomial infections (Coskun et al., 2005). The sample included 52 patients with deep 
sternal SSIs, 36 patients with superficial sternal SSIs, and 88 in a randomly selected 
uninfected control (Coskun et al., 2005). Mortality rates in the deep sternal SSI group 
was significantly greater (19.2%, p < .01) when compared to the superficial sternal SSI 
group (0%) and the uninfected control group (4.5%). Hospital LOS was significantly 
different between groups, with the deep sternal SSI group having the greatest compared 
to the superficial sternal SSI group (47 days vs. 33 days, p  < .001), respectively, and 
uninfected group (47 days vs. 12 days),  p < .01 (Coskun et al., 2005). Identified 
limitations of the study were a single site center study and an observation study design.  
A European case-control study conducted by Graf et al. (2009) examined the 
economic aspects of DSWIs comparing the ICU and hospital LOS, as well as the total 
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costs for patients undergoing CABG surgery depending upon the occurrences of 
subsequent DSWI. Two control patients without any signs or symptoms of an infection 
were matched to each case by 1) type of surgery according to their diagnosis related 
group (DRG), 2) age + 5 years, 3) gender, and 4) duration of preoperative hospital LOS + 
2 days (Graf, et al., 2009). Seventeen CABG patients with DSWI and 34 matched 
controls were included during January 2006 and March 2008 (Graf et al., 2009). Findings 
reflected that LOS in the hospital was doubled and costs almost tripled with the 
development of a DSWI,  p < .001 (Graf et al., 2009). 
Infectious complications have been reported with off-pump CABG surgery as 
well as with CABG surgery with CPB. Rosmarakis et al. (2007) conducted a non-
interventional prospective cohort study including 360 subjects to evaluate the frequency, 
characteristics, and risk factors of nosocomial infections. The study also examined the 
role of laboratory tests C-reactive protein (CRP) and procalcitonin (PCT), and the role of 
sternal wound cultures in the diagnosis of sternal wound infection (Rosmarakis et al., 
2007). Patients were followed for six months postoperatively and infectious 
complications were recorded (Rosmarakis et al., 2007).  Eighteen of the 360 subjects 
(5%) developed postoperative infections including 1.9% sternal wound infections, 1.7% 
superficial wound infections, 0.3% mediastinitis, 1.4% pneumonia, and 1.1% bacteremia 
(Rosmarakis et al., 2007). C-reactive protein levels increased significantly from the day 
before surgery to postoperative day 1 through 3 in patients with and without infection 
(Rosmarakis et al., 2007).  However, CRP levels measured on postoperative day one and 
two after CABG without CPB, were significantly higher in patients with postoperative 
infection compared to patients without infection,  p  < .05 (Rosmarakis et al., 2007). 
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Procalcitonin levels increased significantly from the day before surgery to postoperative 
day 1 and 2 after surgery in patients with and without infection (Rosmarakis et al., 2007). 
Procalcitonin levels measured on postoperative day (POD) 1-3, in patients, that 
underwent CABG without CPB, were significantly higher in patients with postoperative 
infections compared to patients without infection, p < .05 (Rosmarakis et al., 2007).  The 
investigators also found PCT to be superior to CRP in discriminating infection after 
open-heart surgery.  
A backward stepwise multivariate logistic regression model revealed that 
independent risk factors of postoperative infection included a history of major nervous 
system disorder, history of left ventricular heart failure, an emergent operation, blood 
transfusions in ICU, and duration of central venous catheter placement in ICU 
(Rosmarakis et al., 2007). The mortality rate for patients with infection was 11.1% 
compared to 0.6% for patients without infection, p < .05 (Rosmarakis et al., 2007).  
Limitations of this study included a single site center study, and a small sample size of 
infected patients (18) that may not reflect true statistical association between a variable 
and the outcome of interest (Rosmarakis et al., 2007). Many cases were also missing CRP 
and PCT values which may have altered results of the study (Rosmarakis et al., 2007).  
In contrast, Singhal, Mahon, and Riordan (2010) found no difference in mortality, 
stroke, renal dysfunction, atrial fibrillation, or DSWI between off pump and on pump 
CABG surgical patients. They did find that off pump CABG surgical patients received 
less blood transfusions and required less inotropic support than patients with CPB 
(Singhal et al., 2010).  
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While the incidence of DSWI continues to occur, Matros et al. (2010) 
demonstrated a significant reduction in DSWI incidence the last 5 years of a 15-year 
study period.  Matros et al. (2010) conducted a retrospective longitudinal analysis, and 
reviewed all median sternotomies performed at a single institution from 1991 through 
2006.  Two cohorts were separated into periods from 1992 through 2001 and 2002 
through 2006 to identify longitudinal trends in risk factors for DSWI (Matros et al., 
2010). Univariate and matched multivariable analyses were performed (Matros et al., 
2010).  Overall, the study population had increased comorbidities associated with DSWI 
including obesity, diabetes, and advanced age (Matros et al., 2010).  The overall DSWI 
rate was 1.35% (285/21,000), with a noted reduction in infection rates from 1.57% to 
0.88% in the latter 5-year period (Matros et al., 2010). The rate of DSWI among the 
patients with diabetes decreased from 3.2% to 1.0% in the last 5 years (Matros et al., 
2010). Multivariable analysis revealed a diagnosis of diabetes and smoking, while risk 
factors in the first cohort, were not risk factors in the second cohort (Matros et al., 2010).   
Prolonged CPB time was the only identified risk factor independently associated with 
DSWI for the entire study period (Matros et al., 2010). Limitations of the study included 
the longitudinal design opening concerns of practices changes over time.  
Baillot et al. (2010) examined the outcome of patients with DSWI treated with 
vacuum-assisted closure (VAC) therapy as a bridge to sternal osteosynthesis with 
horizontal titanium plate fixation. Over a 15-year period (1992-2007) a consecutive 
cohort of patients were divided into conventional (1992-2001) and contemporary (2002-
2007) groups. Retrospective data in the conventional group (non-VAC) received a 
treatment of debridement/drainage with primary course and irrigation (n = 118), or 
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debridement/drainage, open packing followed by pectoralis myocutaneous flaps (n = 81). 
The contemporary group was a prospective design in which subjects received a variety of 
treatments including non-VAC and pectoralis myocutaneous flaps (n = 24), VAC 
treatment and pectoralis myocutaneous flap (n = 33), VAC and osteosynthesis and 
pectoralis myocutaneous flap (n = 92), or treatment of the VAC therapy alone (n = 125) 
(Baillot et al., 2010).   
Results of the Baillot study revealed a 1.1% DSWI rate overall with 0.9% in the 
first conventional period and 1.4% in the second contemporary period, p = .001 (Baillot 
et al., 2010).  Hospital mortality was 10.25% overall in the study with no statistical 
difference between groups (Baillot et al., 2010). However, it was noted that VAC therapy 
(n = 125) was associated with a lower mortality (4.8% vs. 14.1%), p = .001 (Baillot et al., 
2010). Risk factors identified for DSWI included prolonged intubation in the ICU, use of 
bilateral internal thoracic artery grafting, diabetes, reoperation for bleeding and BMI > 30 
kgm2 (Baillot et al., 2010).  
Studies have shown that the harvest site or donor site is a common surgical site 
infection associated with CABG surgery, with rates reported as high as 35% (Jonkers et 
al., 2003; Olsen et al., 2003; Rosenfeldt et al., 2003; Swenne, Lindholm, Borowiec, & 
Carlsson, 2004). Surgical site infections may have a delayed diagnosis up to 30 to 90 
days post-surgery (Jonkers et al., 2003; Olsen et al., 2003; Rosenfeldt et al., 2003; 
Swenne et al., 2004). Rosenfeldt et al. (2003) investigated two different dressing 
techniques and the impact on saphenous vein harvest site infections. One hundred fifty 
two consecutive patients were randomly assigned to receive either standard postoperative 
leg dressings (control group) or a wrap dressing (interventional group) (Rosenfeldt et al., 
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2003). Results revealed an infection rate of 35% in the patients that had the standard leg 
dressing for harvest surgical sites verses an infection rate of 14% for patients that had the 
interventional wrap dressing,  p = .006 (Rosenfeldt et al., 2003). Rosenfeldt et al. (2003) 
also found that 97% of infections were detected after the patient had been discharged 
from the hospital; only one control group patient had an infection documented while in 
the hospital (3%).  
A retrospective analysis of data from 1,980 subjects obtained over 4 years from 
the institutional STS database was conducted to determine independent risk factors for 
leg harvest SSIs after CABG surgery (Olsen et al, 2003). The analysis showed 76 patients 
(4.5%) developed leg harvest site infections, of which the impact was a significantly 
longer hospital LOS (10.1 days) compared to those patients without an infection (7.1 
days), p < .01 (Olsen et al., 2003). Eight patients (11.9%) developed saphenous harvest 
infections, which were primarily superficial infections (86%) (Olsen et al., 2003).  
Independent risk factors for leg harvest site infection included previous cerebrovascular 
accident, postoperative blood transfusions in excess of 5 units, obesity, and an age of 75 
years or older (Olsen et al., 2003). The study was limited by a small sample size and a 
retrospective design.  
The incidence of SSIs may be underreported. Studies that have investigated 
delayed diagnosis of SSIs have shown that often infections are not present until after 
hospital discharge (Berg et al., 2011; Hannan et al., 2011; Jonkers et al., 2003; Swenne et 
al., 2004).  Swenne et al. (2004) investigated surgical wound infections within 30 and 60 
days of CABG surgery for 374 patients, 197 with diabetes and 199 patients without 
diabetes. The study design was a prospective, post-discharge evaluation of surgical 
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wound infections at 30 and 60 days after surgery (Swenne et al., 2004). The study 
attempted to control for known risk factors for infection including preoperative 
preparation of the skin, antibiotics within one hour of surgical incision, intravenous 
infusion for glucose control during the operation and the first 24 hours postoperatively 
(Swenne et al., 2004). The study revealed a SSI rate of 30.5% (114/374), of which 17.7% 
were harvest site infections, and 12% were superficial sternal infections (Swenne et al., 
2004).  The incidence of mediastinitis was low (0.1%).  Almost all surgical wound 
infections of the sternum (93.3%), and most harvest wound infections (73%) were 
diagnosed within 30 days. Significant risk factors identified for surgical wound infections 
included low preoperative hemoglobin, obesity, and female sex (Swenne et al., 2004).  
Jonkers et al. (2003) studied the prevalence of sternal wound infection and harvest 
site infections during hospitalization as well as 30 and 90 days after open-heart surgery. 
The prospective study included a total of 1,885 patients who underwent open-heart 
surgery from September 1996 to August 1998 (Jonkers et al., 2003). During 
hospitalization, following open-heart surgery, as well as during re-hospitalization, 
infection data were collected using medical records, bacteriological results and infection 
control surveillances (Jonkers et al., 2003). After discharge patients visited the outpatient 
clinic for follow up at 2 and 6 weeks, and the medical attendants completed a wound 
healing questionnaire. Patients completed a wound healing questionnaire at 90 days 
postoperatively (Jonkers et al., 2003).  
The infection rate for the entire study period was 9.0% for sternal wounds and 
7.9% for harvest sites (Jonkers et al., 2003). Of the sternal wound infections 1.3% were 
categorized as deep infections, and 7.7% were categorized as superficial infections 
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(Jonkers et al., 2003). More SSIs were diagnosed at the 30-day post discharge compared 
to during hospitalization (11.4% vs. 6.2%), respectively (Jonkers et al., 2003). The 90-
day post discharged had an even higher rate of SSIs than the 30 day post discharge period 
(16.3% vs. 11.4%) (Jonkers et al., 2003).    
A retrospective analysis by Hannan et al. (2011) looked at 30-day re-admissions 
for 33,936 patients in New York State during a two-year period. Findings showed that 
postoperative infections (16.9%) were the most common reason for readmission after 
CABG surgery (Hannan et al., 2011). They also found a slight correlation between the 
risk-adjusted 30-day readmission rate of hospitals, and risk-adjusted in-hospital 30-day 
mortality rate, which was 0.32 (p = .047). Factors that were associated with readmission 
included advanced age, female sex, African-American race, obesity, Medicare or 
Medicaid status, longer LOS with original surgery. These patients were also sicker, 
having multiple co-morbidities, and experiencing postoperative complications with initial 
surgery, specifically renal failure and surgical re-exploration (Hannan et al., 2011).  
Saphenous vein and/or donor site infections have been reported to have severe 
clinical consequences including non-healing ulcers, cellulitis that require debridement, 
skin graft, and/or amputation (Paletta et al., 2000; Young, Washer, & Malani, 2008). 
Young et al. (2008) reviewed and discussed risk factors and management strategies for 
SSIs among older adults undergoing surgery, including open-heart surgery. They noted 
that SSIs were an important source of morbidity and mortality in the older patient, and 
treatment of significant infections often requires prolonged courses of parenteral and/or 
oral antimicrobial therapy, as well as surgical interventions.  
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Paletta et al. (2000) presented the experience in treating 23 patients with major leg 
wound complications after saphenous vein harvest for coronary revascularization. A 
retrospective review of 3,525 bypass procedures over a 10 year period was conducted, 
and results showed that lower extremity wound complications occurred in 4.1% 
(145/3,525) of patients undergoing open-heart surgery (Paletta et al., 2000). Of the 
patients that experienced a postoperative lower extremity wound infection, 0.65% 
(23/3,525) required additional surgical interventions (Paletta et al., 2000). Surgical 
procedures that were required included 32 wound debridements, 8 skin grafts, 11 vascular 
procedures, 5 amputations, 3 fasciotomies, 2 free tissue transfers, and 1 fascio-cutaneous 
flap (Paletta et al., 2000).  
The introduction of endoscopic harvest of the saphenous vein has decreased 
harvest site complications to an overall complication rate of 2-4% (Athanasiou et al., 
2003; Bonde, Graham, & MacGowan, 2002; Yun et al., 2005).  Yun et al. (2005), using a 
randomized control trial (RCT), compared angiographic patency rates, of greater 
saphenous veins removed during CABG surgery, in patients who had endoscopic vein 
harvest technique or open vein harvest technique. Two hundred patients undergoing 
CABG surgery with CPB, were randomized to receive endoscopic or traditional 
saphenous vein harvest during a six month trial (Yun et al., 2005). The researchers found 
leg wound complications were significantly reduced in the endoscopic vein harvest group 
compared to the open harvest vein group (7.4% vs. 19.4%) respectively,  p = .014 (Yun et 
al., 2005).  
Bonde et al. (2002) investigated, in a prospective RCT, the quality of wound 
healing in 60 patients with saphenous vein harvests performed either by endoscopic 
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technique or traditional open technique. In a three month period patients were 
randomized to either the endoscopic vein harvest group (n = 30) or the open long 
saphenous vein harvest group (n = 30). Infection rate was determined by the additional 
treatment, serous discharge, erythema, purulent exudates, separation of deep tissue, 
isolation of bacteria, stay duration as inpatient (ASEPSIS score; Bonde et al., 2002). In 
the open vein harvest group the ASEPSIS score was 15 (range 2-38) indicating a 
disturbance of wound healing compared to 2.13 (range 1-3) in the endovascular vein 
harvest group, p < .01 (Bonde et al., 2002). Investigators also found that patients with the 
endoscopic approach to vein harvesting had a statistically significant lower infection rate 
and postoperative pain score than patients who underwent the traditional open vein 
harvest technique, p = .001 (Bonde et al., 2002).  
Athanasiou et al. (2003) conducted a meta-analysis of studies that investigated the 
effect of traditional vein harvest versus endoscopic vein harvest on wound healing and 
hospital LOS. When considering randomized studies, the total number of non-infective 
wound disturbances was lower in minimally invasive endoscopic vein harvest (4%) 
compared to the traditional open vein harvest (13%) group (Athanasiou et al., 2003).  
Hospital LOS was significantly reduced in the endoscopic minimally invasive group in 
comparison to the traditional open harvest group (Athanasiou et al., 2003).  
In summary, studies investigating the incidence and impact of postoperative 
infection in open-heart surgery were observational, primarily retrospective. These studies 
infered the presence of postoperative infection increases morbidity and mortality, as well 
as an increasing hospital LOS. The observational research also suggested an association 
between postoperative infections and risk factors of obesity and a diagnosis of diabetes 
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mellitus. However, while an association exists between certain risk factors and poor 
patient outcomes, it does not implicate these risk factors as a cause for poor patient 
outcomes.  
Infectious Biomarkers 
This section summarizes studies examining biomarkers utilized in identification 
of postoperative SSIs for open-heart surgery, specifically C-reactive protein (CRP) and 
procalcitonin (PCT). While there is an increasing body of evidence supporting the use of 
biomarkers for diagnosis of infection and sepsis, evidence of its use in cardiac surgery is 
limited.  
C-reactive protein. 
It has been known for several years that C- reactive protein (CRP) is one of the 
non-specific acute phase reactants that is elevated during the inflammatory response 
process (Ho, 2009). C- reactive protein belongs to the pentraxin family of proteins; 
having five subunits that form a pentameric structure (Ho, 2009). The gene for CRP is 
located on chromosome 1, and baseline CRP variability between individuals can be as 
high as 40% (Ho, 2009). C-reactive protein plays an important role during the innate 
immune response to infection. It belongs to the humoral response of the immune system 
and functions by activating opsonization and the complement system, and in modulation 
of platelet activation (Moodley, 2012; Neumaier & Scherer, 2008). It is a marker of 
general tissue damage in addition to inflammation, and bacterial infection (Neumaier & 
Scherer, 2008).  
The production of CRP occurs almost exclusively in the liver by hepatocytes as 
part of the acute phase response upon stimulation by interleukin-6 (IL-6), and to a lesser 
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extent tumor necrosis factor alpha (TNF α), and IL-1-Beta originating at the site of 
inflammation (Ho, 2009; Welsch et al., 2007).  The plasma half-life is approximately 19 
hours and clearance of CRP from the plasma occurs entirely by the liver (Ho, 2009).  C-
reactive protein has been used as a prognostic indicator in a variety of clinical scenarios 
from primary care to surgery and critical care.  
Studies on how CRP concentrations are affected by uncomplicated surgery have 
produced a general consensus that a rise in CRP occurs as a result of surgical trauma, and 
peaks at 48 hours postoperatively (Cole, Watts, Scott-Coombes, & Avades, 2008). 
Patients who exhibit higher than normal CRP concentrations (0.5 mg/L) preoperatively 
have been shown to experience later peak CRP levels and prolonged elevation in CRP 
postoperatively (Cole et al., 2008).  Specific to cardiac surgery Meng et al. (2008) 
conducted a study aimed at assessing the release and timing of cardiac biochemical and 
inflammatory markers in patients undergoing elective CABG with CPB. Forty patients 
had blood samples collected for biochemical measurements at time points: prior to 
induction of anesthesia, 1, 6, 12, and 24 hours after initiation of CPB (Meng et al., 2008). 
The results of the study showed serum high-sensitivity CRP levels started to elevate 12 
hours after CPB (p < .01) and continued to increase 24 hours after CPB (Meng et al., 
2008). C-reactive protein is one of the biochemical markers that if monitored could help 
to determine implementation of protective interventions during CABG with CPB (Meng 
et al., 2008). This is consistent with the findings of Franke et al. (2005), who found CRP 
elevated 4-6 hours post surgery (with or without CPB) peaking on day 3 and lasting to 
postoperative day five.  Parolari et al. (2007) found that high sensitivity CRP increased 
after surgery up to eight days postoperatively in patients with and without CPB.  
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While several studies exist investigating CRP and surgery, its role in open-heart 
surgery has been limited to primarily risk stratification related to preoperative CRP levels 
and to a lesser extent intra and postoperative blood values alone, or in combination of 
other inflammatory biomarkers for evidences of adverse outcomes. The majority of 
studies have investigated the use of preoperative or baseline CRP values for identification 
of postoperative adverse events in cardiac surgery and/or identification of patient 
populations that have higher baseline levels (Biancari et al., 2003; Cappabianca et al., 
2006; De Lorenzo, Pittella, & Rocha, 2012; Elenbaas et al., 2010; Fellahi et al., 2009; 
Gaudino et al., 2002; Kangasniemi et al., 2006; Kim et al., 2009; Lo, Fijnheer, Nierich, 
Bruins, & Kalkman, 2005; Perry et al., 2010; Xu et al., 2010).   
Of the studies investigating preoperative CRP most have found that patients with 
higher baseline CRP have increased postoperative risks, including an increase risk for 
cerebrovascular complications (Biancari et al., 2003; Kim et al., 2009), renal dysfunction 
(Kim et al., 2009), prolonged ventilation (Kim et al., 2009), myocardial infarction, low 
cardiac output (Biancari et al., 2003; Fellahi et al., 2009), atrial fibrillation (Lo et al.,  
2005), re-exploration and/or re-vascularization (Fellahi et al., 2009; Kim et al., 2009; Xu 
et al., 2010), increased platelets and fibrinogen levels (Gaudino et al., 2002), increased 
hospital LOS (Perry et al., 2010), long-term mortality (Fellahi et al., 2009; Kangasniemi 
et al., 2006; Perry et al., 2010), 30 day mortality (Biancari et al., 2003; Cappabianca et 
al., 2006; De Lorenzo et al., 2012), and DSWI or infection (Cappabianca et al., 2006; 
Elenbaas et al., 2010; Kim et al., 2009). In addition, it was found that patients with a 
preoperative diagnosis of diabetes mellitus, history of  myocardial infarction (MI), 
peripheral vascular disease (PVD), low cardiac output states, and emergent surgery had 
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higher preoperative CRP concentrations than patients without these co-morbidities 
(Biancari et al., 2003).   
Padayachee, Rodseth, and Biccard (2008) conducted a meta-analysis of the utility 
of pre-operative CRP in predicting early (< 30 days), intermediate (30-180 days), and 
long term (> 180 days) mortality, and major adverse cardiac events, cardiac mortality, 
and non-fatal MI following vascular surgery. Meta-analysis revealed that a preoperative 
CRP level of in excess of 3 mg/L was associated with mortality (p = .02), cardiac death 
(p = .005), and major adverse cardiac events (p = .004) (Padayachee et al., 2008).  
Perry et al. (2010) examined the value of preoperative CRP levels less than 10 
mg/L for predicting long-term, all cause mortality and hospital LOS in 914 surgical 
patients undergoing primary, non-emergent CABG surgery. Preoperative CRP was 
stratified into four categories (< 1, 1-3, 3-10, and > 10 mg/L) in a prospective study. 
Patients in the higher CRP categories (3-10 mg/L and > 10 mg/L) were more likely to be 
women, current smokers, have a higher BMI, have a higher incidence of recent MI, and 
have longer CPB times (Perry et al., 2010).  Results revealed that the two groups with 
higher preoperative CRP values, 3-10mg/L and > 10mg/L, experienced greater long-term 
all cause mortality (hazards ratios = 2.5, CI [1.22, 5.16],  p = .01; and 2.66, CI [1.21-
5.80], p = .02), respectively and extended hospital LOS (1.32, CI [1.07-1.63],  p < .001 
and 1.27, CI [1.02-1.62],  p = .001), respectively (Perry et al., 2010).   
However, there are a few studies that have shown no difference in patient 
outcomes of renal dysfunction (Gaudino et al., 2002), incidence of postoperative atrial 
fibrillation  (Ahlsson, Bodin, Lundblad, & Englund, 2007), or postoperative mortality, 
MI, or stroke for those patients with higher preoperative CRP levels (> 5 mg/L) 
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compared to those with lower CRP values preoperatively (Gaudino et al., 2002; Xu et al., 
2010). The cutoff value for CRP classified as high varied in the studies from as low as 3 
mg/L to as high as 10 mg/L, reflecting a significant variability in the high-risk category 
of patients.  
Only three studies investigated preoperative CRP and relationship with 
postoperative wound infection. All three studies found that higher preoperative CRP 
concentrations yielded more postoperative infectious complications (Cappabianca et al., 
2006; Kim et al., 2009; Elenbaas et al., 2012). Preoperative CRP was identified as a risk 
factor for the development of postoperative infectious complications in a study conducted 
by Cappabianca et al. (2006). The study evaluated the effect of preoperative 
inflammatory status, via CRP on short-term and mid-term outcome after cardiac surgery. 
A secondary outcome was to verify the effect of preoperative inflammatory status on in-
hospital mortality and morbidity (Cappabianca et al., 2006). Five-hundred ninety seven 
patient records were reviewed in a retrospective study in which patients were separated 
into a high inflammatory state (n = 243, CRP > 0.5 mg/dl), and a low inflammatory state 
(n = 354, CRP < 0.5 mg/dl). Results showed that median CRP values were significantly 
higher in the high inflammatory state group than the lower inflammatory state group for 
all 5 time points preoperative, day of surgery and postoperative day (POD) 1, 2 and 4 (1.1 
mg/dl vs. 0.2 mg/dl, p < .001; 2.2 mg/dl vs. 0.3 mg/dl, p = .001; 11.6 mg/dl vs. 7.3 mg/dl, 
p = .001; 20.3 vs. 17.8 mg/dl, p = .02; and 18.6 mg/dl vs. 13.6 mg/dl, p = .008), 
respectively (Cappabianca et al., 2006). Differences in preoperative clinical status 
showed the high inflammatory state group had a significantly greater number of co-
morbidities including hypertension, carotid stenosis exceeding 50%, and creatinine level 
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exceeding 2 mg/dl (Cappabianca et al., 2006). Results on postoperative outcomes showed 
the high inflammatory status group experienced a higher incidence of in hospital 
mortality (8.2% vs. 3.4%, p = .01), death from sepsis (2.9% vs. 0.3%, p = .007), death 
from bleeding (1.2% vs. 0%, p = .04), acute renal failure (3.7% vs. 1.4%, p =. 07), overall 
infections (16.5% vs. 5.1%, p = < .001), sternal wound infections (10.7% vs. 2.8%, p < 
.001), and sepsis (3.2% vs. 0.8%, p = .03) compared to low inflammatory group, 
respectively (Cappabianca et al., 2006).  
Kim et al. (2009) conducted a prospective study to investigate the predictive value 
of preoperative high sensitivity CRP (hsCRP) concentration for major postoperative 
complications following off-pump CABG surgery. The study included 185 subjects 
undergoing elective CABG during the year 2007. Subjects were allocated to a low CRP 
group (n = 137, < 0.3 mg/dl) and a high CRP group (n = 48, CRP > 0.3 mg/dl). The study 
found no significant differences between the groups for postoperative CRP 
concentrations with both peaking on the second day postoperative. However, the white 
blood cell count (WBC) was statistically significantly higher in the high CRP group on 
POD 2. Univariate analysis of preoperative variables showed that reduced ejection 
fraction, history of MI or stroke or renal failure and baseline hsCRP  > 0.3 mg/dl were 
risk factors for major postoperative complications (Kim et al., 2009). In a follow-up 
multivariate logistic regression adjusting for significant univariate predictors, 
preoperative renal failure and baseline hsCRP > 0.3 mg/dl remained significant 
independent predictors of major complications including MI, prolonged ventilation, 
DSWI, stroke and renal dysfunction (Kim et al., 2009). The study also is consistent with 
other studies that indicated an inflammatory process is present in off-pump as well as on-
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pump CABG surgery. This speaks to the significant acute inflammatory response as a 
result of surgical trauma and warm regional myocardial ischemia that occurs with off-
pump CABG surgery (Raja & Berg, 2007). Unfortunately, the only infectious outcome 
measure was DSWI, which is the least prevalent of all postoperative infectious 
complications. Considering this, with the finding that patients with high preoperative 
hsCRP also had significantly greater leukocytosis on POD 2, it leaves questions to the 
possibility of undiagnosed superficial infections.  
Elenbaas et al. (2010) analyzed data from all patients undergoing CABG surgery 
from 1998 to 2008 to determine risk factors for the development of postoperative 
mediastinitis. Mediastinitis was present in 100 out of the 11,748 patients (Elenbaas et al., 
2010).  Patients that developed postoperative mediastinitis were older, had more COPD, 
PVD, diabetes, atrial fibrillation, a BMI greater than 35 kg/m2 , and a higher preoperative 
CRP level (Elenbaas et al., 2010).   Univariate and multivariate logistic regression 
analyses were performed to investigate the effect of biomedical variables on the 
development of mediastinitis (Elenbaas et al., 2010). Preoperative atrial fibrillation and 
preoperative CRP level were important independent predictors of the development of 
mediastinitis (Elenbaas et al., 2010).  
Use of postoperative CRP as a marker for infection in cardiac surgery has not 
been explored extensively. Corral et al. (2009) conducted a prospective, clinical cohort 
study to determine the possible correlation between inflammatory activation after cardiac 
surgery with CBP, measured by postoperative CRP. Two hundred sixteen consecutive 
patients, that underwent CABG, valve surgery or a combination of valve and CABG, 
were included in the study. Results showed that postoperative CRP concentrations did not 
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correlate with variables reflective of outcomes and therefore, was not a useful marker in 
predicting outcome after 48 hours in the post cardiac ICU (Corral et al., 2009).  
Unlike PCT, CRP is influenced, and increased, by extraneous factors, such as 
advanced age, male gender, diagnosis of diabetes, hypertension, and operation site and 
time; therefore may not be as useful in diagnosing postoperative infection as PCT (Chung 
et al., 2011). C-reactive protein does not differentiate specifically enough between 
patients developing an infection and those exhibiting an acute phase response following 
cardiac surgery. However, it does increase the specificity for identifying infections when 
used in addition to PCT levels (Rothenburger et al., 1999). Rothenburger et al. (1999), in 
a prospective study, investigated if PCT was more helpful than CRP in identifying 
infection from a normal acute phase response following open-heart surgery 
(Rothenburger et al., 1999). In a one year period, 7 out of 563 patients (1.2%) developed 
systemic infections after open-heart surgery, and an additional 8 patients (1.4%) had local 
wound infections requiring surgical therapy (Rothenburger et al., 1999). Blood samples 
for PCT and CRP measurement were taken preoperatively, at the onset of infection, as 
well as on the 3rd, 5th, and 7th day following diagnosis of infection (Rothenburger et al., 
1999). Forty-four randomly selected patients undergoing open-heart surgery without 
clinical signs of infection served as a control to assess the PCT and CRP contribution to 
acute phase response (Rothenburger et al., 1999). The researchers found that a pattern of 
high PCT levels and high CRP levels were indicative of systemic infection, while low 
PCT levels and high CRP indicated either acute phase response or local wound problems, 
but no systemic infection (Rothenburger et al., 1999).  A  PCT level > 4 ng/ml combined 
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with a CRP level > 170 mg/L was indicative of a systemic infection in patients following 
cardiopulmonary bypass (Rothenburger et al., 1999).  
Simon, Gauvin, Amre, Saint-Louis, and Lacroix (2004) performed a meta-
analysis to evaluate the accuracy of determination of PCT and CRP levels for the 
diagnosis of bacterial infection. The analysis included published studies that evaluated 
CRP and PCT for the diagnosis of bacterial infections in hospitalized patients (Simon et 
al., 2004). Findings included that the PCT level was more sensitive 88%, (95% CI [80, 
93]) versus 75%, (95% CI [62, 84]) and more specific 81%, (95% CI [67, 91]) versus 
67%, (95% CI [56, 77]) than the CRP level for differentiating bacterial from non-
infective causes of inflammation (Simon et al., 2004).  
Procalcitonin. 
Procalcitonin is a 116-amino acid polypeptide precursor to the calcium regulatory 
hormone calcitonin, and has a molecular weight of 13 kDa (Becker, Snider, & Nylen, 
2008; Oczenski, Fitzgerald & Schwarz, 1998; Schneider & Lam, 2007). It is the 
precursor protein of the hormone calcitonin which consists of 32 amino acids known to 
be produced in the thyroid gland, and is composed of three sections: the amino terminus 
(N-ProCT), immature calcitonin, and katacalcin (Becker et al., 2008; Oczenski, et al., 
1997; Schneider & Lam, 2007). The Calc-1 gene located on chromosome 11 regulates 
synthesis of PCT. In healthy individuals production of PCT and subsequently calcitonin 
is restricted to the thyroid C-cells (Becker et al., 2008; Schneider & Lam, 2007). The 
normal healthy patient, without infection or inflammation, usually has very low PCT 
concentrations in circulating blood, < 0.05 ng/mL. (Karlsson et al., 2010; McGee & 
Baumann, 2009; Reinhart, Meisner, & Brunkhorst, 2006). The half-life of PCT is 
	  	  50	  
approximately 24 hours, with peak levels occurring at 12-16 hours after initial stimulus, 
and decreasing halve daily when host immune system controls insult (Becker et al., 2008; 
Brunkhorst, Heinz & Forycki, 1998; McGee & Baumann, 2009; Schuetz, Albrich & 
Mueller, 2011).  
Literature supports that a number of stimuli, such as endotoxin, and 
proinflammatory cytokines, induce PCT, raising values reflective of the severity of the 
insult and/or bacterial load (Becker, Nylen, White, Muller, & Snider, 2004; Christ-Crain 
et al., 2006; Muller et al., 2010; Muller et al., 2007; Schuetz et al., 2011; van Nieuwkoop 
et al., 2010). Several observational studies support the use of PCT as a diagnostic marker 
for infection and or complications in various clinical situations. Evidence supports the 
use of PCT differential diagnosis in cases of bacteremia (Muller et al., 2010; Schuetz, 
Mueller & Trampuz, 2007; van Nieuwkoop et al., 2010), endocarditis (Knudsen et al., 
2010; Mueller et al., 2004), pyelonephritis and urinary tract infection (Pecile et al., 2004; 
van Nieuwkoop et al., 2010), abdominal infections (Gurda-Duda, Kusnierz-Cabala, 
Nowak, Naskalski & Kulig, 2008; Markogiannakis et al., 2011; Sand et al., 2009), and 
postoperative fever (Hunziker et al., 2010).  
There have also been several RCTs conducted investigating the role of PCT in 
differential diagnosis for pulmonary infections (Christ-Crain et al., 2006; Kristoffersen et 
al., 2009; Long et al., 2011; Schuetz et al., 2009; Stolz et al., 2009), postoperative 
infections (Hochreiter et al., 2009; Schroeder et al., 2009), and sepsis (Bouadma et al., 
2010; Nobre, Harbarth, Graf, Rohner, & Pugi, 2008), and its benefit in reduction in the 
use of antibiotic therapy (Bouadma et al., 2010; Christ-Crain et al. 2006; Hochreiter et 
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al., 2009; Jensen et al., 2011; Kristoffersen et al., 2009; Long et al., 2011; Schroeder et 
al., 2009; Schuetz et al., 2009; Stolz et al., 2009).  
Studies have shown that PCT can be induced after surgery, when no bacterial 
infection is present, and is reflective of the type and severity of the surgical trauma 
(Chung et al., 2011; Hunziker et al., 2010; Meisner, Tschaikowsky, Hutzler, Schick, & 
Schuttler, 1998; Meisner et al., 2002; Prat et al., 2008). Different mechanisms may be 
involved in inducing this non specific acute inflammatory response, including the use of 
CPB, the surgical trauma, transfusions including cell saver, blood loss, ischemia-
reperfusion and endotoxin release, and hypothermia (Cremer et al., 1996; Delannoy, 
Guye, Slaiman, Lehot & Cannesson, 2009; Falcoz et al., 2005; Laffey, Boylan & Cheng, 
2002; Meisner et al., 2002). This non-specific systemic inflammatory response syndrome 
(SIRS), a term proposed to identify non-specific generalized inflammatory process 
independently from any causative factor, makes early diagnosis of postoperative 
infectious process difficult to identify in open-heart patients (Delannoy et al., 2009; Prat 
et al., 2008).  
Procalcitonin has been used as a reliable diagnostic parameter to detect and to 
monitor postoperative complications including infection, morbidity and mortality, with a 
predictive PCT concentration level 0.5 ng/ml to 1.5 ng/ml suggestive of complications 
(Falcoz et al., 2005; Jebali et al., 2007; Macrina et al., 2005; Meisner et al., 2002; Prat et 
al., 2008; Sinning et al., 2010).  A slow decrease or further increases in PCT values after 
the second or third postoperative day may indicate that systemic inflammation or 
infection complication is likely (Oczenski et al., 1997; Whicher, Bienvenu, & Monneret,  
2001). While PCT does increase with systemic inflammatory response syndrome (SIRS), 
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it occurs in modest increases, whereas significant increases in levels of PCT are 
correlated with an infectious process and sepsis (Falcoz et al., 2005; Jebali et al., 2007; 
Macrina et al., 2005; Meisner et al., 1998; Whicher et al., 2001).  
Falcoz et al. (2005) investigated the utility of PCT in the early detection of 
infection after thoracic surgery, specifically lung surgery. A twofold aim of the 
prospective study was to assess the accuracy of PCT as a marker of postoperative 
infection after thoracic surgery, and to compare it with CRP (Falcoz et al., 2005). The 
sample consisted of 157 patients who were classified as non-infected (n = 132) or 
infected (n = 25; Falcoz et al., 2005). Results included a mean PCT value that was 
significantly higher in patients with postoperative infection than in those with no 
postoperative infection (3.6 + 5.5 vs. 0.63 + 0.62 ng/ml),  p < .001 (Falcoz et al., 2005). 
The onset of infection most frequently occurred on postoperative day 2 (43% of patients); 
maximum PCT and CRP concentrations most frequently appeared on postoperative day 1 
(56% of patients) and day 2 (63% of patients), respectively (Falcoz et al., 2005). The best 
cutoff value for detection of infection with PCT was 1 ng/ml, and with CRP, 100 mg/L 
(Falcoz et al., 2005). Procalcitonin was better than CRP for detecting postoperative 
infection (Falcoz et al., 2005).  
A prospective observational study conducted by Macrina et al. (2005) 
investigated the predictive role of PCT and CRP changes during the immediate 
postoperative period. Thirty-two patients that underwent CABG surgery were enrolled 
and followed up to the 7th postoperative day (Macrina et al., 2005). At the end of follow-
up, patients were divided into two groups, one if they had an uncomplicated course and 
the other if they experienced a complicated postoperative course (Macrina et al., 2005). 
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Postoperative complications included re-sternotomy, need of an intra-aortic balloon pump 
postoperatively, or intestinal ischemia (Macrina et al., 2005). The researchers found that 
serum PCT concentrations increased from baseline in both groups during the first two 
days after surgery (Macrina et al., 2005). The increase in serum PCT concentration was 
significantly greater in the group with a complicated course than the group without 
complications (Macrina et al., 2005). The study defined a perioperative PCT value of > 
0.5 ng/ml as abnormal (Macrina et al., 2005). Preoperatively and immediate 
postoperatively the PCT values were below 0.5 ng/ml in patients without complications 
compared to > 0.5 ng/ml in patients that experience a complication. (Macrina et al., 
2005). An absolute PCT concentration change of 0.20, 0.40, and 0.60 ng/ml carried an 
approximate risk of 5, 26, and 69%, respectively of postoperative complications in the 
first week post surgery (Macrina et al., 2005).  
Jebali et al. (2007) in a prospective study investigated the accuracy of PCT to 
diagnose postoperative infection after cardiac surgery with CPB and compared it with 
CRP, WBCs, and IL 6 and IL 8 (Jebali et al., 2007). Blood samples of 100 patients were 
taken before surgery and each day over the 7-day postoperative period. A blinded expert 
panel of individuals determined diagnosis of infection. Of the 16 patients diagnosed with 
infection, PCT concentrations were significantly higher versus those without infection 
(Jebali et al., 2007). A PCT value of > 1.5 ng/ml beyond the second day diagnosed 
postoperative infection with a sensitivity of 0.93 (95% CI [0.70, 0.99]) and a specificity 
of 0.80 (95% CI [0.70, 0.87]). Procalcitonin was also significantly higher in patients who 
died compared to patients who survived (27.5 vs. 1.2 ng/ml), p < .001 (Jebali et al., 
2007).  
	  	  54	  
Sponholz, Sakr, Reinhart and Brunkhorst (2006) conducted a systematic review of 
the literature with the aims of: 1) describing the evolution of serum PCT levels after 
uncomplicated cardiac surgery; 2) characterizing the role of PCT as a tool in 
discriminating infection; 3) identifying the relation between PCT, organ failure, and 
severity of sepsis syndromes; and 4) assessing the possible role of PCT in detection of 
postoperative complications and mortality. Results of the review revealed uncomplicated 
cardiac surgery induces a postoperative increase in serum PCT levels, with peak PCT 
levels reached within 24 hours postoperatively, and return to normal levels within the 
first week (Sponholz et al., 2006). Although PCT values reported in infected patients are 
generally higher than in non-infected patients after cardiac surgery, the cutoff point for 
discriminating infection ranged from 1 to 5 ng/ml, and the dynamics of PCT levels over 
time may be more important than absolute values (Sponholz et al., 2006).  
Prat et al. (2008) attempted to establish the baseline levels of PCT after cardiac 
surgery in order to analyze a possible induction of the inflammatory response that might 
interfere with the diagnosis of infection by PCT. Patients were separated into 3 groups, 
sixty-nine patients undergoing CABG with CPB, sixty-nine patients undergoing valve 
replacement with CPB, and thirteen patients undergoing CABG surgery without the use 
of CPB. A control group consisted of 24 healthy subjects not undergoing cardiac surgery. 
Procalcitonin levels were collected, in 151 patients undergoing open-heart surgery, on 
admission to the ICU and the first two PODs (Prat et al., 2008). Results revealed the 
mean PCT values were significantly higher in the first POD in all groups except the 
control group. While all patients experienced a slight and transient increase in PCT 
postoperatively, only patients who presented with postoperative complications had 
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significantly increased PCT values (> 3 mg/mL) immediately after surgery (p = .004), in 
the first POD (p  < .001), and in the second POD (p < .001) with respect to those who 
recovered uneventfully (Prat et al., 2008). Procalcitonin values were not related to 
duration of CPB, or to aortic clamp time, and there was no difference in PCT values for 
those patients that were on CPB compared to those patients off CPB (Prat, et al., 2008). 
Studies reviewed in this section showed CRP and PCT are significantly increased in 
patients with infection or postoperative complications. The use of these biomarkers may 
be beneficial in the early detection of postoperative complication and infection.  
The Influence of Diabetes in Surgical Site Infections 
This section will review the influence of diabetes in SSIs in open-heart surgical 
patients. Patients with diabetes after open-heart surgery have increased hospital LOS, 
poorer wound healing, higher infection rates, and higher mortality rates than patients 
without diabetes (Brown, Edwards, O’Conner, Ross, & Furnary, 2006; Bucerius et al., 
2003; Carson et al., 2002; Guvener et al., 2002; Ji et al., 2009; Woods, Smith, Sohail, 
Sarah, & Engle, 2004). Brown et al. (2006) conducted a retrospective review of two large 
registries: the STS database and the Northern New England Cardiovascular Disease 
Study Group (NNECDSG) to benchmark diabetic outcomes prior to the widespread use 
of glycemic control in 2001. The STS database revealed 30-day mortality rates were 
higher for diabetic patients when compared to non-diabetic patients regardless of the type 
of open-heart surgery (Brown et al., 2006). Results showed lower mortality for non-
diabetic patients compared to patients with diabetes in isolated CABG surgery (2.82% vs. 
3.96%, p < .01), aortic valve replacement (AVR) (3.57% vs. 6.53%, p < .01), and mitral 
valve replacement (MVR) (5.52% vs. 11.07%),  p < .01. The NNECDSG reported similar 
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findings in mortality in non-diabetic patients compared to diabetic patients undergoing 
isolated CABG (2.96% vs. 3.93%, p < .01), concomitant CABG/valve (9.55% vs. 
15.81%, p < .01), AVR (5.48% vs. 8.51%, p < .05), and MVR (7.76% vs. 13.01%),  p < 
.05 (Brown et al., 2006).  
The STS database was used to identify DSWI rates at 30 days after open-heart 
surgery and found patients with diabetes had nearly twice the number of DSWIs as 
patients without diabetes, regardless of the procedure (Brown et al., 2006). The specific 
rates for non-diabetic patients versus diabetic patients showed isolated CABG (0.45% vs. 
1.02%, p < .01), AVR (0.41% vs. 0.78%, p < .01), and MVR (0.35% vs. 0.72%, p < .01). 
The NNECDSG database revealed rates of infection were significantly higher for diabetic 
patients than non-diabetic patients undergoing isolated CABG (1.97% vs. 1.16%, p < 
.01), but not higher for diabetics undergoing CABG/valve, or valve only procedures 
(Brown et al., 2006).  
On average, diabetic patients were more likely to have longer hospital LOS 
following open-heart surgery (Brown et al., 2006). In the STS database, the mean post 
procedure LOS for non-diabetic patients and diabetic patients was 7.08 and 8.05 days, 
respectively for CABG; 8.28 and 10.03 days for AVR; 9.86 and 12.82 days for MVR (all 
p < .01; Brown et al., 2006). The NNECDSG postoperative LOS was similar when 
comparing non-diabetic patients to diabetic patients for isolated CABG at 7.60 versus 
8.87 days; 11.91 versus 15.12 days for CABG/valve; 9.54 versus 17.67 for AVR; and 
10.52 versus 16.25 days for MVR (all p < .01; Brown et al., 2006).  
Guvener et al. (2002) studied the relationship between perioperative glycemic 
control and infectious complications in diabetic and non-diabetic patients. A total of 
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1,090 adults (400 diabetic and 690 non-diabetics) who underwent CABG surgery in a 
five year period were included in a retrospective cohort study based on chart review 
(Guvener et al., 2002). Intraoperative and postoperative blood glucose levels in diabetic 
patients were manipulated by means of a continuous insulin infusion to maintain blood 
glucose levels between 150-200 mg/dl; non-diabetic patients received no standard insulin 
treatment (Guvener et al., 2002).  
Mean blood glucose levels for the diabetic patient on postoperative day 1 was 
significantly higher (191 + 36 mg/dl) compared to the patient without diabetes (140 + 24 
mg/dl),  p = .003 (Guvener et al., 2002). In the diabetic group, 5% (20/400) of patients 
developed a postoperative infection, which included superficial sternal SSI (0.75%), 
harvest site SSI (1%), mediastinitis (1.25%), urinary tract infection (1.5%), and lung 
infection (0.5%). The diabetic group had a significantly higher prevalence of 
mediastinitis, harvest SSI, urinary tract infection, and total infection as compared to the 
non-diabetic group (p = .048, .013, .009, and .044), respectively (Guvener et al., 2002). In 
diabetic patients who developed an infection, the mean glucose level two days 
preoperative was significantly higher (201 + 47 mg/dl) compared to diabetic patients who 
did not develop an infection (165 + 37 mg/dl).  High preoperative mean glucose levels, in 
the first and second preoperative days, were the main risk factor for the development of 
postoperative infection (p = .012 and p = .028), respectively (Guvener, et al., 2002). 
Mortality was higher among diabetic patients than in non-diabetic patients (3% vs. 
1.73%), p = .048 (Guvener et al., 2002).  
An eight year prospective cohort design by Woods et al. (2004) investigated 
postoperative outcomes and operative mortality of 6,711 patients (2,178 diabetic and 
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4,522 non-diabetics) who underwent CABG surgery to determine if any outcome 
differences existed. Univariate analysis comparing diabetic status with demographic 
variables and co-morbidities found that the diabetic population was significantly more 
likely to be women, have left ventricular hypertrophy, have a history of cerebrovascular 
disease, hypertension, COPD, obesity, higher creatinine levels, more likely to be African-
American, and less of a history of tobacco use compared to non-diabetic patients (all p < 
.05; Woods et al., 2004). The researchers found that patients with diabetes experienced 
significantly higher mortality than patients without diabetes (OR = 1.67, 95% CI [1.20, 
2.30], p < .004). However, there was no difference between diabetic and non-diabetic 
patients in the incidence of postoperative morbidity (Woods et al., 2004).   
Bucerius et al. (2003) conducted a prospective observational study aimed to 
delineate the prevalence and the impact of diabetes on perioperative outcomes on 16,184 
patients undergoing open-heart surgery over a 5 year period (Bucerius et al., 2003). They 
found the prevalence of diabetes mellitus was 33.3% (5,389/16,184), and compared to 
non-diabetic patients the group with diabetes mellitus was older (p < .001), and had a 
significantly lower ejection fraction (p < .001). The researchers also found diabetes to be 
an independent predictor for seven postoperative outcome variables including prolonged 
ICU stay, sternal SSI, sternal revision, respiratory insufficiency, postoperative delirium, 
perioperative stroke, renal dysfunction, and postoperative re-intubation (Bucerius et al., 
2003).  
In a retrospective cohort study of 434 hospitals in North America, researchers 
sought to determine the impact of diabetes mellitus on short term mortality and morbidity 
in patients undergoing CABG surgery (Carson et al., 2002). The study sample included 
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146,786 patients who underwent CABG surgery during 1997, of which 41,663 were 
diagnosed with diabetes and 105,123 without diabetes (Carson et al., 2002). The 
researchers found the 30-day mortality was 3.7% in patients with diabetes mellitus and 
2.7% in patients without diabetes (Carson et al., 2002). Morbidity and infections occurred 
more commonly in diabetic patients and were associated with an adjusted risk 
approximately 35% higher in diabetic patients than non-diabetic patients, particularly 
among insulin treated diabetics (Carson et al., 2002). Limitations of the study included 
the retrospective design with a historical control.  
Similarly, Ji et al. (2009) found patients with diabetes had a higher rate of 
infection post-CABG surgery. In a retrospective chart review investigators analyzed 393 
elderly patients (121 with diabetes) evaluating the impact of diabetes mellitus on patients 
undergoing CABG surgery (Ji et al., 2009). Intensive insulin therapy was used in the 
perioperative period, with a target glucose level of 80 to 110 mg/dl for both diabetic and 
non-diabetic patients (Ji et al., 2009).  Patients with diabetes were less likely to have 
undergone previous percutaneous coronary intervention (p = .012), compared with 
patients without diabetes mellitus (Ji et al., 2009). Univariate and multivariate logistic 
regression analysis showed that patients with diabetes had a higher rate of deep sternal 
SSIs (OR = 2.28, 95% CI [1.29, 6.84], p = .002), while sharing similar rates for other 
morbidities and mortality compared with the patients without diabetes mellitus despite 
maintaining tight glycemic control (Ji et al., 2009). While studies showed a diagnosis of 
diabetes mellitus increased the risk of SSIs, hyperglycemia with or without a diagnosis of 
diabetes has also been implicated as a risk factor for SSIs.  
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The Influence of Hyperglycemia in Surgical Site Infections 
Hyperglycemia, preoperatively, intraoperatively and postoperatively, has been 
implicated in more infectious complications, longer hospital stays, higher morbidity, 
mortality and increased resource utilization after open-heart surgery (Ascione, Rogers, 
Rajakaruna, & Angeline, 2008; Doenst et al., 2005; Estrada et al., 2003; Gandhi et al., 
2005; Imran et al., 2010; Knapik, Ciesla, Filipiak, Knapik, & Zembala, 2011; Knapik et 
al., 2009; Ouattara et al., 2005; Sato et al., 2010; Swenne, Lindholm, Borowiec, Schnell 
& Carlsson, 2005; Umpierrez et al., 2002).   
The American Diabetes Association (ADA) has recommended the use of 
glycohemoglobin (HbA1c) as a method of assessing long-term glycemic control in 
diabetic patients, and recommends levels are maintained less than 7% (ADA, 2012). 
Glycosylated hemoglobin, indicates a patient’s blood glucose control during the previous 
3 to 4 months and is formed when glucose in the blood binds irreversibly to hemoglobin 
to form a stable glycated hemoglobin complex (Halkos et al., 2008). Glycosylated 
hemoglobin is not affected by short-term glycemic lability; it allows a reflection of longer 
term glucose control.  
Preoperative hyperglycemia, as evidenced by preoperative blood glucose, or 
HbA1c, significantly contributes to morbidity and mortality after cardiac surgery 
(McAlister, Man, Bistritz, Amad & Tandon, 2003; Halkos et al. 2008; Imran et al., 2010; 
Knapik et al., 2011; Sato et al., 2010). Sato et al. (2010) conducted a prospective cohort 
study, of 143 non-diabetic and 130 diabetic patients, to assess the association between the 
quality of preoperative glycemic control, intraoperative insulin sensitivity, and adverse 
events after cardiac surgery. Results showed that diabetic patients with poor glycemic 
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control had a greater incidence of major complications (p = .010) and minor infections (p 
= .006). They also received more blood products and spent more time in the intensive 
care unit (p = .030) and the hospital (p < .001) than non-diabetic patients (Sato et al., 
2010).  
In a prospective observational study, Halkos et al. (2008) investigated if 
preoperative HbA1c was a predictor of adverse outcomes after CABG surgery. In- 
hospital mortality for all patients was 1% (31/3,089). An elevated HbA1c level predicted 
in hospital mortality after CABG surgery (OR = 1.40 per unit increase, p = .019) (Halkos 
et al., 2008).  Receiver operating characteristic curve analysis revealed that HbA1c 
greater than 8.6% was associated with a 4-fold increase in mortality (Halkos et al., 2008). 
For every unit increase in HbA1c, there was a significantly increased risk of MI, and 
DSWI. By using receiver operating characteristic value thresholds, renal failure 
(threshold 6.7, OR = 2.1), stroke (threshold 7.6, OR = 2.24), and DSWI (threshold 7.8, 
OR = 5.29) occurred more commonly in patients with elevated HbA1c (Halkos et al., 
2008).  
Knapik et al. (2011) conducted a retrospective review of 2,665 patients, 782 
(29%) of which had diabetes mellitus, to determine the prevalence of elevated HbA1c 
among diabetic patients scheduled for CABG surgery and if this influenced postoperative 
outcomes. Patients with preoperative normal or elevated HbA1c (> 7%) were compared 
regarding their hospital mortality, morbidity, and LOS (Knapik et al., 2011). Results 
showed elevated HbA1c levels were present in 38.4% of diabetic patients, 57.1% of 
patients among insulin-dependent diabetics, 27.3% of patients on oral medication, and in 
7.7% of patients whose diabetes was treated with diet only (Knapik et al., 2011). There 
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was no difference between mortality, or LOS, whether ICU or hospital, and the only 
significant difference was perioperative MI. Patients with an elevated HbA1c had 
significantly more perioperative MIs than patients with normal preoperative HbA1c, 
particularly if the patients had insulin dependent diabetes (Knapik et al., 2011). 
Glycosylated hemoglobin has also been used as a predictor of postoperative glucose 
variability and hyperglycemia in CABG surgery patients (Masla, Gottschalk, Durieux & 
Groves, 2011).  
Masla et al. (2011) investigated the relation of HbA1c and/or a prior diagnosis of 
diabetes mellitus and intra- and postoperative hyperglycemia and glycemic variability. 
The retrospective data analysis looked at 120 patients undergoing isolated CABG surgery 
and found that diabetics and/or patients with elevated HbA1c had higher postoperative 
glucose levels, a higher standard deviation, and a higher coefficient of variation of 
glucose values (Masla et al., 2011). However, higher glucose variability was not 
associated with higher rates of complication, and intraoperative glucose values and 
variation did not differ significantly between groups (Masla et al., 2011). Increased mean 
blood glucose values were associated with and increased risk of infection. Additionally, 
this study found that preoperative fasting glucose could better predict intraoperative 
hyperglycemia than HbA1c (Masla et al., 2011).  Other studies have investigated 
preoperative blood glucose and found a significant increase in morbidity in patients 
undergoing CABG surgery (Imran et al., 2010).  
A Canadian study by Imran et al. (2010) investigated the impact of admission 
serum glucose level on outcomes in CABG surgery. A prospective observational study 
collected data on 2,856 consecutive patients undergoing CABG surgery and divided them 
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into two groups, those patients with admission blood glucose levels below 9.2 mmol/L 
(167 mg/dl) 76.3% of patients, and those patients with an admission blood glucose level 
> 9.2 mmol/L (167 mg/dl) 23.7% of patients. Patients with elevated admission glucose 
levels tended to be females, have diabetes, preoperative renal failure, an ejection fraction 
less than 40%, triple vessel disease or left main disease, and a prior MI within 21 days of 
surgery (Imran et al., 2010). There was no difference between the two groups in-hospital 
mortality rates (p = 0.12). However, patients admitted with higher blood glucose levels 
were more likely to suffer major morbidity postoperatively, as measured by a composite 
measure, than patients with admission blood glucose below 9.2 mmol/L (167 mg/dl). 
Morbidity, as measured by composite, included outcomes of stroke, MI, sepsis, DSWI, 
acute renal failure, increased inotropic support, and prolonged ventilation (Imran et al., 
2010). Patients who were not diabetic but had admission blood glucose levels > 9.2 
mmol/L did not experience an increase in morbidity as the diabetic patients with 
preoperative hyperglycemia did (Imran et al., 2010). This is in contrast to a study 
completed by Ascione et al. (2008), which found poor blood glucose control led to 
increase mortality and morbidity, whether the patient was a diabetic or non-diabetic.  
Ascione et al. (2008) prospectively investigated the effect of blood glucose 
control (BGC) in 8,727 patients on clinical outcomes after open-heart surgery. The 
highest blood glucose level recorded over the first 60 hours postoperatively was used to 
classify patients as having good (< 200 mg/dl), moderate (200-250 mg/dl), or poor (> 250 
mg/dl) BGC (Ascione et al., 2008). They found 85% (7,547) of patients had good BGC, 
10 % (905) had moderate BGC, and 4% (365) had poor BGC (Ascione et al., 2008). 
Diabetic patients comprised 52% of the poor control category with, 31% having moderate 
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control, and 8% good BGC (Ascione et al., 2008). Inadequate BGC, but not a diagnosis 
of diabetes, was associated with in-hospital mortality (good BGC 1.8%, moderate BGC 
4.2%, poor BGC 9.6%). Additionally, inadequate BGC was associated with postoperative 
MI, pulmonary and renal complications in patients without known diabetes mellitus 
(Ascione et al., 2008).   
The association between perioperative hyperglycemia and outcomes in patients, 
with and without diabetes mellitus undergoing CABG surgery, was investigated by 
Estrada et al. (2003). A retrospective historical study of 1,574 patients, 545 (34.6%) with 
diabetes and 1,029 patients without diabetes was conducted for patients that underwent 
CABG surgery over a year time period (Estrada et al., 2003). The researchers found that 
every 50 mg/dl blood glucose increase, regardless of diabetic status, was associated with 
increased hospital LOS by 0.76 days (95% CI [0.36, 1.17], p < .01); increased 
hospitalization charges to patients by $2,824 (95% CI [1,599, 4,049], p < .01); and 
increased hospitalization cost by $1,769 (95% CI [928, 2,610], p < .01). They also found 
that infections occurred more frequently in patients with diabetes (6.6% vs. 4.1%, p = 
.03) than patients without diabetes (Estrada et al., 2003).  
Umpierrez et al. (2002) in a retrospective review of 2,030 patients aimed to 
determine the prevalence of in-hospital hyperglycemia, survival rates, and functional 
outcome of patients who experienced hyperglycemia with and without a history of 
diabetes. Results revealed hyperglycemia (fasting blood glucose level > 126 mg/dl, or 
random blood glucose > 200 mg/dl) was present in 38% of patients admitted to the 
hospital, of whom 26% had a known history of diabetes, and 12% had no history of 
diabetes before the admission (Umpierrez et al., 2002). Hyperglycemia in previously 
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undiagnosed patients was associated with higher in-hospital mortality rate (16%) 
compared with those patients with a prior history of diabetes (3%) and patients with 
normoglycemia (1.7%; both p < .01). This indicated that in-hospital hyperglycemia was 
an important marker of poor clinical outcome and mortality in patients with and without 
diabetes (Umpierrez et al., 2001).  
A retrospective review of 374 patient charts was performed by Swenne et al. 
(2005) to determine the significance of postoperative blood glucose control as a risk 
factor for surgical wound infection in open-heart surgery. The sample included patients 
with and without diabetes that underwent CABG surgery over four years (Swenne et al., 
2005). Analysis of blood glucose concentrations postoperatively and patient’s evaluation 
of infection 30 and 60 days post-surgery revealed no difference in the risk factor for 
surgical wound infections between patients that were diabetic and patients that were 
hyperglycemic (Swenne et al., 2005). However, the study did show that hyperglycemia in 
patients without a preoperative diagnosis of diabetes was associated with an increased 
risk of mediastinitis compared to patients with a diagnosis of diabetes (Swenne et al., 
2005).  
A retrospective observational study examined the relationship between 
intraoperative glucose concentration and postoperative complications in 409 consecutive 
patients who underwent open-heart surgery (Gandhi et al., 2005). The primary 
independent variable was the mean intraoperative glucose concentration, and the primary 
end point was a composite of death, and operative complications developing within 30 
days postoperative (Gandhi et al., 2005). They found that patients experiencing a primary 
end point were more likely to be male, older, have diabetes mellitus, undergo CABG 
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surgery, and receive insulin during surgery (Gandhi et al., 2005). Atrial fibrillation (n = 
105), prolonged pulmonary ventilation (n = 53), delirium (n = 22), and urinary tract 
infection (n = 16) were the most common complications (Gandhi et al., 2005). The initial, 
mean and maximal intraoperative glucose concentrations were significantly higher in 
patients experiencing the primary end point (p < .01 for all comparisons; Gandhi et al., 
2005). In a multivariable analysis, mean and maximal glucose levels remained 
significantly associated with outcomes after adjusting for potentially confounding 
variables, including postoperative glucose concentration (Gandhi et al., 2005). 
Intraoperative hyperglycemia was identified as an independent risk factor for 
complications, including death, after open-heart surgery (Gandhi et al., 2005).   
Knapik et al. (2009) in a retrospective review of 814 patients investigated the 
influence of CPB on postoperative glucose and insulin consumption in patients with and 
without diabetes mellitus undergoing CABG surgery. Additionally, the study investigated 
if a marked hyperglycemia in the early postoperative period was a factor associated with 
early mortality and morbidity (Knapik et al., 2009). Outcome variables for the study 
included difficult glycemic control (postoperative blood glucose levels > 11.0 mmol/L or 
200 mg/dl), hospital mortality, and morbidity.  
Results of the study revealed glycemic control was significantly worse in patients 
who underwent CABG surgery with CPB, in comparison to patients who underwent 
CABG surgery without CPB (Knapik et al., 2009). Patients with difficult glycemic 
control had more serious postoperative complications and higher mortality (2.5% vs. 
0.4%), p = .02 (Knapik et al., 2009). Multivariate analysis revealed difficult glycemic 
control was significantly associated with a female sex, presence of diabetes, and the 
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usage of CPB (OR = 2.36, 2.22 and 1.81), respectively (Knapik et al., 2009). Mortality 
was significantly associated with left ventricular dysfunction, difficult glycemic control, 
and previous stroke (OR = 7.38, 7.06, and 5.66), respectively (Knapik et al., 2009). 
Difficult glycemic control was also significantly associated with postoperative morbidity 
(OR = 1.87; Knapik et al., 2009). The retrospective design of the study is a limitation of 
the study.  
A retrospective study by Reyes, Jensen, Stewart and Kidd (2008) examined the 
relationship between preoperative and postoperative blood glucose levels and outcomes 
in cardiac surgery patients with and without diabetes mellitus. Specifically, they 
investigated if maintaining preoperative blood glucose below a value of 11 mmol/L  (198 
mg/dl) made a difference in postoperative outcomes in diabetic and non-diabetic patients. 
Results revealed no difference in postoperative outcomes between patients with and 
without diabetes, however patients with diabetes did have a significantly longer LOS in 
the ICU (3.6 + 6.4 vs. 2.2 +2 days, p = .03) and hospital LOS (18 +18.9 vs. 12.8 + 9.5 
days, p = .01) than patients without a diagnosis of diabetes (Reyes et al., 2008).  
Interestingly, preoperative and postoperative blood glucose values did not correlate with 
LOS in the ICU (r = 0.05, p = .29; r = .03, p = .61), respectively, or hospital (r= 0.03, p = 
.63; r= 0.07, p = .20), respectively (Reyes et al., 2008). Elevated preoperative and 
postoperative blood glucose levels > 11 mmol/L was associated with increased BMI (p < 
.001 and p = .001), respectively. Factors affecting increased hospital LOS included 
increased age (p < .01). Factors that increased ICU LOS included longer aortic cross 
clamp time and CPB time (p = .01,  p = .001), respectively, and elevated HbA1c values, p 
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= .001 (Reyes et al., 2008). Factors that affected both ICU and hospital LOS included 
undergoing combined CABG and valve surgery, p = .004 (Reyes et al., 2008).  
Studies reviewed in this section suggest hyperglycemia with or without a 
diagnosis of diabetes mellitus is associated with increased risk of postoperative 
complications, and mortality. Thereby supporting the need for further research focused 
on prevention of hyperglycemia and glycemic control in the pre-, intra-, and 
postoperative period are important.  
Glycemic Control 
Glycemic control in the postoperative period. 
Postoperative glycemic control has been a main focus in the ICU setting to 
decrease mortality and morbidity, including infectious complications. A variety of 
continuous insulin infusion protocols have been published and many modifications of 
these protocols have been instituted in ICU settings, across the nation. Studies that have 
reported beneficial results with the use of continuous intravenous insulin infusions for 
glycemic control in the ICU have resulted in improved glucose control; reduce infections, 
reduced morbidity and mortality (Hruska, Smith, Hendy, Fritz, & McAdams, 2005; Van 
den Berghe et al., 2001; Zerr et al., 1997; Zimmerman, Mlynarek, Jordan, Rajda, & 
Horst, 2004). 
In a retrospective observational study of 1,585 diabetic patients who underwent 
open-heart operations, Zerr et al. (1997) aimed to determine the rate of infection between 
diabetic and non-diabetic patients, and to evaluate the effects of an insulin infusion in the 
postoperative period on wound infection. The study utilized a historical cohort (first 
cohort) of patients (n = 990, 1987-1991) that received subcutaneous insulin to maintain 
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blood glucose levels between 150 and 200 mg/dl (Zerr et al., 1997). However, recorded 
blood glucoses in this cohort ranged from 175-240 mg/dl (Zerr et al., 1997).  From 1991 
through 1998, an intravenous insulin protocol was utilized, for a second cohort of 
diabetic patients (n = 595), to maintain blood glucose levels < 200 mg/dl in the 
postoperative period (Zerr et al., 1997). The rate of DSWI in diabetic patients dropped 
from 2.8% in the historic cohort to 0.74% in the second cohort treated with intravenous 
insulin. The overall mortality rate in the diabetic population was 5.7% (90/1,585). Of 
those patients who died, 6.7% (6/90) had DSWI, and patients with DSWIs had a 
mortality rate of 18% (6/33; Zerr et al., 1997). Blood glucose levels were significantly 
associated with deep wound infections (p < .002). Infected diabetic patients had a higher 
mean blood glucose level through the first 2 postoperative days than non-infected patients 
(208 + 7.1 vs. 190 + 0.8 mg/dl); p < .01 (Zerr et al., 1997). The study inferred the use of a 
continuous insulin infusion, to maintain blood glucose levels below 200 mg/dl, in the 
postoperative period for patients undergoing open-heart surgery significantly reduced 
major infectious morbidity (Zerr et al., 1997). Limitations of the study included the 
nature of the retrospective, historical control group.  
Van den Berghe et al. (2001)  in a RCT attempted to determine whether 
normalization of blood glucose levels with intensive insulin therapy reduced mortality 
and morbidity among critically ill patients. Of the 1,548 adults patients admitted to a 
surgical ICU 62% were post open-heart surgical patients, who were receiving mechanical 
ventilation (Van den Berghe et al., 2001).  Patients were randomly assigned to receive 
either intensive insulin therapy (maintenance of blood glucose at a level between 80 and 
110 mg/dl) or conventional treatment (infusion of insulin only if the blood glucose level 
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exceeded 215 mg/dl, and then blood glucose level was maintained between 180 and 200 
mg/dl; Van den Berghe et al., 2001).  
Results of the study showed that the mortality rate in the intensive insulin therapy 
group was 4.6% compared to 8% in the conventional treatment, p < .04 (Van den Berghe 
et al., 2001). This observed reduction in mortality with intensive insulin therapy occurred 
exclusively in patients with an ICU LOS > 5 days (10.6% mortality in the intensive 
insulin group vs. 20.2% in the conventional group), p = .005 (Van den Berghe et al., 
2001).  Intensive insulin therapy when compared to conventional therapy reduced overall 
in-hospital mortality by 34%. Intensive insulin therapy also reduced bloodstream 
infections by 46% compared to the conventional therapy (Van den Berghe et al., 2001). 
Bloodstream infections in the intensive insulin group was 4.2% (32/765) versus 7.6% 
bloodstream infection rate in the conventional group (61/738), p = .003 (Van den Berghe 
et al., 2001). Acute renal failure requiring dialysis or hemofiltration was also reduced by 
intensive insulin therapy by 41% (Van den Berghe et al., 2001).  The intensive insulin 
group renal failure rate was 4.8% (37/765) versus the conventional therapy group renal 
failure rate of 8.2% (64/738), p = .007; and the median number of blood transfusions was 
reduced by 50%, ( p = .001). They also found that patients receiving intensive insulin 
therapy were less likely to require prolonged mechanical ventilation (Van den Berghe et 
al., 2001). Conclusions of the study included intensive insulin therapy to maintain blood 
glucose at or below 110 mg/dl reduced morbidity and mortality among critically ill 
patients in the surgical ICU (Van den Berghe et al., 2001).  
Hruska et al. (2005) conducted an observational study aimed to evaluate the 
effects of a continuous insulin infusion protocol on postoperative infection and mortality. 
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The sample consisted of 761 patients who underwent CABG surgery from January 1997 
through December 1998 (Hruska et al., 2005). The conventional group included patients 
who underwent CABG surgery in 1997 (n = 436) and were treated with subcutaneous 
insulin sliding scale to control postoperative hyperglycemia (Hruska et al., 2005). The 
insulin infusion group included patients who underwent CABG surgery in 1998 (n = 
325), and were treated with an insulin drip protocol to maintain blood glucose levels 
between 120 mg/dl and 160 mg/dl in the immediate postoperative period (Hruska et al., 
2005).  
Researchers found that the overall wound infection rate for all patients was 3% 
(23/761; Hruska et al., 2005).  In the conventional therapy group the infection rate was 
significantly higher in diabetic patients than non-diabetic patients, p < .001 (Hruska et al., 
2005). Initiation of an insulin infusion protocol and the subsequent tight control of blood 
glucose levels in the immediate postoperative period reduce the incidence of wound 
infection in the diabetic population to that of the non-diabetic population (Hruska et al., 
2005). There was no significant difference between the two groups in the mortality rate 
of patients with diabetes (conventional group 4% vs. tight control group 5%), p = .575 
(Hruska et al., 2005).  Limitations of the study included a single center, observational 
design with a historical cohort comparison group and the use of different insulin delivery 
methods between groups. 
A large international RCT investigated the use of an algorithm to determine if 
intensive glucose control reduced mortality at 90 days (Finfer et al., 2009). The  
Normoglycemia in Intensive Care Evaluation-Survival Using Glucose Algorithm 
Regulation (NICE-SUGAR) study included 6,104 patients admitted to surgical and 
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medical ICUs of 42 hospitals (38 academic tertiary care hospitals and 4 community 
hospitals). Adults who were expected to require more than 3 days of intensive care were 
randomized to either conventional control therapy (n = 3,050) or intensive control 
therapy (n = 3,054) for blood glucose control (Finfer et al., 2009). The conventional 
glucose control therapy consisted of an insulin infusion to maintain blood glucose 
between 140-180 mg/dl, while the intensive insulin therapy group consisted of an insulin 
infusion to maintain blood glucose levels between 80-108 mg/dl (Finfer et al., 2009).  
The study had an overall mortality rate of 13.58% (829/6,104), with 27.5% in the 
intensive group and 24.9% in the conventional control group (Finfer et al., 2009). The 
absolute difference in mortality was 2.6 percentage points 95% CI [0.4, 4.8], and death 
with intensive control (OR =1.14 95% CI [1.02, 1.28]), p = .02 (Finfer et al., 2009). 
Severe hypoglycemia (blood glucose < 40 mg/dl) was reported in 6.8% of the intensive 
control group compared to 0.5% in the conventional control group, p < .01 (Finfer et al., 
2009). The intensive glucose control increased mortality among adults in the ICU: a 
blood glucose target of 180 mg/dl or less resulted in lower mortality than did a target of 
81-108 mg/dl (Finfer et al., 2009). Representation of open-heart patients enrolled in the 
was not reported. 
Leibowitz et al. (2010) investigated the impact of intensive insulin therapy on the 
clinical outcomes of hospitalized patients subsequent to cardiac surgery. Diabetic 
patients, or patients with a blood glucose level > 150 mg/dl post cardiac surgery were 
treated in the ICU with an intravenous insulin protocol to maintain blood glucose levels 
between 110 to 150 mg/dl (Leibowitz et al., 2010). The study utilized a historical control 
(n = 207) in which insulin treatment ranged from insulin infusion to subcutaneous 
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injections. The interventional group (n = 203) received intravenous insulin in all patients, 
with or without a diagnosis of diabetes. Results showed the intervention group had a 
lower mean blood glucose in the ICU and ward compared to the control group (151 + 19 
vs. 166 + 27 mg/dl and 157 + 32 vs. 184 + 46 mg/dl), respectively, p < .001 (Leibowitz et 
al., 2010).  There was no significant difference in the number of hypoglycemic events 
that occurred. The intensive insulin treatment decreased the risk for infection form 11% 
to 5% (56% reduction, p = .018), mainly by reducing the incidence of graft harvest site 
infection (6.9% vs. 2.5%, p = .034). The incidence of atrial fibrillation after CABG 
decreased from 30% to 18% (39% risk reduction) p = .042 (Leibowitz et al., 2010).  
Studies reviewed in this section suggest that patients with and without diabetes 
with persistently elevated blood glucose levels (> 180 mg/dl) would benefit from 
intravenous insulin therapy to maintain levels below 180 mg/dl while in the ICU (Lazar 
et al., 2009). Evidence also suggested critically ill patients requiring vasopressor support, 
prolonged ventilation and extended ICU stays may benefit if blood glucose levels are 
kept below 150 mg/dl (Lazar et al., 2009).  Debate remains to what the lower limits of 
glycemic control should be. Studies have shown mixed results on the benefits  of tight 
glycemic control when blood glucose levels are allowed at normoglycemic levels (80-110 
mg/dl) in the postoperative ICU period.  
 Glycemic control in the perioperative period. 
Several studies support the use of intensive insulin therapy in the perioperative 
period (intraoperative and postoperative) for open-heart patients, in both diabetic and 
non-diabetic patients, suggesting that aggressive glycemic control decreased overall 
mortality, cardiac related mortality, and infection in patients (Carr et al., 2005; Furnary et 
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al., 2004; Lazar et al., 2004). Furnary et al. (2004) analyzed data from The Portland 
Diabetic Project, which included prior published studies of Zerr et al. (1997); Furnary et 
al. (1999), and Furnary et al. (2003). The Portland Diabetic Project was an ongoing study 
that involved 3,554 diabetic patients who underwent open-heart surgery from 1987 to 
2001(Furnary et al., 2004). Patients were divided into three different cohorts based on the 
years of surgery and the blood glucose values targeted in the interventional group 
(Furnary et al., 2004). The first cohort was treated from 1987 to 1991 and consisted of 
patients who received subcutaneous insulin, given every 4 hours to keep serum blood 
glucose between 150 and 200 mg/dl (Furnary et al., 2004).  From 1991 to 1998 the 
second cohort of patients received a continuous insulin infusion  to maintain blood 
glucose levels between 150-200 mg/dl (Furnary et al., 2004).  In 1998 the third cohort of 
patients received continuous insulin infusion to maintain blood glucose levels between 
100-150 mg/dl (Furnary et al., 2004). The use of continuous insulin infusions 
significantly lowered mean blood glucose levels and glycemic control was significantly 
better in the second and third cohorts than in the historic first cohort that received 
subcutaneous insulin (Furnary et al., 2004). Furnary et al. (1999) found that the mean 
blood glucose levels on the day of operation through the third POD were significantly 
lower within the second cohort that received continuous insulin infusion than the first 
cohort that received subcutaneous insulin therapy (183 + 12 vs. 213 + 41 mg/dl, p < .01). 
Furnary et al. (2003) found mean blood glucose levels on the day of the operation 
through the third POD were significantly lower in the third cohort that received 
continuous insulin infusion than the first cohort that received subcutaneous insulin 
therapy (177 + 30 vs. 213 + 41), p < .01 (Furnary et al., 2003).  
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Use of perioperative continuous intravenous insulin infusion reduced major 
infectious morbidity such as DSWIs compared to subcutaneous insulin therapy (Furnary 
et al., 2004). Furnary et al. (1999) found that the patients in the second cohort that 
received a continuous insulin infusion had a significant reduction in the incidence of 
DSWI 0.8% (12/1,499) compared to those patients in first cohort that received 
subcutaneous insulin group 2.0% (19/968), p = .01 (Furnary et al., 1999). Observed 
mortality with continuous insulin infusion was also significantly lower than with 
subcutaneous insulin, reducing mortality by 50% (Furnary et al., 2004). Furnary et al. 
(2003) observed mortality in the third cohort that received a continuous insulin infusion 
2.5% (n = 65/2612) was significantly lower than with the first cohort that received 
subcutaneous insulin therapy 5.3%, (n = 50/942, p < .01). From 2001 to 2005 the 
researchers developed a new method to assess glycemic control in which the average of 
all glucose values obtained on the day of surgery, the first and second PODs determined a 
“3-BG” score.  An increase in 3-BG score was an independent predictor of perioperative 
mortality (Furnary et al., 2004). The mortality for patients with  3-BG level > 200 mg/dl 
was 6.0% compared to patients with a 3-BG level < 200 mg/dl the mortality was 1.6%, p 
< .001 (Furnary et al., 2004). Indicating the risk of post open-heart mortality is doubled 
for each 50 mg/dl increase in 3-BG value (Furnary et al., 2004). Limitations of the study 
included a retrospective design, with a historical cohort utilizing different treatment 
modalities for glycemic control.  
Ouattara et al. (2005) conducted a prospective observational study of 1,146 open-
heart patients (18% with diabetes) to evaluate the role hyperglycemia (blood glucose 
level > 200 mg/dl), in 200 patients with diabetes, on postoperative outcomes; and to 
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determine whether poor intraoperative glycemic control was associated with increased in-
hospital morbidity.  A standard insulin protocol based on subcutaneous insulin was given 
the morning of surgery and intravenous insulin therapy was initiated intraoperatively for 
blood glucose concentrations > 180 mg/dl and titrated according to a predefined protocol 
(Ouattara et al., 2005). Poor intraoperative glycemic control was defined as four 
consecutive blood glucose concentrations greater than 200 mg/dl despite aggressive 
insulin therapy (Ouattara et al., 2005). All patients received the same postoperative 
insulin therapy to maintain blood glucose concentrations below 140 mg/dl (Ouattara et 
al., 2005).  
Results of the study revealed an overall in-hospital morbidity rate of 29% 
(Ouattara et al., 2005). During the intraoperative period, an insulin infusion was initiated 
in 71 patients (36%), among these 71 patients, 35 (50%) had poor intraoperative 
glycemic control despite aggressive insulin therapy (Ouattara et al., 2005). 
Hyperglycemia was significantly more frequent in patients with severe postoperative 
morbidity (37% vs. 10%, p < .01) when compared to those without hyperglycemia 
(Ouattara et al., 2005). Morbidity in this study was defined as at least one of the 
following adverse outcomes: low cardiac output, hypotension needing intra-aortic balloon 
pump support, malignant arrhythmia, mechanical ventilation > 48 hours, neurologic 
deficit, acute renal failure, infectious outcome including sternal or leg infection, and/or 
septic shock (Ouattara et al., 2005). Multivariate analysis identified poor glycemic 
control as an independent risk factor of severe morbidity along with pulmonary 
hypertension, increased intraoperative blood transfusion, hypothermic CPB, preoperative 
plasma creatinine, and CPB time (Ouattara et al., 2005). In diabetic patients who 
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exhibited poor intraoperative glycemic control, the overall in-hospital mortality rate was 
significantly higher (11.4% vs. 2.4%, p < 0.05), and a prolonged ICU LOS was more 
frequently observed (46% vs. 19%, p < .01) compared to diabetic patients with achieved 
glycemic control (Ouattara et al., 2005). Limitations with the study included an 
observational design. 
Lecomte et al. (2008) retrospectively analyzed two groups of consecutive patients 
undergoing cardiac surgery with CPB to determine the effect of intraoperative and 
postoperative glycemic control on renal function after cardiac surgery based on the risk, 
injury, failure, loss and end-stage kidney failure (RIFLE) criteria, and on the need for 
acute postoperative dialysis. The historic control group (n = 305) received insulin when 
blood glucose levels exceeded 150 mg/dl, and the tight glycemic group (n = 745) 
received insulin to a target blood glucose level 80-110 mg/dl in the intraoperative and 
postoperative period. Results showed that in patients without diabetes, tight glycemic 
control was associated with decreased incidence of renal impairment (p = .01) and failure 
(p = .02) scoring according to the RIFLE criteria, as well as a reduced incidence of acute 
postoperative dialysis (from 3.9% in control to 0.7% in tight group), p < .01 (Lecomte et 
al., 2008). Additionally, the 30-day mortality rate was lower in the tight glycemic group 
compared to the control group (1.2% vs. 3.6%), p = .02 (Lecomte et al., 2008).  
Doenst et al. (2005) performed a multivariate logistic regression analysis on all 
diabetic (n = 1,579) and non-diabetic (n = 4,701) patients undergoing open-heart surgery 
in a two year period to determine the effect of hyperglycemia, during CPB, on 
perioperative morbidity and mortality (Doenst et al., 2005). Boluses of insulin were given 
during CPB when the glucose levels exceeded 270 mg/dl, when the serum potassium 
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level exceeded 6.0 mmol/L, or both (Doenst et al., 2005). Overall mortality was 1.8% 
(115/6,280). Comparison of those patients with peak serum glucose levels during CPB of 
less than and greater than 360 mg/dl in non-diabetic patients revealed those patients with 
severe hyperglycemia (> 360 mg/dl) had significantly more preoperative risk factors than 
patients with peak glucose levels of less than 360 mg/dl (Doenst et al., 2005).  In contrast, 
the risk profiles of diabetic patients with peak glucose levels of greater than or less than 
360 mg/dl were not different from non-diabetic patients (Doenst et al., 2005).   
Overall preoperative risk factors were higher in the diabetic than in the non- 
diabetic patients (Doenst et al., 2005). These risk factors included hypertension, 
preoperative MI, triple vessel disease, peripheral vascular disease, and low ejection 
fraction (Doenst et al., 2005).  Preoperative risk factors associated with severe 
hyperglycemia in the non-diabetic population included congestive heart failure, 
cardiogenic shock, renal failure, undergoing a second CABG, any subsequent open-heart 
surgery (Doenst et al., 2005). Although mortality was less than 2% when the peak 
glucose levels remained less than 360 mg/dl, the incidence tripled when the peak glucose 
level exceeded this value for both diabetic patients and non-diabetic patients (Doenst et 
al., 2005).  In both patient populations, peak glucose level was an independent predictor 
of death, in patients with diabetes (OR = 1.20, 95% CI [1.08, 1.32], p < .005); and for 
non-diabetic patients (OR = 1.12, 95% CI [1.06, 1.19], p < .01).  A high glucose level 
during CPB was also an independent predictor of all major adverse events in both patient 
groups (Doenst et al., 2005). All adverse events included stroke, infection, myocardial 
infarction, and cardiac syndromes that produced a low ejection fraction (Doenst et al., 
2005).  
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Lazar et al. (2004) used a RCT to determine the relationship between tight 
glycemic control, with modified glucose-insulin-potassium (GIK) solution, in diabetic 
patients undergoing CABG surgery, and perioperative outcomes. One hundred forty one 
diabetic patients were randomized to tight glycemic control (blood glucose 125-200 
mg/dl) with GIK in the intraoperative period, and 12 hours postoperatively or standard 
therapy (serum glucose < 250 mg/dl) using intermittent subcutaneous insulin in the 
intraoperative period and continuing for 12 hours postoperatively (Lazar et al., 2004). 
Results showed GIK treated patients achieved significantly better glycemic control, 
immediately before CPB than the standard therapy (169 + 4.9 vs. 209 + 5.3 mg/dl), p < 
.01 (Lazar et al., 2004). Twelve hours postoperative glycemic control was significantly 
better in the GIK group than the standard group (134 + 3.7 vs. 266 + 6.3 mg/dl), p < .001 
(Lazar, et al., 2004). Patients in the GIK group also experienced a lower incidence of 
atrial fibrillation postoperatively (16.6% vs. 42%, p = .0017), a shorter postoperative 
LOS (6.5 + 0.1 vs. 9.2 + 0.3 days, p = .003), and less incidence of pneumonia and wound 
infections (0% vs. 13%, p = .010) than those in standard group (Lazar et al., 2004). In the 
5 year follow up study, the interventional GIK group experienced less episodes of 
recurrent ischemia (5% vs. 19%, p = .01), and developed fewer recurrent wound 
infections (1% vs. 10%, p = .03) when compared to the standard therapy group (Lazar et 
al., 2004).  
In a retrospective analysis of the implementation of a strict insulin protocol to 
achieve tight glucose control in open-heart surgical patients, Carr et al. (2005) aimed to 
determine if tight glycemic control would decreased the incidence of postoperative 
wound infection. Prior to the initiation of an insulin protocol, blood glucose levels of 200 
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mg/dl were acceptable. With the initiation of the protocol, diabetic patients were given an 
insulin infusion when blood glucose values reached 125 mg/dl; non-diabetic patients 
received insulin intravenous bolus for the same value (Carr et al., 2005). In the ICU 
patients were treated with a continuous insulin infusion protocol when blood glucose 
levels reached a trigger value.  Over a period of two years the researcher adjusted the 
trigger value in ICU as follows: phase I-150 mg/dl, phase II-125 mg/dl, and phase III-110 
mg/dl (Carr et al., 2005). Good blood glucose control was defined as a glucose level of < 
130 mg/dl more than 50% of the measured time (Carr et al., 2005). The team found of 
818 patients that underwent CABG surgery, 737 (90%) received insulin, even though 
only 43% of patients had a diagnosis of diabetes mellitus (Carr et al., 2005). They found 
that the factor that was most predictive of glucose being well controlled was the protocol 
with the 110 mg/dl trigger value for initiation of insulin infusion (Carr et al., 2005). The 
researchers also found the rate of mediastinitis decreased from 1.6% to 0% (Carr et al., 
2005).  
Chan et al. (2009) investigated, in a RCT the relationship between different target 
levels of glucose and the clinical outcomes of patients undergoing open-heart surgery 
with CPB. One hundred and nine patients were randomized to either the tight glycemic 
control (n = 55), which maintained blood glucose levels between 80-130 mg/dl or the 
conventional glycemic control (n = 54), which maintained blood glucose levels between 
160-200 mg/dl (Chan et al., 2009). Blood glucose levels were maintained during the 
intraoperative period and 36 hours postoperatively by means of a continuous intravenous 
insulin infusion. All patients also received an intravenous glucose infusion of 8-12 g/hr 
during the intraoperative and first 24 hours postoperatively, after which enteral feedings 
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started (Chan et al., 2009). The researchers found that mean blood glucose levels in the 
tight glycemic group were significantly lower than the conventional glycemic group 
(126.69 vs. 168.21 mg/dl), p < .0016 (Chan et al., 2009). However, there was no 
significant difference between groups regarding clinical outcomes, including the duration 
of mechanical ventilation, ICU LOS, number of blood transfusions, occurrence of 
postoperative infections, hypoglycemic events, neurological dysfunction or 30 day 
mortality rates (Chan et al., 2009). The study may have been under powered due to a 
small sample size, especially for dichotomous variables as infections.  
Pittas, Siegel and Lau (2004) conducted a meta-analysis of RCT studies that 
investigated insulin therapy for critically ill patients. They discovered that in the trials 
that administered insulin perioperatively for open-heart surgery, no benefit of insulin 
administration was noted (Pittas et al., 2004). They also discovered that most RCTs 
utilized GIK solutions as opposed to insulin in normal saline, and when all GIK studies 
were combined, there was a trend for GIK to reduce mortality, but it did not reach 
statistical significance (Pittas et al., 2004). In contrast, studies that administered insulin 
by a method other than GIK (i.e. insulin in normal saline), there was a statistically 
significant relative risk mortality reduction of 27% with insulin therapy (Pittas et al., 
2004).   
Lazar et al. (2011) conducted a RCT to determine whether more aggressive 
glycemic control would results in more optimal clinical outcomes and less morbidity than 
can be achieved with moderate control in patients with diabetes mellitus undergoing 
CABG surgery.  Eighty-two diabetic patients were randomized to aggressive glycemic 
control (90-120 mg/dl) or moderate glycemic control (120-180 mg/dl) using continuous 
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insulin infusion starting at induction of anesthesia and continuing for 18 hours after 
surgery. Results revealed no difference in the incidence of major adverse events between 
the groups (17/42 moderate vs. 15/40 aggressive, p = .91). Major adverse events included 
30-day mortality, MI, neurologic events, DSWIs, and atrial fibrillation. Patients with 
aggressive control had lower mean glucose at the end of 18 hours of insulin infusion 
compared to moderate control (103 + 17 vs. 135 + 12 mg/dl), respectively,  p < .001 
(Lazar et al., 2011). Those patients in the aggressive control group had a higher incidence 
of hypoglycemic events (blood glucose < 80 mg/dl) than the moderate control group 
(30/42 vs. 4/40), p < .001 (Lazar et al., 2011).  These findings are similar to the findings 
of Bhamidipati et al. (2011) that found moderate glycemic control was superior to tight 
glycemic control for patients undergoing isolated CABG surgery.  
Bhamidipati et al. (2011) stratified 8,662 patients who underwent isolated CABG 
surgery into 3 arbitrary postoperative glycemic groups, based on 3-day average 
postoperative serum glucose levels. The tight group was composed of patients with 
average serum glucose not more than 126 mg/dl, the moderate group was composed of 
patients with average serum glucose levels of 126.1 to 179.9 mg/dl, and the liberal group 
was composed of patients with a mean serum glucose of at least 180 mg/dl (Bhamidipati 
et al., 2011). Statistical analysis revealed more patients in the tight group had 
preoperative renal failure (p = .001), and underwent more emergent operations (p = .007). 
However, use of the STS prediction model revealed mortality risk was lower in the tight 
groups, p < .001 (Bhamidipati et al., 2011). The STS model considers the type of surgery, 
preoperative co-morbidities, and intraoperative risks to determine overall risk of poor 
outcomes.  Results showed the moderate glycemic group had the lowest mortality (tight 
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2.9%, 4/134; moderate 2.0%, 56/2785; liberal 3.4%, 59/1739), p = .02. In addition, the 
moderate group had the lowest incidence of major complications (tight 19.4%, 26/134; 
moderate 11.1%, 308/2785; liberal 14.2%, 247/1739), p < .001 (Bhamidipati et al., 2011).  
Limitations of this study include a retrospective design, and a concern that the tight 
glycemic arm was under powered, having only 134 participants compared to the 
moderate glycemic group of 2,785 and the liberal group having 1,739 participants.  
Emam et al. (2010) conducted a prospective study of 120  subjects with a 
diagnosis of diabetes, undergoing open-heart surgery randomized to either a control 
group, simple sliding scale (n = 40) to keep blood glucose < 200 mg/dl or the Braithwaite 
protocol (n = 80) to maintain tight control of 100 to 150 mg/dl. Results of the study 
showed that subjects in the interventional Braithwaite group had blood glucose levels less 
than 200 mg/dl at the end of the 48 hour postoperative, compared to the control group, 
which did not obtain a blood glucose level of less than 200 mg/dl, 48 hours 
postoperatively, in all subjects in the control group (p < .01). There was a significant 
reduction in hospital stay in the tight group compared to the control group (mean in days 
9.1 + 2.3 vs. 12.3 + 7.6 days), p < .001. There was also no wound infection in the tight 
control group compared to 12% (5/40) in the control group (Emam et al., 2010).  
 Glycemic control in the intraoperative period. 
Studies that have investigated the use of intensive insulin therapy exclusively in 
the intraoperative period are very limited. Two studies investigated the effects of 
glycemic control in the intraoperative period on patient outcomes (Azarfarin, 
Sheikhzadeh, Mirinazhad, Bilehjani, and Alizadehasl, 2011; Gandhi et al., 2007). Gandhi 
et al. (2007) compared outcomes of intensive insulin therapy during cardiac surgery with 
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those of conventional intraoperative glucose management. In a RCT, with blinded 
assessment, 400 patients undergoing cardiac surgery with CPB were randomized to 
receive intensive insulin therapy (n = 199) or conventional treatment (n = 201; Gandhi et 
al., 2007). Patients in the intensive insulin therapy group received a continuous 
intravenous infusion of regular insulin implemented when patient blood glucose levels 
exceeded 100 mg/dl; blood glucose levels were maintained between 80 and 100 mg/dl 
during the intraoperative period (Gandhi et al., 2007). The conventional treatment groups 
received insulin during the surgery when their blood glucose levels exceeded 200 mg/dl 
via intravenous bolus injections of 4 units of regular insulin every hour until levels were 
below 200 mg/dl (Gandhi et al., 2007). If the blood glucose level exceeded 250 mg/dl in 
the conventional group, patients were placed on a continuous insulin infusion that was 
continued until the blood glucose levels were less than 150 mg/dl (Gandhi et al., 2007). 
 The mean glucose concentrations were significantly lower in the intensive 
treatment group post- CPB compared to the conventional group (123 +24 vs. 148+ 35 
mg/dl), p < .01 (Gandhi et al., 2007). Blood glucose concentrations were significantly 
lower at the end of surgery in the intensive treatment group compared to the conventional 
group (114 + 29 vs. 157 + 42 mg/dl), p < .01 (Gandhi et al., 2007).   There was no 
difference between the groups in the number of hypoglycemic events, ICU LOS, or 
hospital LOS (Gandhi et al., 2007). More deaths (4 vs. 0, p = .061) and strokes (8 vs. 1, p 
= .020) occurred in the intensive treatment group as compared to the conventional group 
(Gandhi et al., 2007). The authors concluded that the intensive insulin therapy during 
cardiac surgery failed to reduce perioperative death or morbidity (sternal wound 
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infections, prolonged ventilation, cardiac arrhythmias, stroke, acute renal failure), and 
may increase the risk for morbidity (Gandhi et al., 2007).  
Azarfarin et al. (2011) investigated, in a RCT, the effect of blood glucose control 
with insulin in preventing hyperglycemia during and after CABG surgery in non-diabetic 
patients.  One hundred seventeen patients were randomized to a control group (n = 58), 
which received bolus insulin coverage only if blood glucose levels exceeded 200 mg/dl, 
or experimental group (n = 59), which received an insulin infusion to maintain blood 
glucose levels between 110 to 126 mg/dl (Azarfarin et al., 2011). Insulin therapy was 
limited to intraoperative period, but blood glucose levels during surgery and up to 48 
hours after surgery, and early postoperative complications were compared between the 
study and control groups (Azarfarin et al., 2011). Results of the study, showed peak 
intraoperative blood glucose levels in the experimental group were significantly lower 
than in the control group (126.4 + 17.9 vs. 137.3 + 17.6 mg/dl, p = .024). The frequency 
of severe hyperglycemic (blood glucose > 180 mg/dl) events during the intraoperative 
period was greater in the control group compared to the experimental group, (32.7%) 
19/58 versus (10.1%) 6/59, respectively, p = .002 (Azarfarin et al., 2011). There was no 
difference between the groups in the postoperative peak blood glucose, and neither group 
experienced hypoglycemic events (Azarfarin et al., 2011). Early postoperative 
complications composite was greater in the control group than the experimental group, 
(32.7%) 19/58 versus (16.9%) 10/59, respectively, p = .047. The complication composite 
was composed of major complications in cardiac, pulmonary, neuropsychological, renal, 
infectious, and re-exploration.   
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Chaney, Nikolov, Blakeman, and Bakhos (1999) attempted to develop an insulin 
administration protocol to maintain normoglycemia in patients undergoing cardiac 
surgery and to study the effects of intraoperative blood glucose management on serum 
levels of creatine phosphokinase isoenzyme BB (CK-BB) and S-100 protein.  Twenty 
patients without diabetes mellitus diagnosis were randomized to receive either tight 
glycemic control intraoperatively (n = 10), or to receive no control of blood glucose 
intraoperatively (n = 10).   
Results showed that despite the tight glycemic group receiving insulin both 
groups experienced similar significant increases in blood glucose levels during 
hypothermic CPB (Chaney et al., 1999).  The tight glycemic group had significantly 
lower blood glucose levels at sternal closure and ICU admission time (125.4 + 53.1 and 
84.7 + 41 mg/dl), respectively, compared to the group receiving no insulin treatment 
(237.6 + 61.2, and 201.4 + 67.5 mg/dl), respectively, p < .001 (Chaney et al., 1999).  
There was no difference in peak intraoperative blood glucose level between the tight 
glycemic group from the control group (301.6 + 104 vs. 312.6 + 100.7 mg/dl). Forty 
percent of patients in the tight control group required treatment in the ICU for 
hypoglycemia (blood glucose level < 60 mg/dl) compared to zero patients in the no 
control group (Chaney et al., 1999).  
Hypoglycemia 
 Intensive insulin therapy has become a major therapeutic target in cardiac surgical 
patients. It has, however, been associated with an increased risk of hypoglycemia. A few 
studies have investigated hypoglycemia related to cardiac surgery (Chaney et al., 1999; 
Stamou et al., 2011; Wiener, Wiener, & Larson, 2008). Stamou et al. (2011) sought to 
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identify the factors predisposing to hypoglycemia with intensive insulin therapy and 
investigate its effect on early clinical outcomes after cardiac surgery. A concurrent cohort 
study of 2,538 consecutive patients undergoing cardiac surgery over a 5 year period was 
carried out (Stamou et al., 2011). Multivariate logistic regression analysis and propensity 
score matching were used to identify the risk factors for developing hypoglycemia (blood 
glucose < 60 mg/dl) after cardiac surgery, and to compare major morbidity, operative 
mortality, and actuarial survival between patients in whom hypoglycemia developed (n = 
77) and those in whom it did not (n = 2461). To improve balance for analysis, a 
propensity score analysis was used, which included 61 patients in whom hypoglycemia 
developed an 305 patient in whom it did not (1 to 5 matching; Stamou et al., 2011).  
 Results showed risk factors for hypoglycemia included female gender (OR = 2.3, 
95%CI = [1.4, 3.7], p < .001), diabetes (OR = 2.8, 95% CI = [1.7, 4.5], p < .001), 
hemodialysis (OR=3.0, 95% CI [1.3-6.8], p = .009), intraoperative blood transfusion (OR 
= 2.0, 95% CI [1.2, 3.4], p = .010), and an earlier date of surgery (historic cohort) 
(OR=2.1, 95% CI [1.2, 3.7], p = .007). Hypoglycemia, compared to normoglycemia, 
increased the risk for operative mortality in univariate (10% vs. 2%; p < .001), but not in 
propensity score-adjusted analysis (OR = 2.5, 95% CI [0.9, 6.7], p = .11). The propensity 
score-adjusted analysis demonstrated a significant increase in hemorrhage-related re-
exploration (p = .048), pneumonia (p < .001), reintubation and prolonged ventilation (p < 
.001), and ICU and hospital LOS (p < .001) for hypoglycemic compared with 
normoglycemic patients (Stamou et al., 2011).  
Zimmerman et al. (2004) examined the performance of a postoperative insulin 
infusion protocol to maintain tight glycemic control, defined as a blood glucose level of 
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80–150 mg/dl, in cardiothoracic surgical patients, with and without diabetes mellitus. In 
this retrospective cohort study, two periods of measurement were performed: a 6-month 
baseline period prior to the initiation of the insulin infusion protocol (n = 174) followed 
by a 6-month intervention period in which the tight glycemic protocol was utilized in the 
postoperative period (n = 168). The researchers found that blood glucose measurements 
occurred with greater frequency in the tight control group ( baseline group 47%, tight 
control group 67%), p = .01 (Zimmerman et al., 2004). They also found that the median 
time to obtain a blood glucose level < 150 mg/dl was 2.1 hours in the tight control group 
and 9.4 hours in the baseline group, p < .001 (Zimmerman et al., 2004). The occurrence 
rate of hypoglycemia (blood glucose < 65 mg/dl) was 9.8% in the baseline group versus 
16.7% in the tight control group; while more episodes of hypoglycemia occurred in the 
tight control group it was not significant (Zimmerman et al., 2004). The study showed 
that an insulin infusion protocol designed to achieve a goal blood glucose range of 80–
150 mg/dl efficiently and significantly improved tight glycemic control in postoperative 
cardiothoracic surgery patients without significantly increasing the incidence of 
hypoglycemia (Zimmerman et al., 2004).  
Summary of Research for Glycemic Control 
The understanding of the importance of glycemic control in the preoperative,  
intraoperative and postoperative period and its impact on surgical site infections is 
imperative to improve the quality of care for patients undergoing open-heart surgery. 
There is a consensus that surgical site infections have a significant impact on 
postoperative outcomes in the open-heart surgical patients. Mortality, from surgical site 
infection, is increased 3-5 times compared to individuals without infection, and hospital 
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length of stay is increased 2-4 times that of non-infected patients. There are ample 
observational studies that suggest surgical site infections increase mortality and morbidity 
of patients, as well as increase resource utilization of hospitals that must treat these 
infections. Multiple observational studies, and a few interventional studies have 
suggested that diabetes and hyperglycemia, in the perioperative period, are associated 
with more infectious complications, longer hospital stays, higher morbidity, mortality and 
increased resource utilization after open-heart surgery. The few randomized controlled 
trials have been more controversial on the benefits of tight glycemic control. Some 
studies showing benefit, some showing no difference in tight glycemic control compared 
to moderate control and some studies showing worse outcomes with tight glycemic 
control. 
Studies that investigated biomarkers CRP and PCT revealed that patients who 
experienced postoperative complications, including infection, have significantly higher 
values of both CRP and PCT in the preoperative, and immediate postoperative period. 
The studies reviewed reported a wide range of discriminating CRP values in the 
identification of an infectious process and/or postoperative complications. The CRP 
values suggestive of infection ranged from 96 to 170 mg/L in the immediate 
postoperative period, and/or a baseline preoperative high sensitive CRP value of > 3-5 
mg/L (> 0.3-0.5 mg/dl). Studies also showed a wide range of discriminating PCT values 
in the identification of infection and/or postoperative complications. Procalcitonin values 
ranged from 0.5-5 ng/dl in the immediate postoperative period. However, PCT values 
have been identified in multiple studies to be superior to CRP in detection of infection 
and sepsis in the postoperative period.  
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Studies have investigated interventions to reduce infection in open-heart surgery 
including controlling hyperglycemia with continuous insulin infusions. Few studies 
supporting the use of intensive insulin therapy in open-heart patients to improve patient 
outcomes, as infection, are randomized controlled trials. Evidence is primarily derived 
from observational studies that cannot determine a causal link, and these studies have had 
diverse results. Of the studies that utilized randomized controlled trials, most are in the 
perioperative or postoperative period, leaving glycemic control during the intraoperative 
period essentially unstudied. The blood glucose levels maintained in the intensive insulin 
groups varied amongst the studies, with some studies using a value of 80-110 mg/dl and 
other using 120 -150 mg/dl as their definition of tight control. Of the studies using the 
lower glucose target values of 80-130 mg/dl, only the study performed in the 
postoperative period showed improved patient outcomes of reduced mortality and 
reduced infection. The intraoperative and perioperative studies with the tight glycemic 
control (80-130 mg/dl) did not produce improved patient outcomes, and one had 
potentially worse patient outcomes. Of interest, the study conducted in the perioperative 
period that showed improved patient outcomes maintained higher blood glucose levels 
(125-200 mg/dl) in the intensive insulin group. Inferences from these studies would 
suggest that tighter blood glucose control (80-130 mg/dl) may be most effective in the 
postoperative period, and more moderate blood glucose levels should be maintained in 
the intraoperative period.  
Current Gaps in Research for Glycemic Control in Open-heart Surgery 
Lack of randomized controlled trials, which address the causal nature of the 
relationship between hyperglycemia and surgical site infections in open-heart surgery 
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patients, is an identified gap in knowledge, which must be addressed. If hyperglycemia is 
the cause of surgical site infections then it is reasonable to infer that blood glucose levels 
maintained more closely to normal, throughout the perioperative period, would improve 
infection rates. However, if hyperglycemia is only a reflection of the severity of the stress 
response, maintaining euglycemia may not be of benefit, and could be potentially 
detrimental. 
The use and/or benefits of CRP and/or PCT testing in the early identification of 
infection for open-heart patients have yet to be determine. Specific discriminative values 
that identify infection in the early postoperative period are needed, and until more RCT 
studies can be completed decisions for early intervention in the treatment of postoperative 
infection should be based on the entire clinical presentation of the patient and not strictly 
on pre-set biomarker values. It is still undetermined if the use of both PCT and CRP 
biomarkers should be utilized in the identification of postoperative infection, as opposed 
to each individually; or the trending of biomarkers that may give practitioners better 
evidence in infectious identification and decision making regarding treatment.  
The optimal perioperative glycemic range that improves patient outcomes, such as 
reduced infection rates, with minimal risk of hypoglycemia has yet to be identified. 
Closure of this gap is imperative before standardization and/or recommendations of 
intraoperative glycemic protocols are instituted for open-heart surgery. Future studies 
also need to investigate one element of glycemic control, either the route of insulin 
administration, intravenous or subcutaneous, with the same glycemic end target or studies 
that investigate the level of glycemic control, tight or conventional, utilizing the same 
method of insulin delivery, either subcutaneous or intravenous. Until more randomized 
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controlled trials can be conducted, it remains unclear if perioperative tighter blood 
glucose control will improve patient outcomes postoperatively. 
The next chapter discusses the study sample, design, research questions, and 
hypothesis for the effect of intraoperative tight glycemic control on surgical site infection 
rates in patients undergoing open-heart surgery.  
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Chapter Three 
Methods 
Introduction 
This chapter describes the methods that were used to investigate the effects of 
various insulin protocols on intraoperative glycemic control in the open-heart surgical 
patient, and on postoperative surgical site wound infection.  The study design, sample 
characteristics, interventional protocols, measures, data collection and instrumentation 
are described. This is followed by a description of the data analysis plan. 
The primary study aims were to investigate the effects of three different glycemic 
treatment conditions (tight, conventional, and standard) in the intraoperative period on 
postoperative surgical site infection (SSI) rates, and postoperative biomarkers, 
procalcitonin (PCT), and C-reactive protein (CRP), in patients undergoing open-heart 
surgery. Secondary aims were to examine the effects of three glycemic treatment 
conditions on perioperative blood glucose, intraoperative glycemic stability, and 
intensive care unit (ICU) length of stay (LOS) in patients undergoing open-heart surgery. 
Research Design 
A multilevel, single factor, within-subjects design was utilized. Patients were 
nested within anesthesia provider teams. The design was counterbalanced by means of a 
Latin square, where each of three anesthesia provider teams dispensed each of three 
glycemic treatment conditions once. This arrangement spread any practice effects over 
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the three treatment conditions equally. The study used a three-group randomized clinical 
trial design to determine if there was a difference on 1) postoperative surgical site 
infection rates; 2) infection biomarker levels procalcitonin and C-reactive protein; 3) 
blood glucose levels; 4) glycemic stability; and 5) intensive care unit length of stay in 
open-heart surgical patients (Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Research Design 
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Setting 
The study was conducted in the operating room suites at a major Veterans Affairs 
Medical Center in Tampa Florida. A convenience sample for this study was drawn from 
the adult population who were scheduled to undergo coronary artery bypass grafting 
(CABG) surgery, CABG combined with valve repair, or valve repair/replacement surgery 
from June 2010 through June 2011.   
Sample  
A convenience sample of 112 participants was recruited. Inclusion criteria 
included: 1) over the age of 21; 2) on cardiopulmonary bypass (CPB) or off CPB; 3) 
elective or urgent CABG, with or without combined valve surgery; and 4) valve surgery. 
Participants were excluded from the study if they were: 1) chronically 
immunosuppressed, such as steroid dependent, diagnosed with any autoimmune disease, 
or human immunodeficiency virus; 2) suffered from end-stage organ disease such as end 
stage renal or liver disease; 3) currently had active infections such as increased white 
blood cell count, fevers, or productive coughs; 4) underwent emergent or salvage CABG 
surgery where risk for infection is higher; 5) had an implanted insulin pump; or 6) were 
in another interventional clinical trial. After exclusions (n = 35), and patient refusals to 
participate (n = 40), a total of 37 subjects were enrolled in the study over a period over 12 
months, and randomized to the three glycemic control conditions.  
Interventions 
The study used three different glycemic control interventions, during the 
intraoperative period, in an attempt to determine if maintaining blood glucose levels 
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closer to normal values via a continuous infusion would reduce postoperative wound 
infections.  
Intervention group I: tight glycemic control.  
Patients randomized to the tight glycemic group received a continuous 
intravenous infusion of regular insulin in the intraoperative period titrated per a modified 
Portland Protocol from Vanderbilt University Medical Center, Tennessee. The initial 
bolus of insulin and insulin infusion therapy was initiated prior to induction of anesthesia 
if the morning blood glucose is greater than 149 mg/dl or any time intraoperatively that 
the blood glucose elevated above 149 mg/dl (Table 1). 
Table 1. Initial Insulin Infusion Tight Glycemic Intervention Group 
Blood Glucose (mg/dl) Bolus dose of Insulin 
(units) 
Insulin Infusion Rate 
(unit/hour) 
150-180 5 5 
181-200 10 10 
201-250 15 15 
251-350 20 20 
 
The subsequent titration of insulin infusion therapy for the tight glycemic group 
maintained blood glucose levels between 110-149 mg/dl throughout the intraoperative 
period (Table 2). The intraoperative maintenance of blood glucose was monitored, 
recorded and titrated to blood glucose levels sampled every 30 minutes by arterial line 
drop sample, and started 30 minutes after entry into the surgical suite. Upon transfer to 
the ICU the intraoperative protocol ended and all subjects received the standardized 
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glycemic control for the ICU. An insulin infusion of 100 units of regular insulin in 100 
ml of normal saline was used for the study.  
Table 2. Titration of Insulin Infusion Protocol Tight Glycemic Group 
 
 
Intervention group II: conventional glycemic control. 
 Patients randomized to the conventional glycemic group received a continuous 
intravenous infusion of regular insulin in the intraoperative period titrated per a modified 
Portland Protocol from Vanderbilt University Medical Center, Tennessee. The initial 
insulin bolus and infusion was initiated prior to induction of anesthesia if the morning 
blood glucose was greater than 180 mg/dl or any time intraoperatively that the blood 
glucose elevated above 180 mg/dl (Table 3).  
 
 
Responders  
Blood Glucose level 
Defined as a decrease in blood glucose level in response to initial 
insulin treatment 
> 149 mg/dl Maintain insulin infusion at current rate 
110-149 mg/dl Adjust insulin infusion to 10 units /hour or half of initial infusion 
rate (whichever is lower) 
 
Non Responders  Defined as no change or an increase in blood glucose level in 
response to initial insulin treatment 
 
< 200 mg/dl Increase infusion rate by an additional 10 units /hour 
> 200 mg/dl  Double infusion rate up to a maximum of 50 units/ hour and 
double the initial bolus up to a maximum of 25 units.  
Hypoglycemia Treatment 
If  blood glucose level 
< 80mg/dl 
10-15 ml 50% Dextrose (D50) 
Recheck blood glucose in 15 minutes  
Repeat with 20 ml 50% Dextrose if repeat blood glucose less 
than 80 mg/dl  
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Table 3. Initial Insulin Infusion for Conventional Glycemic Group 
 
 
 
 
 
 
The insulin infusion was titrated throughout the intraoperative period to maintain 
blood glucose levels between 150-180 mg/dl (Table 4). The intraoperative blood glucose 
was monitored, recorded and titrated to blood glucose levels sampled every 30 minutes 
by arterial line drop sample method.  Intraoperative blood glucose monitoring started 30 
minutes after entry into the surgical suite. Upon transfer to the ICU the intraoperative 
protocol ended and all subjects received the standardized glycemic control for the ICU. 
The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.  
Intervention group III: standard glycemic control, control group. 
Patients randomized to the standard glycemic group received intravenous 
injections of regular insulin in the intraoperative period titrated per the usual care 
protocol utilized at the study site (Table 5). The initial bolus of insulin was initiated prior 
to induction of anesthesia if the morning blood glucose was greater than 180 mg/dl or any 
time intraoperatively that the blood glucose elevated above 180 mg/dl (Table 5).  
Measures 
Data collection at baseline included the following measures: 
 
Blood Glucose  
(mg/dl) 
Bolus dose of Insulin  
(units) 
Insulin Infusion 
Rate (unit/hour) 
180-200 5 5 
 
201-250 10 10 
 
251-300 15 15 
 
> 300 20 20 
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Demographics. 
 Demographic variables including age, sex, height, weight, race and ethnicity was 
measured and recorded at baseline during the preoperative interview (Appendix A). 
 
Table 4. Titration of Insulin Infusion for Conventional Glycemic Group 
 
Table 5. Standard Glycemic Treatment Group Intravenous Insulin Bolus 
Blood Glucose Level mg/dl Bolus of insulin given U 
180-200 5 
201-250 10 
251-300 15 
> 300 20 
Responders  
Blood Glucose 
Defined as a decrease in blood glucose level in response to initial 
insulin treatment 
>180 mg/dl Maintain insulin infusion at current rate 
 
150-180 mg/dl Adjust insulin drip to 10 units /hour or half of initial infusion rate 
(whichever is lower) 
 
Non Responders  Defined as no change or an increase in blood glucose level in 
response to initial insulin treatment 
 
< 200 mg/dl Increase infusion rate by an additional 10 units /hour 
 
> 200 mg/dl  Double infusion rate up to a maximum of 50 units/ hour and double 
the initial bolus up to a maximum of 25 units.  
 
Hypoglycemia Treatment  
If  blood glucose 
level <  80 mg/dl 
10-15 ml 50% Dextrose (D50)  
Recheck blood glucose in 15 minutes  
Repeat with 20 ml 50% D50, if repeat blood glucose less than 80 
mg/dl  
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Medical history.  
The following variables were collected by chart review at baseline by the 
principle investigator or co-investigator obtaining the patient informed consent. Historical 
variables included type of preoperative diabetic control (insulin, oral, diet or none), 
smoking history (never, past, current), historical co-morbidities (hypertension, congestive 
heart failure, history of myocardial infarction, history of stroke, renal insufficiency, and 
peripheral vascular disease), and American Society of Anesthesiologists (ASA) 
classification (Appendix A). 
Surgical clinical variables.  
Surgical variables measured included the surgeon of record, type of surgery, 
number and type of harvest site grafts, Society of Thoracic Surgeons operative status 
(elective, urgent), first or subsequent surgery, surgery time, bypass time, aortic cross 
clamp time (ischemic time), and ICU length of stay. In addition to standard cardiac 
laboratory studies a preoperative glycosylated hemoglobin (HbA1c) was collected during 
the preoperative visit. The HbA1c was the baseline data for measure of preoperative 
glycemic control. Measures collected the day of surgery included fasting blood glucose 
and glucose every 30 minutes after entry into the surgical suite.  (Appendix A) 
Primary outcome variables. 
The presence or absence of deep, or/and superficial sternal wound infection and 
deep, superficial harvest site infection within in six weeks postoperatively was a primary 
outcome variable. Infection assessment was performed during the intensive care phase, at 
hospital discharge, two-week post hospital discharge and six-week post hospital 
discharge by independent blinded researchers that were part of the cardiothoracic team.  
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Procalcitonin and CRP concentrations were collected in addition to clinical signs 
for indications of infection. These biomarker concentrations were collected the morning 
of surgery, after successful separation from CPB, and every morning for five days 
postoperatively. Values were drawn by anesthesia providers and ICU registered nurses or 
laboratory personnel with the standard morning blood work, and trended over the six-day 
period.  
Secondary outcome variables. 
Blood glucose values were obtained every 30 minutes in the intraoperative period, 
and were drawn and recorded by the certified registered nurse anesthetist (CRNA) 
performing the anesthetic. Blood glucose levels were also monitored every 30 minutes 
for the first six hours in the postoperative period. Blood glucose values obtained in the 
postoperative period were drawn and recorded by the primary ICU registered nurse 
caring for the patient.  
Intraoperative glycemic stability was operationalized as how often blood glucose 
levels were maintained as normal or maintained in the preset target ranges for each 
group. If intraoperative blood glucose levels fell outside of normal or, the preset target 
ranges, for each protocol, 3 consecutive blood glucoses (1.5 hours) despite insulin 
therapy a marker of inadequate glycemic control was recorded.  Length of ICU stay was 
measured by the total number of days each patient stayed in the ICU.  (Appendix A). 
Procedures 
Protection of human subjects. 
Approval for the study was obtained through the research and development center 
at the study site and the University of South Florida Institutional Review Board.  
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Screening and recruitment.   
A member of the anesthesia team during the preoperative interview screened 
patients for inclusion and exclusion criteria. Recruitment of patients occurred Monday 
through Friday for any patient scheduled to undergo CABG, combined CABG/valve, or 
valve surgery from June 1, 2010 through May 31, 2011. One hundred and twelve 
potential subjects were screened for the study.  The refusal rate was 35.7% (40/112) and 
31% (35/112) patients were ineligible to participate due to exclusion criteria leaving a 
total of 37 subjects that were enrolled in the study.  
Informed consent and enrollment.  
The principal investigator or co-investigators explained the study to all open-heart 
surgery patients during the preoperative anesthesia visit, which was usually within the 
week prior to the scheduled surgery. Patients were also given the opportunity to read the 
informed consent and have all questions answered prior to any decisions to participate in 
the study. Informed consent included the potential risks associated with participating with 
the study with the most likely risk of transient hypoglycemia. In addition, patients were 
informed of any additional blood work that would be drawn, which included PCT and 
CRP blood work upon separation from CPB and every morning for 5 postoperative days. 
Informed consent was signed the morning of surgery after the anesthesia care team 
reviewed all laboratory results and before any sedation occurred.  
Randomization.   
The anesthesia provider teams were randomly assigned to the treatment condition 
in the Latin square (Table 6). The random assignment dictated the rotation of anesthesia 
care teams. The team was scheduled in advanced on a monthly basis in accordance with 
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the Latin square design. This design provided a permuted block in which each team was 
scheduled every 3 days, this allowed for each team to receive equal numbers of patients.  
 
Table 6. Latin Square Design 
 
Each anesthesia provider team included a minimum of one anesthesiologist and 
two CRNAs, and each team dispensed one of three treatment conditions for a 4-month 
period before rotating to the next glycemic treatment condition per the Latin square. This 
provider structure ensured the Latin square design was followed, regardless of individual 
practitioner circumstances, such as being on-call. The intervention was implemented in 
the intraoperative period only. Postoperative glycemic control was the same for all 
groups. The postoperative glycemic control was the standard protocol utilized in the 
surgical intensive care unit at the study site. This intensive care protocol is a modification 
 Months 1-4 Months 5-8 Months 9-12 
Anesthesia 
Team 1 
Standard Current 
Glycemic Control 
Treatment for blood 
glucose 150-180 mg/dl 
via IV bolus insulin 
 
Tight Glycemic 
Control Blood 
Glucose 110-149 
mg/dl via insulin 
infusion 
Conventional Glycemic 
Control Blood glucose 
150-180 mg/dl via 
insulin infusion 
Anesthesia 
Team 2 
Tight Glycemic Control 
Blood Glucose 110-149 
mg/dl via insulin 
infusion 
Conventional 
Glycemic Control 
Blood glucose 150-
180 mg/dl via insulin 
infusion 
 
Standard Current 
Glycemic Control 
Treatment for blood 
glucose 150-180 mg/dl 
via IV bolus insulin 
Anesthesia 
Team 3 
Conventional Glycemic 
Control Blood glucose 
150-180 mg/dl via 
insulin infusion 
Standard Current 
Glycemic Control 
Treatment for blood 
glucose 150-180 
mg/dl via IV bolus 
insulin 
Tight Glycemic Control 
Blood Glucose 110-149 
mg/dl via insulin 
infusion 
	  	  104	  
of the Yale protocol published by Goldberg et al. (2004) and is considered a strict 
glycemic control protocol maintaining blood glucoses less than 150 mg/dl. 
Intraoperative protocol.   
The day of surgery, patients were met and evaluated in the preoperative holding 
area where standard lines were placed, a baseline morning laboratory studies (blood 
glucose, PCT, CRP) were drawn and standard preoperative medications given. 
Demographical data, historical data and baseline blood work was collected by one of the 
cardiac anesthesia providers. The patients were then taken to the operating suite where 
standard ASA monitors were placed and induction of anesthesia ensued. If glucose levels 
met criteria for treatment, for each protocol, interventions were initiated upon entry into 
the surgical suite. The majority of surgical parameters remained constant through the 
entire study period including infection prophylaxis, antibiotic coverage, Chloraprep skin 
preparation, and normal preoperative electrolytes values. One surgical parameter for 
standard cardiac protocol did change during the study period. In January 2011 all cardiac 
patients were given Chloraseptic mouth rinse prior to entry into the operating room suite, 
in an attempt to reduce the risk of postoperative infection. The Latin Square design 
controlled for this factor. Specific intraoperative procedures other than the study protocol, 
including monitoring, laboratory testing and treatment, and anesthetic technique were 
determined by the standard protocols and the discretion of the anesthesia care team. This 
protocol ended with the transport of the patient out of the operating room en route to the 
ICU.  
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Postoperative protocol.   
Upon delivery of the patients to the ICU, all patients received the same glycemic 
control, which was the standard ICU glycemic protocol, an intravenous insulin infusion 
protocol based on the Harvard glycemic protocol. Data collection on blood glucose levels 
was continued every 30 minutes, from entry to the unit, for six hours into the 
postoperative period. The intensive care team members were blinded to the intraoperative 
interventions.  
Data collection.   
 The day of surgery the anesthesia care team collected routine blood work and 
study blood work; results were documented in the patient electronic chart and the study 
work sheet. Blood glucose was measured every 30 minutes by means of the 
intraoperative I-Stat monitor with arterial line blood samples. Upon transfer to the ICU 
data collection of blood glucose levels occurred every 30 minutes utilizing a designated 
glucometer monitor; results were documented in the patient’s electronic chart, and ICU 
study worksheet by ICU nurses. The purpose of six hours postoperative blood glucose 
data collection was to evaluate evidence of hypoglycemia that may occur with reversal of 
cardiopulmonary induced insulin resistance. Six hours after admission into the ICU data 
collection for glycemic control ended (Appendix B). Procalcitonin, and CRP levels were 
collected every morning for five days starting with the day of surgery.  
Data on infection status were collected during the ICU phase, at hospital 
discharge; two weeks post hospital discharge, and at a 30-day follow-up appointment. An 
advanced registered nurse practitioner, or member of the cardiothoracic team performed 
wound Infection assessment; all members were blinded to the intraoperative intervention 
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that patients received. Data collection on the outcome variable intensive care length of 
stay was determined from the documented day of discharge from the intensive care unit. 
Statistical analysis.   
Statistical analyses included descriptive statistics on all demographic, and surgical 
variables. Statistical analysis also included the development of a logistic regression 
model to determine the effect of intraoperative glycemic control method (tight, 
conventional or standard) on the dichotomous outcome of postoperative wound infection 
controlling for demographics and covariates (See Figure 1).  A series of repeated 
measures analyses of variances was performed on each continuous outcome variable, 
PCT, CRP levels, and intraoperative blood glucose levels. Analysis of variance was 
performed on intensive care length of stay after adjusting for other known preoperative 
risk factors. Outcome variables were postoperative infection rate, postoperative PCT 
levels, postoperative  CRP levels, intraoperative glycemic stability, intraoperative blood 
glucose levels (high, low and mean) and length of intensive care stay.  All data were 
analyzed run using SPSS software, version 16 (SPSS, Inc, Chicago, Ill).  
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Chapter Four 
Results 
Introduction 
 Chapter four includes a description of participant’s characteristics and 
demographics, and the data analyzed to address the aims and hypotheses described in 
chapter three. In addition findings from exploratory analyses will be presented.  
Demographics and Clinical Characteristics of Participants 
 A total of 112 Veterans, scheduled for open-heart surgery were screened for 
recruitment; thirty-seven Veterans agreed to participate and 35 Veterans completed the 
study. One participant was lost to follow up and one participant died prior to the final 
wound visit. Forty Veterans refused participation and 35 Veterans did not meet 
inclusion/exclusion criteria.  Data from 37 participants were used in statistical analyses 
for surgical site infections (SSIs) since only the final wound assessment data was 
missing. Inspection of data revealed wound visit 3 and 4 were consistent in all 
participants.  Therefore, if no infection was noted at prior visits it was reasoned that there 
would have been no wound infection in the fourth and final visit.  Data from three 
treatment groups, group 1 tight glycemic control (n = 15), group 2 conventional glycemic 
control (n = 11), and group 3 standard glycemic control (n = 11) were analyzed (Figure 
2).  
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Figure 2. Flow of Subjects Through the Study 
 Table 7 summarizes the sample of primarily male non- Hispanic Caucasians with 
a mean age of 65 (± 5) years.   Common co-morbidities of the sample included 
hypertension (92%, 34/37), chronic obstructive pulmonary disease (COPD) (43%, 16/37), 
and prior myocardial infarction (38%, 14/37).  Characteristics of the randomized groups 
were analyzed for pre-intervention differences using chi-square (χ2) for categorical 
Accessed	  for	  Eligibility	  
n=112	  
Assignment	  to	  
Anesthesia	  Teams	  n=37	  
Received	  IntervenEon	  
Standard	  
n=11	  
Analyzed	  	  
n=11	  
Lost	  to	  follow	  up	  	  
n=0	  
Received	  IntervenEon	  
ConvenEonal	  
n=11	  
Analyzed	  	  
n=11	  
Lost	  to	  follow	  up	  	  
n=0	  
Received	  IntervenEon	  	  
Tight	  
n=15	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n=15	  
Lost	  to	  follow	  up	  	  
n=0	  
Decline	  to	  ParEcipate	  
n=40	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variables and analysis of variance (ANOVA) for continuous variables. The groups were 
not significantly different at baseline on any participant demographics. 
Table 7. Baseline Participant Characteristics by Treatment Groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes: a=oral agent controlled; b=insulin and oral agent controlled; COPD=chronic 
obstructive pulmonary disease; CRI = chronic renal insufficiency; CVA= cerebral 
vascular accident; MI= myocardial infarction; PVD= peripheral vascular disease.
 
Characteristic Glycemic Control F/χ2 p 
 Tight   
n =15 
Conventional  
n =11 
Standard  
n =11 
  
Age, mean (SD) 64 (6.9) 66 (7.4) 66 (4) F = .629 .539 
Male, n (%) 15 (100) 11 (100) 11 (100)    
Race, n (%)     χ2 = 2.43 .297 
  Caucasian 15 (100) 11 (100) 10 (90)   
  African American 0 (0) 0 (0) 1 (10)   
Ethnicity, n (%)     χ2 = .921 .631 
  Hispanic 1 (6.7) 2 (18.2) 1 (9.1)   
  Non- Hispanic 14 (93.3) 9 (81.8) 10 (90.9)   
Hypertension, n (%) 13 (87) 10 (91) 11 (100) χ2 = 1.54 .464 
COPD, n (%) 7 (47) 4 (36) 5 (46) χ2 = .306 .858 
PVD, n (%) 2 (13) 1 (9) 3 (27) χ2 = 1.49 .474 
CRI, n (%) 1 (6.7) 3 (27.3) 3 (27.3)   
Diabetes, n (%)    χ2 = 2.66 .851 
   Type I 0 (0) 1 (9) 1 (9)   
   Type IIa 4 (27) 3 (27) 4 (36)   
   Type IIb 2 (13) 1 (9) 2 (18)   
MI, n (%) 6 (40) 5 (45) 3 (27) χ2  = 4.01 .405 
CVA, n (%) 1 (6) 0 (0) 1 (9) χ2  = .967 .616 
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Surgical Characteristics of Participants 
 Table 8 describes the surgical characteristics for the three intervention groups. 
Coronary artery bypass graft (CABG) surgery made up the majority of surgical cases 
(62%, 23/37). Among the 37 participants that underwent open-heart surgery, 32 
procedures were elective in nature (86%) and 35 cases utilized cardiopulmonary bypass 
(CPB) (95%). Surgical times including total operating room times, CPB times, and aortic 
cross clamp time were similar across the three interventional groups. Three cardiothoracic 
surgeons participated in the research study. While the number of surgical procedures was 
not equally distributed amongst the surgeons, the dispersion of treatment groups was 
similar. There was no significant difference in any baseline characteristics, nor were there 
any differences in glycohemoglobin (HbA1c), glucose, C-reactive protein (CRP), 
procalcitonin (PCT) or white blood count (WBC).  
Research Hypotheses 
 The study had two aims, the first aim had two hypotheses investigating SSI and 
biomarkers for SSI, and the second aim had three hypotheses investigating glycemic 
control in the operating room and length of stay (LOS) in the intensive care unit (ICU).  
 Hypotheses for aim 1. 
1.1 It was hypothesized that patients undergoing open-heart surgery, who received 
a continuous intravenous insulin infusion for tight glycemic control (blood glucose 110-
149 mg/dl) during the intraoperative phase would demonstrate fewer thirty-day sternal 
and harvest SSIs at four time points: in ICU, at hospital discharge, at 2 weeks post 
hospital discharge, and at 6 weeks post hospital discharge, compared to patients who 
received continuous intravenous infusion of insulin for conventional glycemic control 
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(blood glucose 150-180 mg/dl) or standard glycemic control via intravenous bolus 
injections of insulin (blood glucose 150-180 mg/dl).  
Cross tabulation with statistical testing chi-square and Cramer’s V was performed 
on infection outcomes to determine if there was any difference in surgical site infections 
between the interventional treatment groups in a thirty-day observation period. In total, 
fourteen of the 37 (37.8%) participants experienced some form of SSI. The majority of 
SSIs were diagnosed 2 weeks post hospital discharge (57%). Two patients diagnosed 
with a SSI at visit 2 (discharge from hospital) continued with a residual SSI at visit 3 (2 
week post-hospital discharge). Of these two patients, one continued with a superficial 
sternal and the other had noted improvement from a deep harvest SSI to a superficial 
harvest SSI. Four patients continued with superficial harvest infections diagnosed on 
wound visit 3 (2 weeks post-hospital discharge) to wound visit 4 (6 weeks post-hospital 
discharge). The majority of infections were superficial in nature (32%, 11/37) occurring 
in harvest sites (27%, 10/37). Deep infections occurred in only three of the 37 
participants (8.1%) and only 4 participants suffered sternal wound infections (10.8%, 
4/37). One participant required multiple sternal debridement surgeries, and a pectoral flap 
for sternal reconstruction. Results of statistical analysis revealed no statistical difference 
in overall SSIs among the three treatment groups (Table 9). 
A logistic regression model was applied to assess the simultaneous effect of multiple 
variables on the dichotomous dependent variable, infection.  The independent variables 
shown in Table 7 and Table 8 were initially analyzed by univariate and bivariate analysis. 
Correlational analyses were used to examine the relationship between all variables and 
SSI.   
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Table 8. Surgical Characteristics of Participants by Treatment Group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes: CABG=coronary artery bypass grafting; CPB=cardiopulmonary bypass; CRP = C-
reactive protein pre operative; HbA1c = glycohemoglobin preoperative; OR Time = 
operating room time; PCT = procalcitonin preoperative; SD=standard deviation; WBC = 
white blood count preoperative; X-Clamp = aortic cross clamp. 
 
 
 
Characteristic  Glycemic Control F/χ2 p 
 Tight  
n =15 
  Conventional  
n=11 
Standard  
n =11 
  
Surgery Type, n (%)    χ2 = 3.177 .529 
  CABG      9 (60)      6 (54.5)     8 (72.7)   
  Valve Surgery      4 (26.7)      5 (45.5)     2 (18.2)   
  CABG & Valve       2 (13.3)      0 (0)     1 (9.10)   
CPB, n (%)    14 (93.3)    10 (90.1)   11 (100) χ2 = .967 .616 
Priority, n (%)    χ2 = .390 .823 
   Elective    13 (86.7)      9 (81.8)   10 (90.9)   
   Urgent      2 (13.3)      2 (18.2)      1 (9.1)   
Surgeon, n (%)    χ2 = 1.670 .796 
   Surgeon A      6 (40)      6 (54.5)      7 (63.6)   
   Surgeon B      6 (40)      3 (27.3)      3 (27.3)   
   Surgeon C      3 (20)      2 (18.2)      1 (9.1)   
Cross-Clamp Time, 
(SD), minutes 
 
   77 (34)    77 (19)    80 (30) F = 0.281 .757 
CPB Time, m (SD)  104 (39)  109 (31)  110 (36) F = 0.463 .634 
HbA1c,  % (SD) 6.33 (0.97) 7.07 (1.53) 6.85 (1.66) F = 0.955 .395 
Glucose,  mg/dl (SD)  116 (24)   135 (39)  117 (42) F = 1.160 .327 
CRP, mg/L (SD) 0.55 (0.31) 0.26 (0.23) 0.51 (0.51) F = 2.153 .133 
PCT, ng/ml (SD) 0.05 (.008) 0.06 (.015) 0.05 (.012) F = 0.107 .899 
WBC, x109/L (SD)   6.6 (1.7)   7.4 (2.3)    6.7 (1.8) F = 0.581 .565 
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Table 9. Surgical Site Infection Rates by Treatment Groups 
Notes: SSI = surgical site infections. 
Table 10 reflects variables that were significantly correlated with SSI. There was 
a moderate positive correlation between experiencing a SSI and peak intraoperative blood 
glucose, and PCT levels on postoperative days 3, 4, and 5 (Table 10). Procalcitonin levels 
on postoperative day 3, 4 and 5 were associated with each other with a Pearson’s 
correlation greater than .70. Therefore, in an effort to limit the risk of multicollinearity, a 
two predictor logistic model was designed using the independent variables peak 
intraoperative blood glucose, and the PCT level on postoperative day three.  
A two-predictor logistic model was the best fit to predict occurrence of SSIs for 
open-heart patients using the peak intraoperative blood glucose levels and the PCT blood 
value on postoperative day 3 as predictors. The peak intraoperative blood glucose levels 
had a mean value of 178 mg/dl (S.D. 29), and a blood glucose range of 119 to 235 mg/dl. 
 
 
 
 Glycemic Control χ2 p Cramer’s V 
 Tight 
n =15 
Conventional 
n=11 
Standard 
n =11 
   
Total SSI, n (%) 4 (26.7) 5(45.5) 5(45.5) 1.34 .512 .190 
Superficial SSI, n (%) 4(26.7) 4(36.4) 4(36.4) .383 .826 .102 
Deep SSI, n (%) 0 (0) 1(9.1) 2(18.2) 2.84 .242 .277 
Harvest SSI, n (%) 3(20) 3(27.3) 4(36.4) .862 .650 .153 
Sternal SSI, n (%) 1(6.7) 2(18.2) 1(9.1) .921 .631 .158 
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Table 10. Correlations Surgical Site Infection, Peak Intraoperative Blood Glucose and 
Procalcitonin n=37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes: N=35 Listwise, ** Correlation at 0.01 (2-tailed), * Correlation at 0.05 (2-tailed), 
SSI=surgical site infection, HIGHBG=highest intraoperative blood glucose, PCT 3= procalcitonin 
postoperative day 3, PCT 4= procalcitonin postoperative day 4,  
PCT 5= procalcitonin postoperative day 5. 
 
Postoperative day 3 PCT level ranged from 0.06 to 3.22 µg/L with a mean of 0.83 
µg/L (S.D. 0.815).  A test of the full model against a constant only model was statistically 
significant, indicating that the predictors reliably distinguished between participants with 
infection and participants without infection (χ2=10.179, p = .006 with df = 2). Of the two-
predictor variables only one was statistically significant, peak intraoperative blood 
glucose. Participants that experienced a higher peak blood glucose level intraoperatively 
exhibited an increase likelihood of exhibiting a SSI.   
The model explained 36.0% (Nagelkerke R2 = .359) of the variance in SSI and 
correctly classified 73.0% of cases. Sensitivity was 54%, specificity was 85%, positive 
 SSI High BG PCT 3 PCT 4 PCT 5 
SSI              r 
                   p 
1 .454** 
.006 
.406* 
.016 
.462** 
.005 
.455** 
.006 
High BG    r 
                   p 
 
 
1 .252 
.144 
.307 
.073 
.225 
.193 
PCT 3          r 
                    p    
 
 
 
 
1 .876** 
.000 
.827** 
.000 
PCT 4          r 
                    p   
 
 
 
 
 
 
1 .920** 
.000 
PCT 5          r                        1 
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predictive value was 70% and negative predictive value was 73.9%. The Wald criterion 
demonstrated that only the peak intraoperative blood glucose values made a significant 
contribution to predication (p = .034). The PCT blood value was not a significant 
predictor (p = .127), indicating that participants that experienced higher peak blood 
glucose levels were associated with an increased likelihood of developing a SSI.  A rise 
in peak intraoperative blood glucose level by one unit (1 mg/dl), had an odds ratio of 
1.04, indicating patients were 1.04 times more likely to develop a SSI.  
While there was no statistically significant difference for infection rates among 
the intervention groups, exploration of the data revealed a significant difference in the 
overall SSI rates depending on the type of surgery performed (Table 11). Surgical site 
infections occurred in 34.8% (8/23) of patients after CABG surgery; 18% (2/11) of 
patients after heart valve surgery; and 100% (3/3) of patients after combined CABG and 
valve surgery. Chi-square analysis with Cramer’s V showed participants who underwent 
combined CABG and valve surgery had significantly higher rates of SSI compared to 
CABG surgery or valve surgery alone (χ2 = 6.927, p = .031 with 2 df; V = .433),  
respectively.  
1.2 It was hypothesized that patients undergoing open-heart surgery, who received 
a continuous intravenous insulin infusion for tight glycemic control during the 
intraoperative phase would have lower PCT levels and lower CRP levels in the first five 
days of the postoperative period compared to patients who received continuous 
intravenous infusion of insulin for conventional glycemic control (blood glucose 150-180 
mg/dl) or standard glycemic control via intravenous bolus injections of insulin (blood 
glucose 150-180 mg/dl). 
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Table 11 Surgical Site Infection Rates by Type of Surgery 
Notes: CABG=coronary artery bypass grafting; SSI = surgical site infection. 
 
Preliminary analysis was conducted to validate of the relationship of the 
biomarkers CRP and PCT to SSIs. The research design used biomarkers PCT and CRP, 
as continuous measures, and predictors of infection. Selection of PCT and CRP as 
significant biomarkers for infection was based upon prior research.  
Procalcitonin. 
Data were evaluated for missing values, outliers, and normality. Investigation of 
PCT data revealed 6 participants with more than 50% non-random missing data. These 
participants were dropped from any data analyses involving PCT.  All other missing data 
for PCT were completely random, and therefore, derived variables were calculated for 
replacement. Calculations for derived PCT levels were based upon knowledge of typical 
trends post surgery. Procalcitonin rises and peaks at 24 hours post-surgery, and  then 
declines to normal values, usually, by the third or fourth day postoperatively. Missing 
values were calculated by taking the mean of the precedent and post PCT surrounding the 
missing value. 
 CABG 
n =23 
Cardiac 
Valve 
n=11 
Combined 
CABG & Valve 
n =3 
χ2 p 
Total SSI, n (%) 8(34.8) 2(18) 3(100) 6.927 .031 
Superficial SSI, n (%) 9(39) 1(9) 2(66.7) 4.810 .090 
Deep SSI, n (%) 1(4.3) 1(9) 1(33) 3.013 .222 
Harvest SSI, n (%) 6(26) 1(9) 2(66.7) 4.348 .114 
Sternal SSI, n (%) 2(8.7) 1(9) 1(33) 1.719 .423 
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Procalcitonin was screened for outliers and the assumption of normality using 
boxplot and Shapiro-Wilk’s test (p < .05) respectively.  Results showed a data 
distribution that was substantially positively skewed; therefore, data were transformed 
using the log transformation. In addition, severe outliers were corrected by replacing 
them with the next largest or smallest value. The assumption of normality for PCT levels 
was satisfied after transformation, as assessed by Shapiro-Wilk’s and inspection of 
normal Q-Q Plots. 
Descriptive data on PCT levels collected over six time points is noted in Table 12. 
The baseline blood value for PCT taken the morning of surgery showed no pre-
intervention differences between the three treatment groups F (2, 35) = 0.134, p = .875.  
Procalcitonin levels were drawn across six time periods; the first level was drawn upon 
successful separation from CPB in the operating room followed by daily morning levels 
for five postoperative days.  
Preliminary analysis of procalcitonin as a significant biomarker for infection. 
A repeated measures analysis of variance (RM ANOVA) with a Greenhouse-
Geisser correction was conducted to determine if PCT levels drawn over time (separation 
from CPB, daily POD 1-5) were significantly related to SSI. One of the assumptions in 
RM ANOVA procedure is that of sphericity.  Mauchly’s test of sphericity, which tests for 
the equivalence of the hypothesized and observed variance/covariance patterns, was 
conducted. 
Result of the Mauchly’s test was highly significant (W = .003, χ2 = 159.536, p < 
.000 with df =14), suggesting that the observed matrix does not have approximately equal 
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variances and covariance. In order to reduce the likely inflation of Type I errors, the 
Greenhouse-Geisser epsilon correction was applied (ε = .309).  
 
Table 12. Procalcitonin Post Cardiopulmonary Bypass, and Postoperative Days 1-5 
Notes. Post CPB = post separation from cardiopulmonary bypass; POD = postoperative 
day. 
 
The between subjects RM ANOVA performed on PCT means indicated that there 
was a significant SSI main effect between the two groups, with or without infection, F (1, 
29) = 5.655, p = .024. Figure 3 reflects that at all time observations, PCT blood levels 
were higher in the presence of a SSI.  Therefore, a RM ANOVA was conducted to 
determine if there was any difference in PCT blood levels over time (post CPB, POD 1-5) 
between the three glycemic treatment groups.  
Procalcitonin differences between treatment groups. 
A 3 X 6 ANOVA with a Greenhouse-Geisser correction was employed to test if 
there was any significant difference in blood levels of biomarkers PCT values over time 
(separation from CPB, daily POD 1-5), for participants randomly assigned to the tight 
glycemic group compared to the convention or standard glycemic group treatments. 
Glycemic Control  Post CPB  POD 1 POD 2 POD 3 POD 4 POD 5 
Tight,  
n = 11 
Mean 0.067  0.949  0.770  0.496  0.303  0.211  
 Standard 
Deviation 
0.032 1.07 0.803 0.461 0.218 0.101 
Conventional,  
n = 10 
Mean 0.052 2.47  1.66   1.21  0.881  0.631 
 Standard 
Deviation 
0.006 2.03 1.30 1.01 0.862 0.680 
Standard,  
n = 10 
Mean 0.071 1.30  0.993 0.864  0.590  0.339 
 Standard 
Deviation 
0.035 0.990 0.902 0.859 0.463 0.236 
Total,  
n = 31 
Mean 0.640  1.55  1.13  0.845  0.582 0.388  
 Standard 
Deviation 
0.029 1.53 1.06 0.829 0.601 0.437 
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These data are shown in Figure 4. The assumption of sphericity was violated, as assessed 
Mauchly’s Test of Sphericity therefore a Greenhouse-Geisser correction was applied 
(Table 13).  
 
Figure 3. Procalcitonin in Participants With and Without Surgical Site Infections.  
Notes n = 31, CPB = cardiopulmonary bypass, POD = postoperative day.  
 
Table 13. Mauchly’s Test of Sphericity Measure Procalcitonin 
 
 
Within 
Subjects 
Effect 
Mauchly’s 
W 
≈ χ2 df p Epsilon 
 
Time 
 
.003 
 
153.478 
 
14 
 
.000 
Greenhouse-
Geisser 
Huynh-
Feldt 
Lower-
Bound 
.319 .359 .200 
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Results of the univariate analysis with epsilon correction, Greenhouse-Geisser, for 
within subjects effects determined that the overall mean PCT concentrations differed 
significantly across the six time points F (5, 140) = 40.00, p < .001, η2p = .588. The 
interaction between the intervention groups and time was not significant   F (10, 140) = 
1.758, p = .166, η2p = .112.  
The between subjects analyses showed there was not a significant treatment arm 
main effect between the groups F (2, 28) = 2.649, p = .088, η2p = .159. The tight 
glycemic control was not statistically significantly different in PCT concentration over 
the postoperative time period compared to the conventional or standard glycemic 
treatment. Although not statistically significant, Figure 4 reflects a consistent pattern of 
PCT concentrations among the three glycemic control groups. Except for post CPB 
separation, all other observations of postoperative PCT concentrations for the tight 
glycemic group were consistently lower than the conventional and the standard treatment 
groups.  
C-reactive protein.  
Data was evaluated for missing data, outliers, and normality. Six participants had 
non-random missing CRP values greater than 50%. Data from these participants were 
dropped from further analyses involving CRP. Outliers were few, and they were 
confirmed as valid, therefore, included in the analysis; they were not expected to 
materially affect the results. C-reactive protein data was normally distributed, as assessed 
by Shapiro-Wilk’s test (p > .05).  
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Figure 4. Postoperative Procalcitonin Concentrations by Treatment Groups. Note CPB = 
cardiopulmonary bypass, POD = postoperative day 
 
Descriptive data on CRP concentrations in the three glycemic treatment groups 
collected in the five-day postoperative period is noted in Table 14. The baseline blood 
value for CRP taken the morning of surgery showed no pre-intervention differences 
between the three treatment groups F (2, 34) = 2.15, p = .133.  C-reactive protein levels 
were drawn across six time periods; the first level was drawn upon successful separation 
from CPB in the operating room followed by daily morning levels for five postoperative 
days. Descriptive data of CRP concentrations for participants with and without SSI is 
noted in Table 15. 
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Table 14.  C-reactive Protein Concentrations By the Treatment Groups. 
Notes. CPB = cardiopulmonary bypass, POD = postoperative day. 
Preliminary analysis of C-reactive protein as a significant biomarker for 
infection. 
A repeated measures analysis of variance (RM ANOVA) with a Greenhouse-
Geisser correction was conducted to determine if CRP levels drawn over time (separation 
from CPB, daily POD 1-5) were significantly related to SSI. The assumption of 
sphericity was violated, as assessed Mauchly’s Test of Sphericity, (W = .117, χ2 = 
58.230, p < .000 with df =14). Therefore a Greenhouse-Geisser correction was applied (ε 
= .644). The CRP concentration was statistically different over the postoperative time, as 
noted by the within subjects tests F (5, 145) = 126.177, p < .000. However, there was no 
significant difference in CRP concentrations whether or not a SSI was present, as noted 
in the between subjects tests F (1, 29) = 1.170, p = .288.  Figure 5 reflects CRP 
Glycemic  
Control 
 Post CPB  POD 1 POD 2 POD 3 POD 4 POD 5 
Tight, 
 n = 11 
Mean, mg/L 0.352 7.745 19.29 20.47 16.91 13.90 
 Standard 
Deviation 
 
0.199 2.25 3.09 5.28 5.20 5.12 
Conventional,  
n = 10 
Mean, mg/L 0.144 6.81 16.17 17.60 13.10 12.00 
 Standard 
Deviation 
 
0.158 1.84 2.82 5.06 4.51 6.51 
Standard,  
n = 10 
Mean, mg/L 0.317 7.17 20.64 22.72 19.53 13.50 
 Standard 
Deviation 
 
0.341 2.32 6.27 6.95 5.50 3.96 
Total,  
n = 31 
Mean, mg/L 0.274 7.26 18.72 20.27 16.52 13.16 
 Standard 
Deviation 
0.253 2.12 4.57 5.99 5.58 5.18 
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concentrations postoperatively between participants with and without SSI. C-reactive 
protein was not a significant predictor of SSI. Therefore, no further analyses of CRP and 
its relationship to infection was conducted. 
 
Table 15. C-reactive Protein in Participants With and Without Surgical Site Infections in 
the Postoperative Period. 
  Post CPB  POD 1 POD 2 POD 3 POD 4 POD 5 
No SSI,  
n = 20 
Mean, mg/L 0.299 7.26 18.88 20.54 17.35 14.46 
 Standard 
Deviation 
 
0.269 2.38 4.60 5.77 4.79 4.74 
SSI Present, 
n = 11 
Mean, mg/L 0.228 7.26 18.42 19.78 15.02 10.79 
 Standard 
Deviation 
 
0.226 1.63 4.73 6.62 6.78 5.31 
Total,  
n = 31 
Mean, mg/L 0.274 7.26 18.72 20.27 16.52 13.16 
 Standard 
Deviation 
0.253 2.12 4.57 5.99 5.58 5.18 
Notes. CPB = cardiopulmonary bypass, POD = postoperative day, SSI = surgical site 
infection. 
  
	  
Hypotheses for aim 2. 
Intraoperative blood glucose levels. 
2.1 It was hypothesized that patients undergoing open-heart surgery who received 
a continuous intravenous insulin infusion for tight glycemic control (blood glucose 110-
149 mg/dl) during the intraoperative period would have significantly lower blood glucose 
levels during this period compared to patients who received continuous intravenous 
infusion of insulin for conventional glycemic control (blood glucose 150-180 mg/dl) or 
standard glycemic control via intravenous bolus injections of insulin (blood glucose 150-
180 mg/dl). 
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Figure 5. C-reactive Protein in Participants With and Without Surgical Site 
Infections. Notes CPB = cardiopulmonary bypass, POD = postoperative day. 
 
Investigation of data revealed non-random missing data for the variables 
reflecting intraoperative blood glucose levels. Participants varied on the number of blood 
glucose values collected in the operating room because of varying operating room times. 
Blood glucose data was collected on all participants up to the sixth observation (BG 6) 
intraoperative (180 minutes). Five participants were missing two to three data 
observations at 210 and 240 minutes intra-operatively.  Thirty-minute observations on all 
participants continued into the ICU period for six hours. Therefore, data missing from the 
intraoperative period were replaced with the first two or three observations from the ICU 
data. Inspection of these blood glucose levels was found to be lower than levels that 
would have initiated ICU insulin intervention. Data analysis incorporating intraoperative 
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blood glucose levels was conducted utilizing blood glucose levels up to the ninth 
observation in the operating room, yielding 37 participants. Outliers were few, and they 
were confirmed as true values, therefore included in the analysis; they were not expected 
to materially affect the results. Blood glucose levels during the intraoperative period were 
normally distributed, as assessed by Shapiro-Wilk’s test (p > .05). 
Descriptive data on blood glucose levels was collected every 30 minutes during 
the intraoperative period. The baseline blood value for blood glucose taken the morning 
of surgery showed no pre-intervention differences between the three groups. Table 16 
reflects the mean blood glucose values every 30 minutes across 240 minutes of 
intraoperative time. The majority of all participants’ blood glucose values were well 
controlled, regardless of which treatment arm they were randomized to.  The tight 
glycemic treatment group blood glucose means ranged from 120 to 144 mg/dl, the 
conventional glycemic treatment group ranged from 137 to 154 mg/dl, and the standard 
glycemic treatment group ranged from 124 to 173 mg/dl.  
Repeated measures ANOVA with Greenhouse-Geisser correction was employed 
to determine if open-heart surgical participants randomly assigned to the tight glycemic 
control group yielded lower blood glucose levels in the intraoperative period (every 30 
minutes for 240 minutes) than participants who were assigned to conventional glycemic 
control treatment or the standard glycemic control treatment.   
Assumption of compound symmetry was not met based on a significant 
Mauchly’s test of Sphericity (W = .001, χ2 = 218.738, p < .001 with df = 35).  Results of 
the univariate analysis with epsilon correction (ε = .334), Greenhouse-Geisser, for within 
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subjects effects determined that the overall mean blood glucose concentrations differed 
significantly across the six time points F (8, 272) = 7.240, p = .001, η2 = .176. 
Table 16. Intraoperative Blood Glucose Levels by Treatment Groups 
Note: BG 1 = blood glucose at operating room entry, BG 2 – BG 9 = blood glucose 
values every 30 minutes after BG 1.  
 
The main effect between subjects for blood glucose differences was not 
statistically significant F (2, 34) = 2.154, p = .132, η2 = .112.  While the results are not 
significant, there was a moderate effect size. The interaction subject effects for 
interventional treatments across time was not significant F (16, 272) = 1.484, p = .196, η2 
= .08. As with the between subjects main effect, the interaction effect is not significant 
but has close to a moderate effect size. There was no statistically significant difference 
between the three glycemic treatment groups on blood glucose levels, or blood glucose 
variability during the intraoperative period. Results for above analyses may have been 
significant if the study was not underpowered.  
Glycemic  
Control 
 Intraoperative Blood Glucoses Every Thirty Minutes , mg/dl 
   BG 1 BG 2 BG 3 BG 4 BG5 BG 6 BG 7 BG 8 BG 9 
Tight,  
n =15 
Mean 125 120 123 123 131 134 139 138 144 
 S. D. 32.79 20.15 19.03 17.9 16.33 23.82 23.19 16.23 28.95 
Conventional, 
 n = 11 
Mean 137 140 142 144 143 139 145 154 146 
 S.D. 50.33 43.06 26.17 20.9 20.33 23.93 33.92 22.78 24.93 
Standard,  
n = 11 
Mean 124 126 129 142 137 145 163 173 171 
 S.D. 40.50 36.58 34.21 41.6 32.38 33.74 35.32 34.03 27.98 
Total,  
n = 37 
Mean 128 128 131 135 136 139 148 153 152 
 S.D. 40.13 33.40 26.76 28.7 23.18 26.80 31.22 27.92 29.46 
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Glycemic stability. 
2. 2 It was hypothesized that patients undergoing open-heart surgery who received 
a continuous intravenous insulin infusion for glycemic control, whether tight control 
(blood glucose 110-149 mg/dl) or conventional control (blood glucose 150-180 mg/dl), 
during the intraoperative phase would have significantly improved glycemic stability in 
the intraoperative period compared to patients who received the standard glycemic 
control via intravenous bolus injections of insulin (blood glucose 150-180 mg/dl).  
Intraoperative glycemic instability was defined as three consecutive blood glucose 
values that were not within the preset limits of the protocol and outside of normal glucose 
values. Only four participants of the 37 (11%) experienced glycemic instability, and each 
of these participants only experienced one episode of glycemic instability. Of the four 
participants 2 were in the tight glycemic treatment group, and one participant each was in 
the conventional and standard group. All participants returned to the predetermined target 
range for their group by the fourth blood glucose indicating that all three protocols 
brought blood glucose levels under control within 2 hours. Additionally, no participants 
in the group had excessive blood glucose values (> 250 mg/dl). The two events of 
glycemic instability, in the tight glycemic group measured peak intraoperative blood 
glucose levels of 167 mg/dl and 184 mg/dl respectively. The peak blood glucose value, 
for the glycemic instability event, in the conventional glycemic treatment group was 223 
mg/dl, and the peak glucose value, for the glycemic instability event, in the standard 
treatment group was 213 mg/dl.  With so few episodes of glycemic instability, no tests of 
significance were possible.  
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Figure 6 reflects that, while not statistically significantly different, the tight 
glycemic treatment group trended the lowest blood glucose values of the three groups, for 
the majority of the intraoperative period (240 minutes). The two interventional groups 
that delivered the insulin via continuous intravenous infusion (tight glycemic treatment 
group and conventional glycemic treatment group) maintained blood glucose levels 
within a closer range than the interventional group that delivered insulin via intravenous 
bolus injections (standard glycemic treatment group).  This overall pattern, while not 
statistically significant, suggests continuous intravenous infusion may produce better 
glycemic stability during the rewarming period of CPB (BG 7). Additionally, the pattern 
of blood glucose concentrations in participants with and without SSI, suggest patients 
with patients with SSI have higher intraoperative blood glucose concentrations. Figure 7 
reflects that, while not statistically significant, the pattern of blood glucose concentrations 
in infected participates is higher, for all points, save one, than blood glucose 
concentrations for the non-infected participants.	  	  
Intensive care length of stay 
2.3 It was hypothesized that patients undergoing open-heart surgery who received 
a continuous intravenous insulin infusion for tight glycemic control (blood glucose 110-
149 mg/dl) during the intraoperative phase would demonstrate a shorter length of stay in 
the intensive care unit compared to patients who received continuous intravenous 
infusion of insulin for conventional glycemic control (blood glucose 150-180 mg/dl) or 
standard glycemic control via intravenous bolus injections (blood glucose 150-180 
mg/dl).  
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Figure 6. Intraoperative Blood Glucose Levels By Treatment Groups. Note OR = 
operating room. 
A one-way ANOVA was used to determine if participants randomized to the tight 
glycemic control group had shorter ICU LOS than participant randomized to the 
conventional or standard glycemic treatment groups. There was homogeneity of 
variances, as assessed by Levene’s test of homogeneity of variance (p = .531). There was 
no statistically significant difference in the ICU LOS between the different glycemic 
treatment groups F (2, 34) = .096, p = .908.  
 Table 17 reflects descriptive statistics for ICU LOS revealing that all three 
interventional groups had similar length of stay in the ICU. Results of the cross tabulation 
with Chi-square revealed there was no significant difference in total ICU LOS whether or 
not there was a SSI present (χ2 = 17.920, p = .267 with df = 15).  
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Figure 7. Intraoperative Blood Glucose Levels in Participants With and Without Surgical 
Site Infections. Note OR = operating room. 
 
Table 17.  Intensive Care Unit Length of Stay by Treatment Groups  
 
 
 
 
 
 
Summary of Research Findings 
The aims of the study were to determine if maintaining intraoperative blood 
glucose levels in a tight range lowered the rate of surgical site infection (SSI), 
postoperative biomarkers of infection, PCT, CRP, and intraoperative glucose levels 
Glycemic Control Total Intensive Care Unit Days, m, (SD) 
Tight, n = 15 7.00 (5.29) 
Conventional, n = 11 6.18 (4.90) 
Standard, n = 11 7.18 (6.03) 
Total, n = 37 6.81 (5.26) 
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compared to moderate glycemic control in patients undergoing open-heart surgery. 
Additionally, the study hypothesized that  maintaining intraoperative tight glycemic 
control in open-heart surgical patients, with a continuous insulin infusion would provide 
better glycemic stability during the intraoperative period compared to insulin bolus 
injection technique.  Lastly, it was hypothesized that use of intraoperative tight glycemic 
control, in open-heart patients, would decrease patient LOS in the ICU.  
The primary findings of this randomized controlled trial revealed no significant 
difference in the three glycemic interventions on the outcomes SSI, ICU LOS, or 
postoperative plasma concentrations in markers of infection including CRP and PCT.  
Additional findings showed no significant difference between the three glycemic 
interventions on blood glucose levels, or glycemic stability during the intraoperative 
period.  While tight glycemic control of blood glucose failed to show a reduction in 
postoperative SSIs, patients with higher peak intraoperative glucose levels during the 
intraoperative period had a higher incidence of postoperative SSI. Procalcitonin was 
significantly elevated in participants that developed a SSI compared to participants 
without a SSI, while CRP was not significantly related to SSI.   Surgical site infections 
were significantly higher in patients that underwent combined CABG and valve repair 
surgery compared to participants who underwent either CABG surgery or valvular 
surgery independently.  
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Chapter Five 
Discussion 
Introduction 
This chapter provides a discussion of the major findings of the study. The findings 
of this study are compared and contrasted to findings of relevant published literature. 
Clinical implications and recommendations for future research are provided.  
Research Aims of the Study 
This study sought to determine whether open-heart surgical participants who were 
randomly assigned to tight glycemic control during the intraoperative period, compared 
to participant assigned to either the conventional or standard glycemic control treatments, 
would have significantly 1) lower thirty-day surgical site infections (SSIs), and 2) lower 
postoperative procalcitonin (PCT) and C-reactive protein (CRP) plasma levels. In 
addition, the study sought to determine if participants randomized to the tight glycemic 
control group, compared to the conventional or standard glycemic group, would have 
significantly lower intraoperative blood glucose levels, and a shorter length of stay (LOS) 
in the intensive care unit (ICU). Finally, the study sought to determine if the use of a 
continuous intravenous infusion of insulin compared to intravenous bolus injections of 
insulin would result in improved glycemic stability during the intraoperative period.  
Major Findings of the Study 
The main findings of this study were that there were no significant differences 
between the three glycemic interventional treatment groups in 1) thirty-day SSIs; 2) 
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postoperative CRP or PCT concentrations; 3) intraoperative blood glucose levels; 4) 
glycemic stability; or 5) ICU LOS. An association between intraoperative blood glucose 
and SSI was established. Participants that experienced higher peak blood glucose levels 
intraoperatively exhibited an increased likelihood of exhibiting a SSI.  Procalcitonin 
levels were significantly elevated in participants that experienced a SSI, but CRP showed 
no significant difference between participants with or without a SSI. Participants that 
underwent coronary artery bypass graft surgery (CABG) with concomitant valve surgery 
had a significantly higher rate of SSIs postoperatively compared to participants that had 
either CABG surgery or valve surgery.  
Effect of tight glycemic control on postoperative surgical site infections. 
This study found no significant difference in SSIs between any of the three 
glycemic groups. These findings were consistent with the majority of randomized 
controlled trials (RCTs) that have been conducted related to glycemic control, and 
postoperative wound infections (Azarfarin et al., 2011; Chan et al., 2009, Emam et al., 
2010; Gandhi et al., 2007; Lazar et al., 2004; Lazar et al., 2011). Of the six RCTs that 
were similar to this study, four reported results consistent with the findings of this study 
(Azarfarin et al., 2011; Chan et al., 2009; Gandhi et al., 2007; Lazar et al., 2011) and two 
had contrasting results (Emam et al., 2010; Lazar et al., 2004).   
Chan et al. (2009) investigated the effect of tight glycemic control in patients 
undergoing open-heart surgery with cardiopulmonary bypass (CPB) on postoperative 
outcomes. They defined of tight glycemic control via continuous infusion (n = 55) as 
blood glucose levels from 80-130 mg/dl, and the conventional group via continuous 
infusion (n = 54) as blood glucose levels of 160-200 mg/dl. The study showed no 
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difference between the two glycemic groups in any clinical outcomes  including the 
occurrence of postoperative infections (Chan et al., 2009).  
Similarities between Chan et al. (2009) and this study included a similar patient 
sample (patients with and without a diagnosis of diabetes mellitus), the use of continuous 
insulin infusion for both the tight glycemic and control group, and comparable results, 
that of no significant difference in SSIs between the groups. Their study differed from 
this study in that the intervention was carried out in perioperative period and they used 
different blood glucose parameters. They used a much lower limit in their tight glycemic 
control group compared to this study (80-130 vs. 110-149 mg/dl), respectively, and a 
much higher limit for the control group compared to this study (200 vs. 150-180 mg/dl), 
respectively.  
Gandhi et al. (2007) investigated the effects of tight glycemic control, during the 
intraoperative period, on postoperative adverse outcomes, including deep sternal wound 
infection. Patients with and without a diagnosis of diabetes mellitus were enrolled in a 
RCT, that compared tight glycemic control (n =185), which maintained blood glucose 
levels between 80 - 110 mg/dl via continuous insulin infusion, to conventional glycemic 
control (n = 186), which instituted insulin therapy when blood glucose levels exceeded 
200 mg/dl via intravenous bolus injections of insulin, and for blood glucose levels 
exceeding 250 mg/dl patients received a continuous infusion (Gandhi et al., 2007). 
Gandhi et al. (2007) found no significant difference in sternal wound infections between 
the two groups.  
The current study shared similarities with Gandhi and colleagues (2007) including 
that both studies intervention period was during the intraoperative period exclusively and 
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the inclusion of patients with and without diabetes mellitus. Both studies also showed that 
there was no significant difference in SSIs between treatment groups. The research by 
Gandhi and colleagues differed from the current study by using lower parameters in their 
tight glycemic group compared to this study (80-100 vs. 110-149 mg/dl), and a higher 
limit for the control group (200 vs. 180 mg/dl). They also included only patients that 
underwent CABG surgery with CPB, and the outcome was exclusively deep sternal 
wound infections and not harvest or superficial sternal wounds.   
Lazar et al. (2011) enrolled patients, with a diagnosis of diabetes, undergoing 
CABG surgery with CPB to a tight or moderate glycemic treatments, in the perioperative 
period, to determine if tight glycemic control resulted in more optimal postoperative 
clinical outcomes. Patients randomized to the tight glycemic group (n = 42) had blood 
glucose levels maintained between 90-120 mg/dl and the moderate glycemic group (n = 
40) maintained blood glucose levels between 120-180 mg/dl. Their study showed no 
significant differences in the incidence of deep sternal wound infection between the two 
treatment groups (Lazar et al., 2011).  
As in the current study, Lazar et al. (2011) found no difference in SSIs between 
treatment groups. Other similarities included the insulin delivery method of continuous 
infusions for treatment groups. The current study differed from Lazar et al. in that it 
included all types of open-heart surgery, and Lazar et al. (2011) used lower parameters in 
the tight glycemic group compared to this study (90-120 vs. 110-149 mg/dl), and slightly 
lower limit for the control group compared to this study (120-180 vs. 150-180 mg/dl). 
Finally, their outcome was exclusively deep sternal wound infections.  
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Azarfarin et al.  (2011) investigated the effect of blood glucose control with 
insulin in preventing hyperglycemia during and after CABG surgery, with and without 
CPB, in non-diabetic patients to determine the which protocol optimized outcomes. They 
measured a postoperative composite of various complications, that included SSI, and 
found it was significantly less in the tight glycemic group (n =59), which used a 
continuous insulin infusion to maintain blood glucose between 110-126 mg/dl, compared 
to the control group (n = 58), which used intravenous bolus injections of insulin to treat 
blood glucose levels greater than 200 mg/dl (Azarfarin et al., 2011).  The study did not 
find a significant difference in SSI between the two groups when evaluated 
independently, only when SSI was combined in a composite.  
The current study had similar aspects to Azarfarin and colleagues (2011) like an 
exclusive intraoperative intervention with one group receiving continuous infusion and 
the other receiving intravenous bolus injections as a method of insulin delivery. The 
studies also had similar findings of no significant difference in postoperative SSI between 
treatment groups, when SSI was analyzed independently. The current study varied from 
Azarfarin et al. in surgical procedures, patient population sampled, as well as the 
parameters of intraoperative blood glucose levels. They used lower parameters for the 
tight glycemic group compared to the current study (110-126 vs. 110-149 mg/dl), and a 
higher limit for the control group (200 mg/dl vs. 150-180 mg/dl). Lastly, Azarfarin et al. 
(2011) only investigated deep sternal wound infections.   
In contrast to the findings of the current study, other RCTs investigating 
perioperative glycemic control found a significant decrease in postoperative 
complications, including SSI  (Emam et al., 2010; Lazar et al., 2004). Emam et al. (2010) 
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conducted a prospective RCT of 120 subjects with a diagnosis of diabetes, undergoing 
open-heart surgery to determine a glycemic protocol to produce the best postoperative 
outcomes. Subjects were randomly assigned to either a control group, simple sliding scale 
(n = 40) to keep blood glucose < 200 mg/dl or the Braithwaite protocol (n = 80) to 
maintain tight glycemic control between 100-150 mg/dl. The trial was started on 
admission to the hospital, 24 hours prior to surgery, and carried through postoperative 
day (POD) 2. They found no wound infections in the tight glycemic group compared to a 
12.5% rate of infection (5/40) in the control group (Emam et al., 2010). Specifically, 
patients with a mean 48 hour blood glucose level greater than 200 mg/dl had a 2.2 times 
higher risk of deep sternal wound infection (Emam et al., 2010).  
The current study was similar to Emam et al. (2010) in several aspects including 
the intraoperative interventional treatment arms included one with continuous infusion 
insulin and one with intravenous bolus injection, and glycemic parameters for the tight 
intervention were the same (110-149 mg/dl). Differences between the current study and 
the study by Emam et al. (2010) included blood glucose values for the control group 
compared to the current study (200 vs. 150-180 mg/dl), they also only included only 
patients with a diagnosis of diabetes mellitus for open-heart surgery requiring CPB. 
Additionally, the interventional period for Emam et al. (2010) was started 24 hours 
preoperatively through POD 2, much longer than the current study. Findings between the 
current study and Emam and colleagues was Emam et al. found significantly lower SSIs 
in patients that were randomized to the tight glycemic group compared to the control 
group.   
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Lazar et al. (2004), in a RCT, sought to determine whether tight glycemic control 
(n = 69, 125-200 mg/dl), via a continuous infusion of glucose-insulin-potassium, in 
diabetic patients, undergoing CABG surgery would improve perioperative outcomes 
compared to standard glycemic therapy (n = 72,  < 250 mg/dl) via subcutaneous bolus 
injections of insulin. They found tight glycemic control produced a 13% lower incidence 
of postoperative infections, which included pneumonia and SSIs, compared the standard 
glycemic group (0/72, 0% vs. 9/89), respectively.  
Unlike the current study, Lazar and colleagues (2004) included patients with 
diabetes undergoing CABG surgery with CPB. Lazar et al. (2004) also used a higher limit 
for the tight glycemic group compared to the current study (125-200 vs. 110-149 mg/dl), 
respectively, and a higher limit for the control group, with subcutaneous bolus injections, 
compared to the current study (250 mg/dl vs. 150-180 mg/dl), respectively. Lastly, Lazar 
and colleagues (2004) found significantly lower SSIs in patients that were randomized to 
the tight glycemic group compared to the control group.   
In summarizing the comparisons between previous RCTs in literature with the 
current study, several themes are identified.  The current study showed tight glycemic 
control did not significantly reduce postoperative SSIs, which is consistent with the other 
RCTs that investigated the effect of tight glycemic control on postoperative SSIs and 
maintained blood glucose levels below 200 mg/dl in the control group. Of the six RCTs 
investigating the effects of tight glycemic control on postoperative SSIs compared to 
conventional therapy two showed a significant reduction in SSIs with tight glycemic 
therapy (Emam et al., 2010; Lazar et al., 2004), three showed tight glycemic therapy 
slightly reduced the incidence of SSIs, but not significantly (Azarfarin et al., 2010; Chan 
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et al., 2009; Gandhi et al., 2007), and 1 showed no difference with tight glycemic control, 
as there were no SSIs in the tight control group or the conventional group (Lazar et al., 
2011).   
Possible reasons for the different findings may rest with different operational 
definitions for the tight glycemic group and the acceptable level of hyperglycemia 
permitted in the control groups for the studies. Of the two RCTs that showed a significant 
decrease in SSIs, with the use of tight glycemic control, both studies permitted the control 
groups to experience mean blood glucose levels consistently higher than 200 mg/dl 
during the perioperative period (Emam et al., 2010; Lazar et al., 2004).  Lazar and 
colleagues (2004) permitted blood glucose levels, for patients in the control group, to 
elevate up to 250 mg/dl before intervention with subcutaneous bolus injections of insulin. 
As such, blood glucose levels during the intraoperative period were consistently close to 
250 mg/dl and never below 200 mg/dl.  
Similarly, Emam et al. (2010) permitted blood glucose levels greater than 200 
mg/dl in patients in the control group before intervention with intravenous bolus 
injections of insulin. While they did attempt to maintain blood glucose levels below 200 
mg/dl during the perioperative period, their protocol of intravenous bolus injections was 
inadequate to achieve this. Mean serum glucose levels during intraoperative and the first 
24 hours postoperative period were  greater than 220 mg/dl consistently.  Allowing the 
blood glucose levels to exceed severe hyperglycemic levels (> 200 mg/dl), and utilizing 
the bolus injection method of insulin delivery may contribute to the significant difference 
in SSIs between the two glycemic treatments that these studies found.  
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The only other study that utilized intravenous bolus injections for glycemic 
management in the control group was Azarfarin and colleagues (2010). They were 
successful in achieving blood glucose levels below 200 mg/dl with intravenous bolus 
injections during the intraoperative period. The difference between Azarfarin and 
colleagues from Emam et al. (2010) and Lazar et al. (2004) was the patient population 
selection. Azarfarin et al. only included patients without a diagnosis of diabetes, and the 
other two studies included only patients with a diagnosis of diabetes. It is well established 
that patients with a diagnosis of diabetes mellitus have greater insulin resistance and 
difficult glycemic control in open-heart surgery, especially with the use of CPB (Ascione 
et al., 2008; Knapik et al., 2011).  
 Effect of tight glycemic control on procalcitonin and C-reactive protein.  
In the current study the tight glycemic group did not significantly reduce the 
postoperative serum concentrations of PCT. Analysis of tight glycemic control on CRP 
was not conducted because preliminary analysis of CRP failed to show a significant 
relationship with infection. The current study did show that patients in the tight glycemic 
control group had consistently lower postoperative PCT values compared to the other two 
groups that maintained moderate glycemic control, and while not significant, there was a 
moderate effect size. This is the first study to investigate if tight glycemic control reduces 
the response of the inflammatory biomarker PCT. Only two studies were identified in 
research that investigated the effects of tight glycemic control, in open-heart surgery, on 
inflammatory biomarkers. These two studies investigated biomarkers CRP, interleukins 
(IL), and free fatty acid levels (Koskenkari et al., 2006; Visser et al., 2005).   
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In a RCT of 21 patients, Visser et al. (2005) utilized glucose-insulin-potassium 
therapy via a hyperinsulinaemic normoglycemic clamp for glycemic control, in CABG 
patients, and found this method attenuated the systemic inflammatory response, as 
measured by IL-6, IL-8, and IL-10, and CRP compared to standard treatment.  The  
glucose-insulin-potassium group received a high dose of continuous insulin with a 
variable rate of glucose and potassium to maintain blood glucose between 4.0-5.5 
mmol/L (72-99 mg/dl), during the intraoperative period, and 24 hours after the release of 
the aortic cross clamp. The control group received the standard institutional treatment, 
which was not described. Visser and colleagues (2005) showed the interventional insulin 
group had an overall lowering effect on CRP levels compared with the control group, and 
on the first POD.  
Koskenkari et al. (2006) hypothesized that high dose glucose-insulin-potassium 
treatment could suppress the systemic inflammatory reaction and attenuate myocardial 
ischemia reperfusion injury in patients with unstable angina pectoris after urgent CABG 
surgery. Forty patient were randomized to receive either high-dose insulin treatment with 
a separate glucose potassium infusion or a control treatment. Both groups maintain blood 
glucose levels between 6-8 mmol/L (108-144 mg/dl) during the intraoperative period and 
14 hours postoperatively.  Koskenkari and colleagues found the high dose insulin 
treatment was associated with significantly lower CRP and lower free fatty acid levels 
compared to the control group. While these studies suggest tight glycemic control 
attenuated systemic inflammatory response, they do not discuss reduction in bacterial 
infection or SSI, or any clinical outcome benefits.   
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The studies conducted by Visser et al. (2005) and Koskenkari et al. (2006) vary 
from the current study in many respects. Primarily, the current study utilized insulin only 
as a method to control blood glucose levels and not for the immunomodulatory effects it 
may exert. Additionally, different inflammatory biomarkers were investigated and 
outcomes investigated differed.  
 Effect of tight glycemic control on blood glucose levels. 
In the current study, there was no significant difference on intraoperative blood 
glucose levels between the three treatment groups. Serum glucose values increased in all 
three groups during the surgery, with peak blood glucose values occurring during 
rewarming on CPB. However, all three glycemic protocols were effective in maintaining 
mean blood glucose levels within their preset target range. The tight glycemic group did 
have consistently lower blood glucose levels during the intraoperative period compared 
to the moderate glycemic groups, and while the results were not significant, there was a 
moderate effect size. The current study did not find significantly lower intraoperative 
blood glucose levels in the tight glycemic group. This finding is in contrast to all other 
previous RCTs investigating the use of tight glycemic control on postoperative outcomes 
of wound infections (Azarfarin et al., 2011; Chan et al., 2009; Emam et al., 2010; Gandhi 
et al., 2007; Lazar et al., 2004; Lazar et al., 2011).  A possible reason for this difference 
in the finding includes the difference in the treatment protocol ranges. The current study 
had the most narrow treatment window, between the tight glycemic group and control 
group, compared to other similar RCTs. The narrow treatment range, effectively 
decreased the effect size for this study. Moreover, this study had a much smaller sample 
size (n = 37) than any of the other comparable RCTs with sample sizes ranging from 82-
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400 (Azarfarin et al., 2011; Chan et al., 2009; Emam et al., 2010; Gandhi et al., 2007; 
Lazar et al., 2004; Lazar et al., 2011). This study, with an insufficient sample size, was 
underpowered, which may have contributed to the lack of significance in intraoperative 
blood glucose levels between the three glycemic groups.  
 Effect of tight glycemic control on glycemic stability. 
In this study, episodes of glycemic instability were too few to conduct analysis on 
the effect of continuous insulin infusion on intraoperative glycemic stability compared to 
intravenous bolus injection method.  Intraoperative glycemic instability was defined as 
three consecutive blood glucose values that were not within the preset limits of the 
protocol and outside of normal glucose values. Only four participants of the 37 (11%) 
experienced glycemic instability, and each of these participants only experienced one 
episode of glycemic instability. Of the four participants 2 were in the tight glycemic 
treatment group, and one participant each for the conventional and standard group. All 
participants returned to the predetermined target range for their group by the fourth blood 
glucose indicating that all three protocols brought blood glucose levels under control 
within 2 hours. Utilizing this definition there were too few episodes of glycemic 
instability to analyze for significant differences between the three groups. However, 
evaluating the variability of intraoperative glycemic control showed the intravenous bolus 
injection group experienced twice the variability of the groups that received insulin via 
the continuous insulin infusion method.  
In addition, both the conventional glycemic group and the standard glycemic 
group attempted to maintain intraoperative blood glucose levels between 150-180 mg/dl. 
Yet, during the rewarming phase of CPB, the conventional glycemic intervention via 
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continuous insulin infusion appeared to perform superior to the standard glycemic group, 
via intravenous bolus injections, in maintaining a more stable glucose level. Patients in 
the standard glycemic group experienced an larger increase in the blood glucose levels 
during rewarming on CPB (BG6 = 145 mg/dl to BG8 = 173 mg/dl) compared to the 
conventional treatment group (B6 = 139 mg/dl to BG8 = 154 mg/dl), a pattern, while not 
significant, suggestive that continuous infusion of insulin provides better glycemic 
control when insulin resistance is greatest.  
 The effect of tight glycemic control on intensive care length of stay. 
This study found no significant difference in ICU LOS between the three 
glycemic protocols. This finding is consistent with other similar RCTs that found no 
significant difference in ICU LOS (Azarfarin et al., 2011; Chan et al., 2009; Emam et al., 
2010; Gandhi et al., 2007; Lazar et al., 2011). Emam et al. (2010) while not finding a 
significant decrease in ICU LOS, did find a significant decrease in hospital LOS for 
patients who received tight glycemic control compared to the conventional glycemic 
control.  In contrast, Lazar et al. (2004) found patients who received tight glycemic 
control via a continuous insulin infusion had shorter ICU LOSs compared to patients who 
received conventional therapy, subcutaneous bolus injections of insulin. Reasons for the 
difference in findings are likely the same that were discussed in tight glycemic effects on 
SSIs that of allowing the blood glucose levels in the control group to exceed 200 mg/dl, 
and an inadequate method of insulin delivery for the control group.   
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 Exploratory findings 
  Hypoglycemia. 
Investigation into the incidence of intraoperative hypoglycemia was not a primary 
aim of this study, yet it is a critical area of recent research that has shown negative impact 
on postoperative outcomes (Stamou et al., 2011). The current study showed no difference 
in the incidence of hypoglycemic events between the three glycemic control groups. 
There was only one patient, in the standard glycemic group, that experienced two 
episodes of hypoglycemia (< 70 mg/dl) during the intraoperative and 6 hours 
postoperative period; the episode occurred on arrival to the operating room, and was 
treated with intravenous dextrose successfully.   
The finding that there was no significant difference in hypoglycemic events 
between the tight glycemic group and control group was consistent with the majority of 
previous RCTs that investigated tight glycemic control on postoperative outcomes of 
wound infection (Azarfarin et al., 2011; Chan et al., 2009; Emam et al., 2010; Gandhi et 
al., 2007; Lazar et al., 2004). Only one RCT, Lazar et al. (2011), reported a significantly 
higher incidence of hypoglycemia in the tight glycemic group compared to the 
conventional group. While they experienced significantly greater numbers of 
hypoglycemic events in the tight glycemic control group, there was no significant 
difference in major adverse events (Lazar et al., 2011).  Reasons for the different findings 
is likely due to the varying definitions used for hypoglycemia in the studies. Lazar et al. 
(2011) defined hypoglycemia as a blood glucose level of 80 mg/dl. This is in contrast to 
other studies that used a lower value to define hypoglycemia, such as 50 mg/dl (Chan et 
al., 2009; Emam et al., 2010), and 60 mg/dl (Azarfarin et al., 2011; Gandhi et al., 2007). 
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This current study defined hypoglycemia as 70 mg/dl, congruent with the definition 
designated by the American Diabetes Association (2012).   
Procalcitonin and C-reactive protein relationship to infection. 
The selection of inflammatory biomarkers PCT and CRP was made with the 
expectation that they were reliable precursors to infection. Therefore exploratory analysis 
of CRP and PCT and their relationship to SSIs was conducted. The data indicated that 
PCT was a reliable predictor of infection, but CRP was not.   
After surgery, CRP increased significantly compared with baseline in both 
participants with and without SSI.  Peak serum concentration occurred on POD 3, 
whether a SSI was present or not. There was no significant difference in serum CRP 
concentrations between participant with and without a SSI, even for patients requiring 
longer ICU LOS. This was in contrast to Lannergard and colleagues (2003), who 
investigated several biomarkers for the detection of infection in open-heart surgery, and 
found IL-6 and CRP were significantly higher in patients that developed postoperative 
infections compared to patients without postoperative infections. Biomarkers and 
laboratory markers investigated by Lannergard et al. (2003) included CRP, white blood 
cells, IL-6, and human neutrophil lipocalin. In this prospective observational trial, they 
monitored laboratory markers every day for six postoperative days after open-heart 
surgery. Postoperative bacterial infections were diagnosed in 17 of 54 patients needing at 
least 3 days of ICU postoperatively; patients discharged from the ICU in less than 3 
PODs were excluded from the study (Lannergard et al., 2003). While Lannergard and 
associates found that surgical trauma and CPB elicited a certain degree of an acute-phase 
response, resulting in elevation of IL-6, CRP and white blood cells, a significant 
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difference between patients with and without infection was noted for CRP on POD 2 and 
3. 
In the current study, CRP was not predictive of SSI, which is consistent with the 
results of other studies (Corral et al., 2009; Macrina et al., 2005).  Corral et al. (2009), in 
a prospective observational study of 216 open-heart patients found postoperative CRP 
was not a useful biomarker in the immediate outcome after cardiac surgery with CPB. C-
reactive protein was not correlated with postoperative outcomes and did not predict early 
complications, including infectious complications. Macrina et al. (2005), prospectively 
enrolled 32 post-CABG surgery patients and at the end of the 7th POD, the patients were 
divided into two groups, those with a complicated course and those with an 
uncomplicated postoperative course. C-reactive protein levels were drawn after induction 
of anesthesia (baseline),  at the end of surgery, and daily until POD 2. After surgery they 
found CRP values increased significantly compared to the baseline in both the 
uncomplicated and complicated groups, determining that postoperative CRP values did 
not contribute in prediction of postoperative outcomes (Macrina et al., 2005). Evidence 
that CRP was predictive of SSI was not established; as such, no further investigation on 
the impact of tight glycemic control on CRP levels was conducted.  
While Macrina et al. (2005) did not find CRP to be of value in predicting 
postoperative complications, they did find that absolute changes in PCT values of 0.20, 
0.40, and 0.60 ng/ml carried an approximate risk of 5, 26 and 69% for postoperative 
complications, respectively. Macrina and colleagues did not specify SSI as a specific 
postoperative complication, only a category for all surgical complications requiring re-
sternotomy, which may or may not have included sternal SSIs. 
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In the current study, postoperative PCT serum concentrations were significantly 
higher in the presence of a SSI compared to participants without a SSI. Procalcitonin 
values, in participants without a SSI, increased and peaked on the first postoperative day, 
followed by a return to near normal values by POD 5, compared to preoperative PCT 
levels. Procalcitonin values in participants that experienced an SSI, exhibited the same 
pattern, peaking on the first postoperative day and trending down. However, these values 
were significantly higher compared to participants without SSIs. Results of the current 
study, nor previous research studies, were able to verify a precise value or range for PCT 
that identifies an infectious process compared to an inflammatory process. Specifically, 
in this study PCT levels in patients without a SSI peaked on POD 1 and were less than 
1.5 ng/ml, and in patients who experienced a SSI, PCT values on POD 1 were just above 
2 ng/ml. Yet, elevated PCT concentrations greater than 2 ng/ml have been observed after 
CPB in cases of systemic inflammatory response syndrome without any postoperative 
complications , including infection (Meisner et al., 2002; Rothenburger et al., 1999). 
Other studies have shown PCT levels with a value of 1 ng/ml in the presence of 
postoperative fever was reliable for detecting infection in open-heart patients (Aouifi et 
al., 2000). In another study, Jebali et al. (2007) found a PCT value greater than 1.5 ng/ml 
beyond the second POD diagnosed postoperative infection with a sensitivity of 0.93 
(0.70-0.99) and a specificity of 0.80 (0.70-0.87).   
The patterns of postoperative PCT exhibited in this study are consistent with 
previous studies that have reported a moderate increase and peak on the first 
postoperative day in adults, with and without CPB, followed by a steady return to normal 
(Aouifi et al., 2000; Meisner et al., 2002; Prat et al., 2008; Sponholz et al., 2006).  
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Additionally, the results that PCT levels were significantly higher in participants that 
experienced a SSI compared to those without a SSI is concordant with other studies 
investigating the value of PCT in predicting postoperative complications, such as 
infection (Nahum et al., 2012; Macrina et al., 2005).  
Nahum et al. (2012) utilized a nested case control study to investigate the use of 
procalcitonin to differentiate between bacterial and nonbacterial cause of fever of 
children who underwent cardiac surgery. Of 665 children that underwent cardiac surgery, 
126 had postoperative febrile episodes, 47 with proven infection and 79 without bacterial 
infection. Procalcitonin levels were collected preoperative, post surgery and on POD 1, 2, 
and 5; and on the day a fever occurred.  Sixty-eight children developed fevers during 
PODs 1-5, of which procalcitonin levels at fever day was significantly higher in those 
with bacterial infections (n =16) than in those without bacterial infection (n =52). 
Similarly, in 58 children whom fever occurred after the 5th POD a significant difference 
was found in procalcitonin level at fever day between those children with (n = 31) and 
those without (n = 27) bacterial infection (Nahum et al., 2012).   
Surgical site infection and type of surgical procedure. 
A one-way ANOVA was conducted to determine if there was a difference in the 
rate of SSIs between the three types of surgery that were performed. While there was no 
statistically significant difference for infection rates among the three treatment groups, 
exploration of the data revealed a significant difference in the overall SSI rates depending 
on the type of surgery performed. This study showed participants who underwent 
combined CABG and valve surgery had significantly higher rates of SSI compared to 
CABG surgery or valve surgery alone.  This is consistent with Farzan et al. (2009) and 
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Sakamoto, Fukuda, Oosaka, and Nakata (2003), who found combined CABG and valve 
surgery was an independent risk factor for deep sternal wound infections. Combined 
procedures of CABG and valvular replacement or repair involve longer CPB times and 
aortic ischemic times. As such, this increased time on CPB increases the risks of 
complications, such as hypothermia, coagulopathies and bleeding that may add to 
increase SSIs postoperatively. This is yet another area for continued research.  
Strengths 
The experimental design was a major strength of the current study. The design 
was a multilevel, single factor, within-subjects design with patients nested within 
anesthesia provider teams. By counterbalancing the design with a Latin square, where 
each of three anesthesia provider teams dispensed each of three glycemic treatment 
conditions once, practice effects over the three treatment conditions occurred equally. 
There was no statistical difference, between the three glycemic protocol groups, in 
participant demographic characteristics, surgical characteristics, or preoperative baseline 
values for glycemic control. To minimize bias, the study team evaluating patients for 
SSIs, and ICU nurses were blinded to the glycemic treatment the patient received 
intraoperatively.  
Limitations 
There are noted limitations to the study. First, this study was conducted in a single 
center and the homogeneity of sample, primarily White, non-Hispanic males, limits the 
generalizability of the findings to the broader population.  It is acknowledged that 
statistical power was not sufficient to draw conclusions on the effect of tight glycemic 
control on postoperative outcomes including SSI, CRP, PCT and ICU LOS. Recruitment 
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objectives were not met, and thus the sample size of 37 was insufficient. It is possible that 
with an appropriately powered study the use tight glycemic control would have yielded 
significantly lower PCT concentrations postoperatively and significantly lower SSIs. 
Since the present study was limited to the clinical usefulness of PCT for early detection 
of infection, variables that may explain this mechanism, such as plasma levels of 
endotoxin and cytokines, were not evaluated. The current study, for reasons of safety, 
used current ADA/AACE guidelines to define tight glycemic control compared to prior 
studies that defined tight glycemic control much lower. As such, this study had a smaller 
effect size between the tight and moderate glycemic protocols, and thereby lower 
statistical power. 
Implications for Clinical Practice and Future Research 
Effect of tight glycemic control on surgical site infections.  
Despite a lower intraoperative mean blood glucose values in the tight glycemic 
group, there was no statistically significant difference in the SSIs between the treatment 
groups.  While, the possibility that the current study was underpowered does exist, the 
findings are consistent with similar RCT (Chan et al., 2009; Gandhi et al., 2007; Lazar et 
al., 2011). Clearly, evidence supports maintaining perioperative blood glucose levels 
below 200 mg/dl, and several studies help make the argument that below 180 mg/dl is 
prudent. However, further investigation is needed to determine if the benefits of 
perioperative euglycemia (80-110 mg/dl) surpass the benefits of tight glycemic control 
(110-149 mg/dl), or even moderate glycemic control (150-180 mg/dl), and/or outweigh 
the risks of hypoglycemia. This study does add support that a tight glycemic control, 
defined as 110-149 mg/dl, can be safely achieved, during the intraoperative period, in 
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open-heart patients with little to no risk of hypoglycemia, if a judicious protocol is 
followed.  
Effect of tight glycemic control on procalcitonin. 
The effects of tight glycemic control on postoperative serum concentrations of 
PCT are currently unexplored in research. While this study did not show a significant 
difference in PCT concentrations between the three glycemic groups, the study was 
underpowered. A type II error may have occurred secondary to an insufficient sample 
size.  The pattern produced, that of  consistently lower procalcitonin levels in the tight 
glycemic group compared to the moderate glycemic groups, and an effect size that was 
moderate to large warrants further investigation with an appropriate sample size before 
conclusions are drawn. Replication of this study with an appropriate sample size would 
offer insight if tight glycemic control reduces postoperative procalcitonin levels, and if 
so, to what clinical benefit.   
Additionally, the etiology for PCT  induction in open-heart surgery is not 
completely understood. Generally, infection and/or bacterial endotoxins are a main 
stimulus for the induction of PCT. There is extensive array of possible stimuli, other than 
infection, that may contribute to PCT induction in open-heart surgery. Additional studies 
are needed to explore the impact of CPB on the immune response and activation of 
proinflammatory cytokines, as well as dysglycemia and risk of infection in open-heart 
patients. 
Several studies have investigated the role of PCT as a predictor of postoperative 
complications like infection, in open-heart surgery. However, the cutoff value of PCT as 
a marker of infection remains a matter of debate. Prior research has shown conflicting 
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results with postoperative SSIs being diagnosed with PCT concentrations as low as 1 
ng/ml, and no SSIs found in patients with PCT concentration exceeding 2 ng/ml. 
Unfortunately, this study does not help to identify a reliable PCT concentration for the 
diagnosis of postoperative infection. Further RCTs are needed to determine the ideal PCT 
threshold, and timing, for the identification of postoperative SSIs compared to non-
infectious systemic inflammatory response.   
Finally, this study monitored postoperative SSIs until the sixth week post 
discharge, and found the majority of  SSIs were superficial harvest site infections 
diagnosed post hospital discharge. Future studies are needed to investigate why PCT, an 
acute phase inflammatory biomarker, with a short half life, would be elevated in the 
immediate postoperative period (POD 1-5), when an infection did not surface until 3-7 
weeks post the surgical event. 
Effect of tight glycemic control on blood glucose levels. 
Although this study was not able to conclude that tight intraoperative glucose 
control produced less postoperative SSIs, it should be noted that by introducing 
intraoperative blood glucose control, intraoperative hyperglycemia was avoided, which is 
an independent risk factor for mortality (Doenst et al., 2005).  Furthermore, blood 
glucose levels on admission to the ICU, a surrogate of subsequent glucose control (Egi et 
al., 2006) was lower with the continuous insulin infusion groups compared to the 
intravenous insulin bolus group. By maintaining tight glycemic control with continuous 
insulin infusion in the operating room, ICU target blood glucoses are already at target or 
are reached more quickly (Lecomte et al., 2008) compared to several studies that focused 
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on glucose control only in the postoperative period (Goldberg et al., 2004; Van den Berge 
et al., 2001).  
Additionally, there remains uncertainty if there is a time period more crucial for 
maintaining the tight glycemic control, whether preoperative, intraoperative, 
postoperative or post-hospital discharge. In this study, patients received the interventional 
treatments only during the intraoperative period, with all patients receiving the same 
glycemic protocol during the ICU phase. While the study monitored blood glucose levels 
during the intraoperative period and 6 hours postoperatively, it did not monitor the 
glycemic control throughout the rest of the hospitalization, nor post discharge.  Because 
the majority of our participant’s SSIs were diagnosed post hospital discharge, it is 
possible that glycemic control during ICU, ward, or post hospital discharge may have 
impacted the outcome of SSI.  
Studies have investigated glycemic control in the preoperative, intraoperative, 
perioperative, and postoperative period, but there is yet to be a RCT that investigates 
glycemic control throughout all of these periods. It is not unreasonable to consider that it 
is the glycemic control throughout the entire pre, intra, and complete postoperative period 
that holds the key to improved outcomes. After all, even if plasma glucose levels are 
tightly controlled during a five hour surgery, what real impact will this have if the patient 
has poor glycemic control in longer periods preoperatively, postoperatively, and post-
hospital discharge? Clearly, research supports that avoidance of severe hyperglycemia is 
important not only in the perioperative period, but also in the preoperative and late 
postoperative period, as patients’ transition to the ward. 
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While this study investigated the effect of tight glycemic control on SSIs in open-
heart surgery,  it did not investigate the impact of insulin on the systemic immune 
response, which may offer critical insight to this research area.  Studies have yet to 
elucidate if it is the plasma glucose level that offers the greatest impact or the amount of 
insulin delivered that produces improved outcomes. Studies have suggested that it is not 
the prevention of hyperglycemia that produces better postoperative outcomes, but rather 
the use of high doses of insulin that are utilized in providing tight glycemic control.  
Dandona, Thusu, Hafeez, Abdel-Rahman  and Chaudhuri (1998) showed that 2 hours of 
insulin administration (2 IU/ hr) had similar anti-inflammatory effects as 100 mg of 
intravenous hydrocortisone. Chaudhuri et al. (2004) found low dose insulin had an anti-
inflammatory, antioxidant and pro-fibrinolytic effect, independent of decreased blood 
glucose levels in patients with acute myocardial infarction. In the current study, the total 
amounts of insulin delivered to participants, were not measured. Of the three glycemic 
protocols, the tight glycemic protocol was designed to deliver higher doses of insulin 
compared to the conventional or standard group, but even so no clinical benefit was noted 
that would have suggested anti-inflammatory effects of insulin. Further research is 
needed in this area.  
Lastly, the history of glycemic control in critically ill patients, including open 
heart patients, provides us with much to consider on how practitioners should critically 
assess changes made in the national standards of care and practice guidelines. The 
widespread acceptance of tight glycemic control, and the extrapolation of successful 
postoperative protocols into the perioperative period, in 2004, was based primarily on 
observational studies. Observational studies have inherent problems, most serious of 
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which is selection bias, which may lead to biased estimates of the treatment effects. Even 
the best observational designs, that attempt to control for selection bias, cannot control 
for unobserved differences in patient characteristics.  
With the addition of a greater number of RCTs, in the last 5 years, it has become 
increasingly evident that tight glycemic control, actually euglycemia, advocated in 2004 
may have been too precipitous. The dramatic clinical improvements seen with tight 
glycemic control in observational designs has not been reproducible with RCTs. Until 
more evidence, in the form of RCTs, is available prudent recommendation are for more 
conservative glycemic control in the critically ill patient, including open-heart surgery. 
Currently, ADA and AACE joint statement is to maintain serum blood glucose levels 
between 110-180 mg/dl.  
Conclusion 
Tight glycemic control, during the intraoperative period, did not reduce the 
incidence of postoperative SSIs; decrease ICU LOS, or lower serum concentrations of 
inflammatory biomarker PCT.  Intraoperative tight glycemic control also did not 
significantly lower blood glucose levels or improve glycemic stability during the 
intraoperative period. Elevated intraoperative peak blood glucose levels were associated 
with an increased risk of SSI. As such, this study offers support to current guidelines that 
recommend maintaining blood glucose levels below 180 mg/dl with the use of continuous 
insulin infusion compared to intravenous bolus injections in open-heart surgical patients. 
Additionally, this study showed the use of tight glycemic control during the 
intraoperative period can be achieved safely, with the use of judicious protocols. Patients 
that undergo combined CABG and valve surgery are at an increased risk of developing a 
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SSI compared to patients who undergo CABG or valve replacement surgery alone. This 
study also showed PCT was an early marker of infection, where CRP was not. Addition 
of PCT to routine postoperative blood work in open-heart patients may benefit providers 
in the diagnosis and early treatment of SSIs.  
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Appendix A: Biographical Data & Intraoperative Worksheet 
 
        ID #: ___________ 
 
Data Collector__________      Date: __________ 
Age:__________ 
Initial Vital Signs: (data taken morning of surgical day) 
BP______ HR ______ Respiration______Pulse oximetry ______Temp_____ 
 Height _____ (in) Weight_______(Kg) Date of Birth_________ 
1. Interventional Arm 
 [1] Tight 
 [2] Conventional 
 [3] Standard 
 
2. Race 
 [1] Caucasian 
 [2] African American 
 [3] Asian 
 [4] American Indian/Alaska Native 
 [5] Native Hawaiian/ Pacific Islander 
 [6] Mixed (please specify)____________ 
 [7] Other (please specify) ____________ 
3. Ethnicity 
 [1] Hispanic 
 [2] Non Hispanic 
4. Gender 
 [1] Male 
 [2] Female 
Only list the disease process if the patient has been diagnosed in computerized patient 
record system (CPRS) 
5. Diabetes Mellitus Diagnosis 
 [0] None 
 [1] Type I 
 [2] Type II Oral Agent 
 [3] Type II Oral Agent & Insulin 
 [4] Type II Insulin only 
6. MI History 
 [0] No 
 [#] Yes 
 Total #___________ 
 Date of Last MI ____________ 
7. PVD History 
 [0] No 
 [1] Yes 
8. Cerebral Vascular Disease 
 [0] No 
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 [#] Yes 
 Total # ________ 
 Date of Last CVA __________ 
9. Hypertension History 
 [0] No 
 [1] Yes 
10. Chronic Obstructive Pulmonary Disease (COPD) 
 [0] No 
 [1] Yes 
11. Renal Insufficiency History (creatinine > 1.5 mg/dl) 
 [0] No 
 [1] Yes 
12. Prior Open-heart Surgery  
 [0] No 
 [#] Yes 
 Total # _______ 
 Date of Last OHS__________ 
13. Pre operative Labs:  Hemoglobin________ 
    Hematocrit_________ 
    WBC________ 
    RBC_________ 
    Platelets________ 
    Sodium________ 
    Potassium________ 
    Chloride_________ 
    Glucose_________ 
    BUN__________ 
    Creatinine__________ 
    Calcium__________ 
    Alkaline Phosphatase__________ 
    AST__________ 
    ALT__________ 
    Cholesterol__________ 
    Triglycerides_________ 
    HbA1C__________ 
14. DOS Labs: ISTAT ABG pH__________ 
    PaO2________ 
    PaCO2________ 
    HCO3_________ 
    ABE__________ 
    Sodium_________ 
    Potassium________ 
    Calcium__________ 
    Glucose________ 
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15. Biomarkers  CRP___________ 
    Procalcitonin___________ 
16. Hospital Admission Date _________ 
17. Surgery  Date __________ 
18. ICU Admission Date __________ 
19. ICU Discharge Date ___________ 
20. Hospital Discharge Date __________ 
 
Please circle all pharmacologic classes that the patient is on prior to surgery. Generic and 
Brand names of drugs are listed under each drug class. 
21. Preoperative Medication for Diabetes 
 [0] None 
 [1] Exogenous Insulin 
 [2]Insulin Secretagogues/Sulfonylureas  
Glipizide (Glucotrol, Glucotrol XL), Glimepriride (Amaryl), Glyburide 
(DiaBeta, Glynase, Pres tab, Micronase) 
 [3]Biguanide 
 Metformin (Glucophage) 
 [4]Meglitinides 
 Nateglinide (Starlix), Repaglinide (Prandin) 
 [5]Thiazolidinediones 
 Pioglitazone (Actos), Rosiglitazone (Avandia) 
 [6]Alpha-glucosidase Inhibitors 
 Acarbose (Precose), Miglitol (Glyset) 
 [7] Combined sulfonylurea & biguanide 
 Glyburide & Metformin (Glucovance), Glipizide & Metformin (Metaglip) 
22. Surgeon’s Preoperative Mortality _________% 
Surgeon’s Preoperative Mortality is the estimate the surgeon gives to the patient for 
surgery. If the surgeon gives a range use the highest value.   
23. Primary Surgeon 
 [1] Dr. A 
 [2] Dr. B 
 [3] Dr. C 
24. Surgical Procedure 
 [1] CABG 
 [2] Valve Surgery 
 [3] CABG/Valve combined 
25. Heart Valve Surgery 
 [0] None 
 [1] aortic 
 [2] mitral 
26. CABG Bypass grafts  
 [0] None 
 [1] Yes 
 Total # grafts___________ 
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27. CABG Bypass Harvest Site 
 [0] None 
 [1] IMA 
 [2] Radial 
 [3] Saphenous (open technique) 
 [4] Saphenous (endoscopic technique) 
 [5] IMA/ Saphenous (open technique) 
 [6] IMA/Saphenous (endoscopic technique) 
 [7] IMA/ Radial 
 [8] IMA/ Radial/Saphenous (open) 
 [9] IMA/ Radial/Saphenous (endoscopic) 
 [10] Radial/Saphenous (open) 
 [11] Radial/Saphenous (endoscopic) 
28. ASA Classification 
 [1] ASA 1 
 [2] ASA 2 
 [3] ASA 3 
 [4] ASA 4 
 [5] ASA 5 
29. Surgical Priority 
 [1] Elective 
 [2] Urgent 
30. Operating Room Start Time _________ 
31. Operating Room Stop Time__________ 
Please circle 1-3 if the patient is on inotropic or vasopressor support in the post 
bypass period. This is defined as when the patient leaves the operating room. If the 
patient needed a vasopressor or inotrope temporarily to wean from bypass but is off the 
agent prior to leaving the operating room circle 0 for no support needed.  
32. Inotropic or vasopressor support postoperatively 
 [0] None 
 [1] 1 agent 
 [2] 2 agents 
 [3] more than 2 agents 
33. Cardiopulmonary Bypass 
 [0] No 
 [1] Yes 
 [1a] planned 
 [1b] unplanned 
34. Cardiopulmonary Start Time ___________ 
35. Cardiopulmonary Stop Time ___________ 
36. Aortic Clamp Start Time ___________ 
37. Aortic Clamp Stop Time ___________ 
Intraoperative Phase: Blood Glucose (BG) testing begins with the first BG drawn 
immediately after induction of anesthesia in the operating room (30 minutes post blood 
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glucose drawn in pre-anesthesia holding area). Blood glucose levels will be drawn every 
30 minutes after with ISTAT monitoring. 
BG 1__________  Intervention__________ 
BG2___________  Intervention__________ 
BG3___________  Intervention__________ 
BG 4___________ Intervention__________ 
BG 5___________ Intervention__________ 
BG 6___________ Intervention__________ 
BG 7__________   Intervention__________ 
BG 8___________ Intervention__________ 
BG 9___________ Intervention__________ 
BG 10__________ Intervention__________ 
BG 11__________ Intervention__________ 
BG 12__________ Intervention__________ 
BG 13__________ Intervention__________ 
BG 14__________ Intervention__________ 
BG 15__________ Intervention__________ 
BG 16__________ Intervention__________ 
BG 17__________ Intervention__________ 
BG 18_________  Intervention__________ 
BG 19_________  Intervention__________ 
BG 20_________  Intervention__________ 
C-reactive Protein (CRP) and Procalcitonin (PCT) will be drawn upon successful 
separation from cardiopulmonary bypass. If cardiopulmonary bypass is not utilized in the 
open-heart surgical procedure CRP and PCT will be drawn at the end of surgery 
31. CRP Post pump_________ 
32. PCT Post pump_________ 
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Appendix B: Postoperative Intensive Care Worksheet 
 
Data Collector___________     Date_________ 
        ID # __________ 
Please complete the following vital statistics data upon admission to the ICU.  
1. Blood Pressure________ 
2. Heart Rate  ________ 
3. Respiration ________ 
4. Pulse oximetry________ 
5. Temperature ________ 
Blood Glucose (BG) should be measured immediately upon arrival into ICU and every 
30 minutes after for six hours. Blood glucose testing should be completed by utilizing 
blood drawn from the arterial line and tested with the designated study glucometer. 
Intervention for glycemic control will be the standard ICU protocol that is currently 
approved.  
1. BG initial ______    Intervention_______________ 
2. BG 30 minutes______   Intervention_______________ 
3. BG 60 minutes (1 hr) ______  Intervention_______________  
4. BG 90 minutes  (1.5 hr) ______    Intervention_______________ 
5. BG 120 minutes (2 hr) ______   Intervention_______________ 
6. BG 150 minutes (2.5 hr)______   Intervention_______________ 
7. BG 180 minutes (3 hr)______  Intervention_______________ 
8. BG 210 minutes (3.5 hr)______  Intervention_______________ 
9. BG 240 minutes (4 hr)______   Intervention_______________ 
10. BG 270 minutes (4.5 hr)______   Intervention_______________ 
11. BG 300 minutes (5 hr)______   Intervention_______________ 
12. BG 330 minutes (5.5 hr)______  Intervention_______________ 
13. BG 360 minutes (6 hr)______   Intervention_______________ 
ICU Labs will be drawn upon admission into the ICU from the surgical suite and sent to 
the main laboratory at the study site. 
1. Hemoglobin__________ 
2. Hematocrit__________ 
3. WBC__________ 
4. RBC________ 
5. Platelets_______ 
6. Sodium__________ 
7. Potassium___________ 
8. Chloride_________ 
9. Glucose_______ 
10. BUN_________ 
11. Creatinine_________ 
	  	  191	  
 
Appendix C: Postoperative Worksheet Wound Visit 
 
Data Collector __________     Date_________ 
        ID # __________ 
Vital statistic to be measured the visit day. 
1. Blood Pressure________ 
2. Heart Rate  ________ 
3. Respiration ________ 
4. Pulse oximetry________ 
5. Temperature ________ 
6. Postoperative Visit Phase    
 [1] ICU (immediate postop) 
 [2] Ward (prior to hospital discharge) 
 [3] Clinic Visit 1 (2 weeks postop) 
 [4] Clinic Visit 2 (6 weeks postop) 
The following questions should be based on the superficial or deep surgical site infection 
criteria set by the CDC.  
7. Harvest Surgical Site Infection   
 [0] No 
 [1] Yes 
8. Harvest Surgical Site Infected  
 [0] No 
 [1] Saphenous 
 [2]Radial 
9. Sternal Surgical Site Infection   
 [0] No 
 [1] Yes 
10. Superficial Surgical Site Infection (please select all criteria that apply) 
 [0] No 
 [1] Superficial Infection: Purulent drainage from superficial incision  
 [2] Superficial Infection: organisms isolated from aseptic culture of tissue/fluid 
 [3] Superficial Infection: Pain at the surgical site   
 [4] Superficial Infection: Tenderness at the surgical site 
 [5] Superficial Infection: Redness at the surgical site 
 [6] Superficial Infection: Heat at the surgical site 
 [7] Superficial Infection: Incision opened by surgeon and/or culture positive 
 [8] Superficial Infection: A diagnosis of superficial Incision Infection by surgeon 
11. Superficial Infection: Primary (A superficial incisional infection that is identified 
in the primary incision in a patient who has had an operation with one or more 
incisions (chest incision for CABG surgery with a donor site) 
 [0] No 
 [1] Yes 
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12. Superficial Infection: Secondary: A superficial incisional secondary infection that 
is identified in the secondary incision in a patient who has had an operation with 
more than one incision (donor site incision for CABG) 
 [0] No 
 [1] Yes 
13. Deep Surgical Site Infection (Please select all criteria that apply) 
 [0] No 
 [1] Purulent drainage from superficial incision 
 [2] Deep Infection: organisms isolated from aseptic culture of tissue/fluid 
 [3] Deep Infection: Spontaneous dehiscence   
 [4] A diagnosis of deep Incision Infection by surgeon 
 [5] Abscess by histopathologic, radiologic 
 [6] Deep Infection: Incision opened by surgeon and/or culture positive 
  If one of the following signs are present   
   [a]Fever 
   [b] Localized Pain 
   [c] Localized Tenderness 
14. Deep Infection: Primary. A deep incisional infection that is identified in the 
primary incision in a patient who has had an operation with more than one 
incision (chest incision for CABG surgery with a donor site) 
 [0] No 
 [1] Yes 
15. Deep Infection: Secondary. A deep incisional secondary infection that is 
identified in the secondary incision in a patient who has had an operation with 
more than one incision (donor site incision for CABG) 
 [0] No 
 [1] Yes 
16. Labs 
 Hemoglobin__________ 
 Hematocrit__________ 
 WBC__________ 
 RBC________ 
 Platelets_______ 
  Sodium__________ 
  Potassium___________ 
 Chloride_________ 
 Glucose_______ 
 BUN_________ 
 Creatinine_________ 
 Calcium__________ 
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Appendix D: Postoperative Laboratory and Temperature Monitoring 
 
Please document the peak temperature in a 24 hour period starting on postoperative day 
(POD) 1 and continuing through POD 6. The 24 hour period will start at 6:00 am the 
morning after surgery and end at 5:59 am the second day after surgery.  
1. POD 1 Peak Temperature _____________ 
2. POD 2 Peak Temperature______________ 
3. POD 3 Peak Temperature______________ 
4. POD 4 Peak Temperature______________ 
5. POD 5 Peak Temperature______________ 
6. POD 6 Peak Temperature______________ 
C-reactive Protein (CRP) will be drawn with the scheduled morning laboratory collection 
starting postoperative day 1 continuing through postoperative day 6.  
7. CRP 1________ 
8. CRP 2________ 
9. CRP 3________ 
10. CRP 4________ 
11. CRP 5________ 
Procalcitonin (PCT) will be drawn with the scheduled morning laboratory collection 
starting postoperative day 1 and continuing through postoperative day 6.  
12. PCT 1_______ 
13. PCT 2 _______ 
14. PCT 3 _______ 
15. PCT 4________ 
16. PCT 5________ 
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Appendix E: Institutional Review Board Approval 
 
 
